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Since its discovery in 1988 the powerful vasoconstrictor endothelin-1 (ET-1), has
been widely implicated in the pathophysiology of renal and cardiovascular disease.
ET antagonists have favourable effects in experimental models of these conditions
and orally acting ET antagonists appear very promising in clinical trials of
pulmonary and systemic hypertension. However, there is a paucity of human data
regarding the role of ET-1 and its receptors both on renal function and in renal
disease. In this thesis, using selective ET receptor antagonists, I have therefore
explored the systemic and renal haemodynamic and renal tubular effects of ET-1, in
a series of acute clinical studies.
After confirming, in a dose ranging study, that ETA receptor blockade produces
vasodilatation in healthy subjects, I have shown, in patients with chronic renal failure
(CRF), that selective ETA but not combined ETA/B receptor antagonism produces
substantial reductions in blood pressure that are associated with renal vasodilatation,
a reduction in EFF and a reduction in proteinuria, suggesting a renoprotective action.
These data show that ET-1 plays a major role in regulating blood pressure and renal
vascular resistance in CRF, consistent with activation of the ET system in this
condition. By contrast, selective ETB receptor antagonism alone produced substantial
systemic and renal vasoconstriction in both healthy subjects and CRF. Thus the
effects of ETB receptor blockade, whether in the presence of ETA receptor blockade
or not, suggest the net effect of ETB receptor activation on the circulation, in health
and renal disease, is to produce vasodilatation. Clearance of ET-1 from the
circulation is also reduced during ETB receptor blockade and studies of urinary ET-1
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excretion under conditions of ET receptor blockade suggest that renal tubular
excretion of ET-1 is at least partly mediated through the ETB receptor.
I have also explored the interaction between the ET and renin-angiotensin systems,
demonstrating that, while ETA receptor antagonism does not alter the pressor effect
of angiotensin II, prior ACE inhibition will enhance the effect of ETA receptor
blockade in healthy subjects to produce a picture similar to that seen in CRF, an
action mediated by nitric oxide, and abolished by concomitant ETB receptor
blockade.
In summary,these studies confirm a role for ET-1 in the pathophysiology of systemic
and renal vasoconstriction in CRF and suggest that ETA, rather than combined
ETA/B receptor antagonism is potentially the most useful stratagem for ET system
blockade in the treatment of CRF, particularly in combination with ACE inhibitors.
Chronic studies are now needed in patients with CRF to confirm this potential.
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1. Studies
All clinical studies were performed by myself with the exception of Studies 1 & 2
(Chapters 3 & 4) which were performed as joint studies in conjunction with Dr JC
Spratt and Dr IB Wilkinson.
2. Assays
Because of the very large number of samples produced by clearance studies requring
analysis, these were performed in conjunction with the laboratory staff of the
Clinical Pharmacology Unit*. All immediate processing of samples was undertaken
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the laboratory staff (PAH, BQ-123, ET-1, ANG II) and those which I observed but
were all analysed by the laboratory staff (PRA, Aldosterone, serum ACE activity,
urinary protein). Cyclosporin was performed in the main hospital laboratory.
*Mr NR Johnston, Miss FE Howe, Miss L Coppard
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ACE Angiotensin converting enzyme
ANG II Angiotension II
ARAS Atherosclerotic renal artery stenosis
AVP Arginine vasopressin
CAD Coronary artery disease




CRF Chronic renal failure
CTF C-terminal fragment
CyA Cyclosporin
ECE Endothelin converting enzyme
EFF Effective filtration fraction
EPO Erythropoietin
ERBF Effective renal blood flow
ERPF Effective renal plasma flow
ERVR Effective renal vascular resistance
ET Endothelin
FeNa Fractional excretion of sodium
FWC Free water clearance
GFR Glomerular filtration rate
Hct Haematocrit
HPLC High performance liquid chromatography
IHD Ischaemic heart disease
IVC Inferior vena cava
IMCD Inner medullary collecting duct
L-NMMA L-A^-monomethyl-arginine
LV Left ventricle
LVH Left ventricular hypertrophy
MAP Mean arterial pressure
NE Noradrenaline
NO Nitric oxide
NOS Nitric oxide synthase
PAH Para-aminohippurate
PHT Pulmonary hypertension
PIH Pregnancy induced hypertension
PET Pre-eclampsia
PVD Peripheral vascular disease
RBF Renal blood flow
SAH Sub-arachnoid haemorrhage
SVRI Systemic vascular resistance index
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Since its discovery in 1988, endothelin (ET) has been widely implicated in the
pathophysiology of renal and cardiovascular disease. ET receptor antagonists have
favourable effects in experimental models of these conditions and have proved
useful in elucidating the role of the ET system. Orally acting ET receptor antagonists
appear promising in clinical trials in pulmonary and systemic hypertension, but there
is a paucity of human data regarding the role of ET and its receptors both on renal
function and in renal disease. This thesis therefore explores the systemic and renal
haemodynamic and renal tubular effects of ET, using selective ET receptor
antagonists.
1.2 Biology of Endothelins
The endothelins are a family of 21 amino acid peptides with powerful
vasoconstrictor and pressor properties that were first described by Yanagisawa in
1988 [1], Three different isopeptides, ET-1, ET-2 and ET-3, have so far been
identified, each with distinct genes and tissue distributions [1-3]. Each has a
common structure of a hydrophobic C terminal end and two disulphide bonds within
the peptide that form a loop [2, 3]. ET-2 differs from ET-1 by 2 amino acids and ET-
3 from ET-1 by 6 amino acids. Endothelins are highly conserved peptides that show
a similarity to sarafotoxins, cardiotoxic constrictor snake venom peptides produced
by the Israeli burrowing asp Actractaspis engaddensis [4] (Fig 1.1).




Of the three peptides, ET-1 is the major endothelial isoform and is thus likely to be
the most important in the regulation of vascular function. Its main site of production
is the vascular endothelial cell but it is also produced by other cell types including
renal tubular and mesangial cells, vascular smooth muscle cells and epicardial cells.
(Table 1.1).
1.2.1 ET-1 biosynthesis
The gene product is the 212 amino acid pre-pro-ET-1. Regulation of the production
ofET is thought to be at the level of gene transcription. Enhanced gene transcription
occurs with a wide range of stimuli including other vasoactive hormones such as
angiotensin and vasopressin [20-22] cytokines such as interleukin-1, platelet derived
growth factor, transforming growth factor beta [23, 24], endotoxin [25, 26] hypoxia
[27], insulin [28] oxidized low density lipoprotein [29] and cyclosporin (CyA) [30].
In contrast, prostacyclin [31], nitric oxide [32], the natriuretic peptides [33],
oestragen [34] and heparin all inhibit gene transcription.
Table 1.1 sites of ET biosynthesis
ET-1 ET-2 ET-3
Vasculature
- endothelial cells [5];




















Pre-pro-ET-1 is cleaved by intracellular furin-like proteases to proET-1 then big ET-
1 (38 amino acids) which is largely, but not wholly, biologically inactive [35].
Endothelin converting enzyme (ECE), a metalloproteinase [36], then splits big ET-1
to the biologically active ET-1 and C-terminal fragment (CTF). Two ECEs have
been identified, ECE-1, existing in four distinct isoforms [37-39] and ECE-2 [40],
both of which preferentially catalyse the cleavage of big ET-1. Each ECE has a
different tissue distribution and different pH at which it acts [37, 41]. ET-1 can also
be produced from big ET-1 by chymases [42], which can also cleave big ET-1 to
produce the vasoconstrictor ET-11.31 [43], and non-ECE metalloproteases. ET-1
secretion from endothelial cells is largely abluminal, towards the adjacent vascular
smooth muscle [44] (Fig 1.2).
1.2.2 ET receptors
Two ET receptors have been identified and cloned in mammals. Both are seven
domain trans-membrane proteins. ETA receptors [45] have a high affinity for ET-1
compared to ET-2 and ET-3, whereas ETB receptors [46] have an equal affinity for
all three ET peptides. Within the circulation, ETA receptors are found on vascular
smooth muscle cells [45, 47] and their activation results in vasoconstriction. ETB
receptors are also found on vascular smooth muscle cells [48], where they can
mediate vasoconstriction, but are primarily found on the vascular endothelium [49]
where their activation results in vasodilatation via the nitric oxide (NO) system [50]
and prostacyclin [51] (Fig 1.2). Within the kidney, in man, ETA receptors are
localised to vascular smooth muscle, notably in the glomeruli, vasa recta and arcuate
arteries. ETB receptors are more numerous (ETB to ETA ratio 2:1) and more
widespread with a high concentration in the collecting system [11, 52],
1.2.3 ET receptor signalling
Signal transduction is via coupling to a G protein [53] and activation of intracellular
phospholipase-C with subsequent hydrolysis of phosphatidyl inositol [54, 55],
activation of protein kinase C [56] and changes in intracellular calcium [57, 58].
Binding of ET-1 to its receptors is irreversible, largely due to the internalisation of
the receptor-ligand complex, and produces slow onset, sustained actions (Fig 1.2).
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Figure 1.2 ET-1 biosynthesis
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1.2.4 Actions of ET-1
Endothelin was originally identified as a vascular endothelial cell derived peptide
acting on vascular smooth muscle cells to produce a biphasic response on blood
vessels of a transient ETB receptor mediated vasodilatation [59] followed by a
sustained ETA receptor mediated vasoconstrictor and pressor response [60].
However, in addition to its vasoconstrictor properties, it is clear now that it has many
other functions in vascular and other tissues.
ET-1 can produce contraction of other cell types eg. airway smooth muscle cells
producing bronchoconstriction [61], detrusor smooth muscle cells causing bladder
contraction [62] and mesangial cells reducing the filtration coefficient [63]. ET-1
also functions as a powerful mitogen promoting cell growth in a wide variety of cell
types [63-65] and interacting with other growth factors (eg. vascular endothelial
growth factor in vascular smooth muscle and endothelial cells [66]). It is pro¬
inflammatory [67, 68] modulating cytokine production (eg. TNF-a and interleukin-6
in mast cells [69], interleukin-l(3 in astrocytes [70]) and pro-fibrotic [71]. It
modulates other hormone systems, (eg. atrial natriuretic peptide [72], angiotensin
[73], noradrenaline (NE) [74], arginine vasopressin (AVP) [75], and aldosterone
[76]) and also influences ion and fluid transport in the gut [77], lungs [78] and
kidneys [79-81]. ET-1 can also act as a neuropeptide in the brain [82] and mediate
pain nociception [83],
Knockout models have also demonstrated that ET is vital in normal embryonic
development of tissues derived from the neural crest. ET-1 knockout mice die
shortly after birth from craniopharyngeal malformations [84], ETB receptor
knockout mice have aganglionic megacolon and an abnormal coat colour




The half-life of exogenously administered ET-1 in the circulation is ~1 min [25, 86].
Clearance of ET-1 from the circulation is by receptor and non-receptor mediated
mechanisms. ETB receptor binding and internalisation with intracellular degradation
accounts for the majority of clearance particularly in the pulmonary circulation, with
splanchnic and renal circulations also contributing [86]. In rats -70% of ET-1 is
removed in the lungs, in man this is -50% [87, 88]. Renal clearance [86] and
enzymatic degradation by neutral endopeptidases on endothelial cell membranes [89]
also occurs.
1.3 Plasma ET-1 concentrations
In studying the activity of the ET system, a marker of that activity should be sought.
Throughout this thesis, plasma ET-1 concentration is given. However, in
interpretation of its significance, it must be borne in mind that, though big ET and its
cleavage products can all be detected in the circulation, most ET-1 is released from
endothelial cells abluminally [44] where it acts on smooth muscle cells. Because of
ET-l's paracrine action, plasma ET-1 concentrations may not be an appropriate
measure of endothelial synthesis.
Also, plasma ET level will represent a balance between production and clearance.
ET-1 is rapidly cleared from the circulation. Though it will exert effects for up to 60
minutes, the plasma half-life in normal subjects is about 1 minute [25], Reductions in
ETB receptor numbers or in renal function may reduce this clearance increasing
plasma ET-1 concentrations without altering production, though there is no evidence
yet as to whether these elevated concentrations consequent upon reduced clearance
are biologically active as opposed to simply immuno-competent and thus detected by
current assays. Measurement of big-ET and CTF have been promoted as more
accurate reflectors of endothelial synthesis because their removal from the
circulation is slower and more consistent [90, 91]. ETB inhibition (i.e. reduced
receptor clearance) results in a rise in plasma ET-1 but not big ET-1 or CTF i.e. no
increase in production.
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Finally, in considering the kidney, because less than 1% of injected radiolabeled
ET-1 is recovered in the urine [92], neither glomerular filtration nor tubular secretion
of plasma ET-1 accounts for urinary ET-1, which is therefore assumed to be
primarily of renal origin. Thus urinary ET-1 excretion rate may be used as a marker
of renal ET-1 production.
1.4 ET receptor antagonists
ET receptor agonists and antagonists have been used to define the role of the
endogenous ET system and confirm its importance in cardiovascular function and
dysfunction. Attention is now focusing increasingly on drugs that may have a role in
clinical medicine. Though ECE inhibitors and monoclonal antibodies have been used
experimentally, and the former may be a potential future therapeutic option, most
clinical work to date has been with ET receptor antagonists.
ET receptor antagonists can be divided, according to their receptor selectivity, as
ETA or ETB selective, and non-selective ETA/B receptor antagonists. The term
ETA selective is generally used for compounds with >1000 fold selectivity for the
ETA over the ETB receptor. It is important to appreciate that so-called 'non¬
selective' antagonists are still generally selective for the ETA receptor but the ratio
of ETA to ETB effect is less than for the selective agents (Table 1.2). In practical
terms, more work with these selective vs. non-selective receptor antagonists is
needed to delineate the respective roles of ETA and ETB receptors in normal
physiology and, more critically, in pathophysiology before conclusions can be drawn
regarding which are likely to be most beneficial in a given clinical situation.
A further division, in terms of their clinical potential, must be made into orally active
compounds and those available only as parenteral preparations. There will be certain
situations where an intravenous preparation is preferred, notably to counter an acute,
isolated insult (such as the cerebral ischaemia following subarachnoid haemorrhage
or stroke, unstable angina, acute myocardial infarction, acute renal failure and post¬
operative pulmonary hypertension). However, many of the anticipated indications
for the ET receptor antagonists currently in development (including hypertension,
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chronic heart failure and coronary restenosis) will require chronic treatment and,
thus, oral agents are more suitable (Table 1.2).
A series of peptide antagonists have been developed from the modification of the ET
peptides to produce compounds that bind to, but do not activate the receptors. Cyclic
peptides mimic the hairpin loop of the endothelins; BQ-123 is a cyclic pentapeptide,
ETA selective receptor antagonist developed from BE 18257B (a natural product of
Streptomyces misakiensis) [93, 94] and TAK-044, a cyclic hexapeptide, non¬
selective ETA/B receptor antagonist [95]. Modification to produce a series of linear
peptides can generate ETB selective receptor antagonists such as BQ-788 [96]. As
peptides, these agents are broken down in the gut and are thus only active
parenterally, and then with only relatively short half-lives. Experimentally, the half-
life of BQ-123 can be increased by side-chain modifications that reduce hepatic
extraction [97], but the clinical applicability of this group of compounds remains
limited by the lack of oral analogues.
Screening libraries for compounds with ET blocking activity, and molecular
modelling, has resulted in a series of non-peptide antagonists with greater
bioavailability. Ro 47-0203, bosentan [98], is a sulphonamide compound with non¬
selective receptor blocking activity that has the benefit of being available as both an
oral and intravenous preparation. Practically, this would allow treatment to be started
in the acute situation, say, an exacerbation of undiagnosed heart failure, with the
intravenous preparation and continuing treatment thereafter with the oral formulation.
SB 209670, a carboxylic acid derivative, is a more potent non-selective receptor
antagonist but is only available as an intravenous preparation [99]. SB 217242
(enrasentan) is an analogue of this compound with improved bioavailability, currently
in clinical studies as an oral drug [100]. Orally active and selective ETA receptor
antagonists have also been developed. ABT 627 is a carboxylic acid derivative with
2000-fold selectivity for the ETA vs. the ETB receptor and a half-life of 24 hours in
humans [101] making it theoretically a very attractive choice where chronic selective
receptor antagonism is required. Minor modifications to this structure produce
compounds highly selective for the ETB receptor [101]. TBC 11251 and TA 0201 are
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sulphonamide derivatives with high bioavailabilities which are also highly selective for
the ETA receptor [102]. TA 0201 has a half-life of only 0.9 hours in pharmacokinetic
studies but generates an active metabolite with demonstrable inhibitory effect at 8
hours [103].
Table 1.2: Endothelin receptor antagonists in development
1.2a: ETA selective endothelin receptor antagonists
Name Route ETA Stage of Anticipated Manufacturer
selectivity* Development indication
TBC 11251 O + IV x7000 Phase III PHT Encysive/ Texas
(Sitaxentan) Phase II CHF Biotechnology
LU 135252 O+IV xl30 Phase III CHF Knoll
(Darusentan) Preclinical Arrhythmias
Unknown HT
ABT 627 0 x2000 Phase I Coronary restenosis Abbott
TA 0201 o x2700 Phase I CHF Tanabe Seiyaku
Preclinical PHT, BPH
ZD 1611 o xlOOO Phase I PHT AstraZeneca
Preclinical CHF, HT, COPD
RO 611790 IV xlOOO Phase I Renal failure, solid Roche
tumours
S 0139 IV NK Phase II Cerebral vasospasm, Shionogi
neuroprotection
BQ-123 IV x2500 Preclinical Arrhythmias, IHD, Banyu
cerebral ischaemia, HT,
PVD, CHF
PD 147953 IV x7000 Preclinical Coronary disease Fujisawa
(Parke-Davis)
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1.2b: Non-selective endothelin receptor antagonists
Name Route ETA Stage of Anticipated Manufacturer
selectivity* Development indication
RO 470203 O + IV x20 US licence PHT Roche






SB 217242 0 xl 10 Phase II PHT SmithKline
(Enrasentan) Phase I CHF Beecham
Preclinical Restenosis, CRF, stroke
J 104132 o x5 Phase I HT Merck & Co
Preclinical CHF
TAK-044 IV xl8 Phase II IHD, CRF, SAH Takeda
Phase I HT (Parke-Davis)
Preclinical CHF
RO 610612 IV NK Phase II/III CHF, HT Roche
(Tezosentan) Preclinical Reperfusion injury (Actelion)
PD 145065 IV x4 Preclinical HT, CRF Parke-Davis
Unknown Coronary disease
Key: O - Oral, IV - intravenous, NK - not known, * based on binding and functional assays
BPH - benign prostatic hypertrophy, CHF - Congestive heart failure, COPD - Chronic
obstructive pulmonary disease, CRF - chronic renal failure, DM - diabetes, HT -
hypertension, IHD - ischaemic heart disease, PHT - pulmonary hypertension, PVD -
peripheral vascular disease, SAH - sub-arachnoid haemorrhage
A potentially interesting preclinical development is the description of L-747072, an
angiotensin receptor antagonist with non-selective ET receptor antagonist activity,
providing a possible dual target approach for the treatment of hypertension and other
cardiovascular conditions [104],
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1.5 Endothelin and the kidney
1.5.1 Physiology
Within the kidney, ET-1 is synthesised by endothelial, mesangial, glomerular
epithelial and medullary collecting duct cells [13, 105-107] and may act as a
paracrine/autocrine regulator of renal and intrarenal blood flow, glomerular
haemodynamics and sodium and water homeostasis [80, 108]. Though the tubular
effects are probably intra-renal and paracrine in nature, and ET-1 probably also acts
locally to regulate glomerular haemodynamics, there is some evidence that
circulating ET may also be important in renal functional changes in cardiorenal
states ofET activation such as heart failure [109],
In animals, exogenous ET-1 causes renal vasoconstriction, sometimes preceded by
transient vasodilatation [110-113]. Indeed, the renal vasculature is more sensitive to the
vasoconstricting effects of ET-1 than other vascular beds [114]. Studies suggest that
this vasoconstriction is primarily cortical [115, 116] with an initial medullary
vasodilatation [115, 117]. In man, the effect of exogenous ET-1 on the renal vasculature
is to cause vasoconstriction, a fall in glomerular filtration rate (GFR), and an increase in
filtration fraction [118-120].
There are abundant ET receptors in the kidney but the roles of the ET-A and ET-B
receptors may show a species difference. In pigs, rabbits and dogs, ET-A inhibition
blocks the vasoconstricting effects of exogenous ET-1 [59, 121-123], while, in dogs,
administration of an ET-B agonist causes vasodilatation [124] and ET-A inhibition
unmasks a presumably ET-B mediated vasodilatation in response to ET-1 [123].
Conversely, in rats there is some evidence to support ETB as well as ETA receptor
mediated renal vasoconstriction. ET-B agonist administration has been shown to
causes renal vasoconstriction [125] and combined ETA/B inhibition to abolish
whereas ETA receptor blockade only attenuate ET-1 induced vasoconstriction [126,
127],
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Studies of intrarenal changes in blood flow suggest that the observed cortical
vasoconstriction is mediated by ETA receptors [115, 116] whereas the medullary
vasodilatation is ETB receptor mediated and NO dependent [115, 117].
In respect of tubular functions, the highest concentrations of ET-1 are found in the
medulla. [128, 129], and there is now a substantial body of evidence supporting a role
for ET-1 in the renal regulation of volume homeostasis. ET-1 is produced by inner
medullary collecting duct cells (IMCD) where it inhibits the AVP stimulated retention
of water [80], and extra-cellular sodium concentrations may regulate IMCD ET-1
production [108], Additionally, the ETB receptor appears to have a natriuretic role at
least in animals. ET-1, acting via ETB and NO can inhibit chloride transport, thus
promoting natriuresis, in the medullary thick ascending limb of Henle [130, 131].
Additionally, in vitro low dose picomolar concentrations ET-1, binding to ETB
receptors, will activate amiloride-sensitive sodium channels in distal tubular cells,
though higher, nanomolar doses inhibit this channel by a non-ETB receptor dependent
mechanism [132], In vivo, dogs subjected to high-grade ETA blockade demonstrate a
vasodilatation and natriuresis in response to administration of exogenous low dose ET-
1 presumed to be an unmasking of an ETB receptor effect [123] and ETB receptor
blockade shifts the pressure diuresis and natriuresis response to the right in rats (ie. a
greater renal perfusion pressure is needed to excrete the same salt and water) [133],
Finally, ETB knockout mice, and ETB antagonist treated rats, develop a sodium
dependent hypertension [134, 135], and collecting duct-specific ET-1 knockout mice
develop salt retention and hypertension on a high salt diet [136].
In man, the effect of exogenous ET-1 on the renal vasculature is to cause
vasoconstriction, a fall in glomerular filtration rate (GFR), an increase in filtration
fraction and a profound retention of salt and water, probably as a consequence of the
renovascular changes rather than any direct ET-1 effect. [118-120], Within the human
kidney, ET-A receptors are localised to vascular smooth muscle, notably in the
glomeruli and vasa recta and arcuate arteries. ET-B receptors are more numerous (ET-B
to ET-A ratio 2:1) and more widespread with a high concentration in the collecting
26
system [11, 52]. The distribution of the receptors in man would suggest a vasoactive
role for ET-A receptors and a role in sodium and water handling for ET-B receptors.
Human studies comparing exogenous ET-1 and ET-3, as ET-A and ET-B receptor
agonists respectively, suggests that ET induced renal vasoconstriction is ET-A receptor
mediated [137]. However, renal vasoconstriction with ET-3 has also been
demonstrated, although at high dose, suggesting a possible constrictor role for ET-B
receptors [138], ET-A blockade can counter the effects of exogenously administered
ET-1 on renal blood flow (RBF) and GFR but has no effects alone on renal function
[120, 139-141] suggesting again that ETA receptors mediate ET-1 induced renal
vasoconstriction, but that endogenous ET-1 has little role in the maintenance of normal
renovascular tone. However, administration of the non-selective ETA/B receptor
antagonist SB209670 does produce a significant increase in RBF compared to placebo
[142], No studies in man to date have demonstrated significant effects on salt and water
homeostasis.
Thus, the paucity of work with antagonists in the human kidney has left significant
uncertainties regarding the importance of endogenous ET and the roles of the receptor
subtypes in the kidney in human physiology.
1.5.2 Pathophysiology
ET-1 has been widely implicated in renal disease, both in acute renal failure eg.
ischaemia induced renal injury, CyA nephrotoxicity and radiocontrast nephrotoxicity
[143-147] and progressive renal dysfunction [148].
Radiocontrast nephrotoxicity
As contrast induced nephrotoxicity is characterised by intense renal vasoconstriction,
ET-1 has been proposed as a potential mediator of this condition. Contrast media
increase ET-1 gene transcription in endothelial cells [149] and increases in both
plasma and urinary ET-1 have been observed after contrast media administration in
animals [149, 150] and in patients with CRF [151]. Additionally, non-selective ET
receptor antagonism abolishes contrast induced renal vasoconstriction in dogs [152],
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as does selective ETA receptor antagonism in rats [153]. Selective ETA receptor
antagonism also prevents contrast induced renal medullary hypoxia in rats [154].
However, in patients with CRF undergoing cardiac angiography, ET receptor
antagonism with SB 209670 was associated with a worse outcome than hydration
alone [155].
Ischaemic acute renal failure
Hypoxia can increase ET-1 production in renal tubules [156]. Increased ET-1
peptide expression is seen in the renal vasculature and in the cortical tubular
epithelium of kidneys after ischaemia reperfusion [157], Specifically, ET-1 increases
in renal medullary interstitial cells, damaged tubules at the corticomedullary junction
and peritubular capillaries surrounding these damaged tubules. An increase in renal
cortical and medullary ETA and cortical ETB receptors can also be demonstrated
within 24hrs of ischaemia, with changes being maximal at 8 days. By contrast,
medullary ETB receptors decrease [158],
ET receptor antagonists have ameliorated ischaemia-reperfusion injury in animal
models [147, 157, 159-162] and can improve the warm [163] and cold [164]
ischaemic injury that occurs during transplant retrieval. As selective ETB antagonists
are not protective in ischaemia-reperfusion [165], it appears that ET-1 mediated
vasoconstriction via the ETA receptor is the pathogenic mechanism abrogated. There
is also some evidence from knockout models that the ETB receptor is involved in the
renal recovery after ischaemia reperfusion [166], an observation supported by a
study demonstrating that non-selective ETA/B, but not selective ETA receptor
blockade during ischaemia reperfusion is associated with increased tubulointerstitial
fibrosis and proliferation at 6 months [167],
Cyclosporin nephrotoxicity
CyA is associated with both acute and chronic renal dysfunction, the former
probably consequent upon changes in renal haemodynamics, the latter associated
with irreversible structural changes. CyA is well documented as causing acute renal
vasoconstriction in animal models with a reduction in RBF and GFR. [168]. In vitro,
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CyA has been shown to increase gene transcription and secretion of ET-1 from
endothelial and smooth muscle cells [169-171]. CyA treatment increases ET-1 in
proximal tubules in rats [172] and CyA causes down regulation of ET receptors in
the kidney [173]. Increased activity of the ET system is also indicated by the ability
of ET receptor antagonism to attenuate CyA induced smooth muscle cell contraction
[171] and CyA induced renal vasoconstriction [145],
In vitro, ET receptor antagonism attenuates CyA induced smooth muscle cell
contraction [171]. In vivo, ET receptor antagonists can improve acute CyA induced
renal vasoconstriction in animal models [144, 145, 174-176], and a similar
attenuation of CyA induced fall in RBF, but not blood pressure rise, has been
demonstrated in healthy men with bosentan [177]. Plasma ET-1 concentrations [178]
and big ET-1 concentrations [179] are elevated in patients on CyA, but, as yet, no
studies with ET receptor antagonists have been performed in patients on chronic
treatment.
Chronic renal failure
Beside its haemodynamic effects ET-1 has mitogenic and pro-fibrotic properties that
may play a role in CRF. In support of a role for ET-1 in CRT, low renal mass models
are associated with increased production intra-renally, both in vascular and renal
tissues, of ET-1 with a positive correlation between ET-1 levels and
glomerulosclerosis [148, 180-182] apparent indirectly in increased urinary ET-1
excretion [180, 182], Also combined ETA and ETB blockade, drops the filtration
fraction whilst maintaining the GFR [134] raising the possibility that ET promotes
hyperfiltration with its consequent potential for renal injury.
ET receptor antagonists have been shown to prevent or attenuate the progression of
renal insufficiency in a rat remnant kidney model [182-185]. While non-selective
ETA/B receptor antagonists have produced positive results [183], the effect is less
than that seen with selective ETA receptor antagonism [185], and concomitant
administration of a selective ETB receptor antagonist abolishes the beneficial effects
of ETA receptor antagonism [184], A reduction in cortical ETB mRNA receptor
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expression by contrast with an increase in ETA receptor and ET-1 expression may
explain this differential response [184], and have implications for the use of non¬
selective ET receptor antagonists in CRT.
Human data supporting a role for ET-1 in CRT progression is more circumstantial.
In patients with autosomal dominant polycystic kidney disease, intra-renal ETA
mRNA is increased 5-10-fold compared to healthy controls [186]. Plasma and
urinary ET-1 concentrations in patients with nephrotic syndrome due to focal
segmental glomerulosclerosis are significantly higher than in normal controls [187]
and nephrotic patients who show a reduction in proteinuria with immunosuppressive
therapy also show reductions in urinary ET-1 excretion [188]. Urinary excretion of
ET-1 is doubled in patients with CRF compared to healthy controls. This occurs
alongside a reduction in prostaglandin U urinary metabolites suggesting that a
vasoconstrictor-dilator balance present in healthy kidneys is disrupted in CRF [189],
While the above points to the therapeutic potential of ET receptor antagonists in CRF,
to date only one interventional study has been performed in patients. Type I diabetics
with proteinuria but essentially normal renal function treated for 6 weeks with an ETA
receptor antagonist showed no alterations in RBF but did have a reduction in
proteinuria, a potentially renoprotective effect [190].
1.6 Endothelin and the cardiovascular system
1.6.1 Physiology
The importance of ET-1 in cardiovascular function is suggested by the actions of
exogenous ET-1. In respect of the vasculature, in vitro, activation of vascular smooth
muscle ETA receptors causes smooth muscle contraction and blood vessel
constriction, and the administration of exogenous ET-1 is associated with a sustained
increase in blood pressure and peripheral vascular resistance [59, 60, 119]. In
animals, this is preceded by a transient period of hypotension and vasodilatation [59,
60] mediated by ETB receptors [59].
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In man, forearm models in healthy volunteers have shown that ETA receptor
antagonism causes local vasodilatation [191-195] consistent an important role for
ET-1 in the maintenance of normal vascular tone via the ETA receptor. These
forearm findings are disputed [196, 197], but differences may be attributable to
concentrations of antagonists used [198], However, acute systemic studies in healthy
men [139, 199, 200] have failed to demonstrate a significant effect of ETA receptor
antagonism on basal haemodynamics. Similarly, while non-selective ETA/B receptor
antagonism with TAK-044 has been shown to cause vasodilatation and a reduction
in blood pressure in healthy volunteers [201], studies using the non-selective
antagonists bosentan [202], and SB 209670 [142] have demonstrated little effect on
systemic haemodynamics in healthy subjects. Thus, while the ETA receptor
mediates ET-1 induced vasoconstriction, the role of the ETA receptor in the
maintenance of vascular tone is not proven.
ETB receptors can be both vasodilator (endothelial) and vasoconstrictor (vascular
smooth muscle) in function. The balance of these two functions in health has yet to
be fully elucidated. Selective ETB receptor agonists can cause constriction in vitro
and increase blood pressure in vivo [203-205], but the relative importance of
vasoconstrictor ETB receptors appears to vary between species and vessel type
[206],
In man, ETB agonists cause constriction of forearm resistance and hand capacitance
vessels in vivo in healthy subjects [207, 208], suggesting that ETB receptors also
mediate ET-1 induced vasoconstriction. However, the vasoconstriction produced by
exogenous ET-1 can be abolished by ETA receptor blockade alone both locally [209],
and systemically [139]. Forearm studies have also demonstrated vasoconstriction in
response to ETB receptor blockade in healthy volunteers [194, 196] and an attenuation
of the vasodilator actions of ETA receptor blockade when ETB receptor antagonists
are concurrently administered [194], Similarly, systemic administration of ETB
receptor antagonists produces increases in systemic vascular resistance [210]
consistent with the net result of ETB receptor activation being vasodilatation in normal
physiology.
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The direct effects of ET-1 on the heart are probably species specific but a positive
inotropic response to ET-1 is seen in isolated cardiac tissue from rats and humans [211,
212], and in in vivo models where coronary vasoconstriction is countered with a
vasodilator [213]. The integrated haemodynamic response is, however, much more
complicated. ET-1 associated increased peripheral vascular resistance and blood
pressure produce reflex reductions in HR and cardiac output and coronary
vasoconstriction can cause myocardial ischaemia and cardiodepression.
1.6.2 Pathophysiology
1.6.2a Hypertension
With respect to pathophysiology, in addition to its haemodynamic actions,
exogenous ET-1 has been demonstrated in vitro to be mitogenic, thus causing
vascular remodelling and cell proliferation, and causes renal sodium retention [118],
features of hypertension. Production of ET-1 is increased in some (such as the Dahl
salt-sensitive and the stroke-prone spontaneously hypertensive rat), but not all rat
models of hypertension. Those models where ET-1 production is increased (mostly,
but not exclusively salt-dependent types) are associated with increased vascular
growth and a response to both selective and non-selective ET receptor antagonists.
This response comprises not only a modest reduction in blood pressure but also a
marked regression of vascular growth [214]. Altered intrarenal ET-1 production may
contribute to essential hypertension. Animal studies indicate that tubular ET-1 has an
important role in the physiological regulation of sodium excretion and volume status
and hence blood pressure. Knockout mice with no collecting duct ET-1 retained
sodium and developed salt sensitive hypertension [136] and ET-1 produced by
IMCD also inhibits the AVP stimulated retention of water [80]. Urinary ET-1
excretion is reduced in hypertensives compared to normal controls suggesting that
either renal ET-1 synthesis is reduced or breakdown is enhanced [215, 216], Hence
ET nephron production or handling may be deranged in essential hypertension, there
may be inappropriate sodium and water retention aiding the development or
maintenance of hypertension. Spontaneously hypertensive rats provide an
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experimental model of this in that they have reduced medullary ET levels after the
development of hypertension [217],
In man, elevated plasma ET concentrations are found in hypertension, though this is
not consistent [218], These high concentrations would appear, mostly, to be a feature
of severe hypertension or indicative of the presence of complications or co-existing
disease. Prepro ET-1 and ECE mRNA is increased in the vascular smooth muscle
cells of hypertensive patients [219], and there is also evidence to suggest that
endothelial function, specifically endothelium-dependent vascular relaxation, is
impaired both in hypertension, and in groups at risk of hypertension [220, 221].
Forearm studies with ETA and ETB receptor antagonism suggest increased vascular
ET activity in patients with essential hypertension compared to normotensive
controls, (though this has not been confirmed by other groups [222]) and a greater
response to non-selective antagonism compared to selective ETA antagonism [196,
223], suggestive of a possible increase in the importance of vascular smooth muscle
vasoconstrictor ETB receptors in disease.
To date, one major study has examined the anti-hypertensive effects of ET receptor
antagonism in man. In 293 hypertensive patients, bosentan at a dose of 500 to 2000
mg/day for 4 weeks produced a reduction in blood pressure equivalent to that with
20 mg of enalapril [224]. This reduction was achieved without a reflex increase in
activity of the sympathetic nervous system (as measured by plasma NE levels and
HR) or renin-angiotensin system. Further confirmatory work is needed but, given the
number of different anti-hypertensive drugs already available, a new class of drug
would have to demonstrate greater efficacy, a better side-effect profile, or actions
additional to its blood pressure lowering abilities. It is here that potential benefits in
terms of reduction in long-term structural changes in the blood vessel (vascular
hypertrophy or atherogenesis) or myocardium, an amelioration in endothelial
dysfunction, or a beneficial effect on salt and water balance, might accrue.
Hypertensive sub-groups such as salt sensitive patients, or black hypertensives (with
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higher plasma ET levels and impaired endothelium-dependent relaxation [221, 223,
225]) might potentially be targeted.
Chronic renal failure and hypertension
Hypertension in CRF is a major cause of morbidity and mortality. ET-1 has been
implicated as a mediator of this hypertension by a number of mechanisms. Firstly, as
a consequence of reduced renal clearance, plasma ET concentrations are certainly
consistently elevated in CRF [216, 226-228], The effect of exogenous ET-1 on the
renal vasculature is to cause vasoconstriction (which will activate the renin-
angiotensin system) and profound salt and water retention, both having the potential
to raise blood pressure [118]. It is not proven yet whether the elevated concentrations
of ET-1 seen in CRF represent biologically or just immunologically competent
peptides but in an animal model where exogenous ET-1 was administered to
bilaterally nephrectomised rats, there was a prolonged rise in blood pressure
compared to sham-operated rats associated with an increased plasma half-life of ET-
1 [229] suggesting that there is potential for elevated plasma ET concentrations to
cause hypertension.
Secondly, renal ET-1 production [181] and urinary excretion [216] are increased in
CRF. Additionally, in experimental nephritis associated with mesangial proliferation,
the renal vasculature is more sensitive to the constricting effects of ET than in
normal kidneys [230] hence an amplification of the renovascular effects of ET-1
could be envisaged in CRF, an effect that could be exacerbated by the higher plasma
ET concentrations due to reduced renal clearance. ETB receptors appear to be
important in protecting against hypertension in CRF. In a 5/6 nephrectomy remnant
kidney model of CRF, ETB receptor deficient rats have higher renal ET-1 content, a




Recombinant human erythropoietin (EPO) is widely used to improve the haematocrit
of patients with CRF and is associated with a rise in blood pressure [232, 233], In
vitro, EPO has been shown to increase production of ET-1 from endothelial cells
[234]. In transgenic mice overproducing EPO, increasing haematocrit to 80% is
associated with increased ET-1 mRNA levels in aorta, liver, heart, and kidney,
despite systemic vasodilatation [235]. In man, intra-arterial infusion of ET-1 causes
less forearm vasoconstriction after EPO therapy than before [233]. If plasma ET
were to be increased by EPO therapy, this might cause a down-regulation in
receptors and thus a reduced response to exogenous ET. Thus a link between EPO
associated hypertension and plasma ET has been sought.
Patient studies, however, are again conflicting. Some do not show an elevation in
plasma ET after EPO treatment [233, 236, 237] but in two studies, chronic
administration was associated with an eventual rise in plasma ET concentration,
correlating additionally with blood pressure [232, 238].
Atherosclerotic renal artery stenosis (ARAS)
Lerman et.al. [239] surveyed patients with symptomatic atherosclerosis and found a
significant correlation with plasma ET levels and the number of sites affected by
atherosclerosis. More recently, ET-1 mRNA and ET-1 have been demonstrated not
only in endothelial cells but also in cell rich areas of atherosclerotic plaques
particularly foamy macrophages [240, 241]. Mechanical injury to vascular
endothelium with a balloon angioplasty catheter has been shown to cause
accumulation of ET within the injured vessel in animal studies and occlusion during
angioplasty procedures released ET distally in human coronary arteries in vivo [241,
242]. Similarly, after aortic cross-clamping for atheromatous aortic aneurysm repair,
increased levels of plasma ET have been observed [243].
In ARAS, atherosclerosis and ischaemia co-exist; the supplying vessel to the kidney
will be atheromatous and the kidney ischaemic because of the stenosis. Thus, the
possibility of a role for ET in the secondary hypertension of ARAS arises, a theory
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supported by the observation that, in a rat model, ET antagonism will attenuate the
rise in blood pressure that occurs after single renal artery clipping [244].
The elevation of plasma ET does not need to be systemic; an elevation in the post¬
stenotic renal vessels might suffice to have a sodium retaining effect via renal
vasoconstriction that will generate hypertension, but one might expect to see changes
in renal vein ET levels. Unfortunately, while some studies in man have shown at
least a trend towards higher plasma ET concentrations in ARAS and an elevated
renal vein ET ratio ( [Renal vein ET - inferior vena cava (IVC) ET] / IVC ET ) on
the stenotic side [245-247], others cannot demonstrate any significant difference in
either systemic or renal vein ET concentrations in ARAS compared to essential
hypertension or normal controls [248, 249], Given the local nature of ET activity,
receptor antagonist studies in man are required to establish a role for ET here;
plasma ET probably does not have a role in diagnosis or prognosis ofARAS.
Pregnancy induced hypertension (PIH) and pre-eclampsia (PET)
With a few exceptions [250-252], plasma ET has repeatedly been demonstrated to be
elevated in PIH/PET when compared to normal pregnancies of similar gestational
age and to pregnant patients with pre-existing hypertension, the latter suggesting that
the increased plasma ET is not due to a blood pressure effect per se [253-260] Also,
while the elevated plasma ET concentrations do correlate negatively with creatinine
clearance, they are probably not simply due to reduced renal clearance consequent
upon renal dysfunction as elevated plasma ET concentrations are seen in PIH
patients with normal renal function [261],
However, though elevated ET levels may correspond to disease severity, with a
positive correlation between plasma ET and serum urate levels [255], and return to
normal after parturition [253, 257-259] no clear relationship between ET levels and
blood pressure has been demonstrated [256, 257]. PET is a disease characterised by
vascular endothelial damage and thus the elevated ET levels might simply be a
marker of generalised endothelial injury. However, increased ET-1 mRNA has been
demonstrated in the placental villous tissue of pre-eclamptic pregnancies suggesting
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an increased local production [262]. This could conceivably contribute to local blood
flow redistribution and thus the placental ischaemia central to the pathogenesis of
PET. A significant negative correlation exists between plasma ET levels and birth
weight, low birth weight, in this respect, being a response to placental ischaemia
[260, 263]. Thus, in respect of the hypertension of PET, the role of ET may be at the
level of the placenta effecting a rise in systemic blood pressure by more general
secondary mechanisms. Plasma ET does, however, appear to be a potentially useful
correlate of disease severity in this condition.
Pulmonary hypertension (PHT)
ET-1 is elevated in experimental models of PHT [264] and in man, possibly
consequent upon increased pulmonary production as the pulmonary venous
concentration of ET-1 exceeds the arterial concentration [265], Also, tissue levels of
mRNA for ET-1 appear to correlate with the pulmonary vascular resistance [266],
Thus PHT, a disease characterised by endothelial injury, vascular smooth muscle cell
proliferation and pulmonary vasoconstriction, is another potential target for ET
receptor antagonists.
Non-selective and selective ET receptor antagonism are both able to prevent NG-
monomethyl-L-arginine (L-NMMA) induced pulmonary vasoconstriction in a rat
monocrotaline model of PHT [264], The lack of effect of ETB antagonism suggests
this is an ETA effect. In a pig hypoxic model, again, selective ETA and non¬
selective receptor antagonists were equally effective in countering hypoxia induced
increases in pulmonary artery pressure with ETB selective drugs having no effect
[267].
Consistent with these animal studies, two recent studies in 32 [268] and 213 patients
[269] with PHT treated with bosentan over 12-16 weeks produced a clear
improvement in clinical status. Similar initial encouraging results have been seen
with the ETA receptor antagonist sitaxentan [270].
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Systemic sclerosis
Systemic sclerosis is a disease characterised by vascular injury, fibrosis and,
occasionally, malignant phase hypertension (hypertensive renal crisis) or pulmonary
hypertension. While plasma levels of ET-1 are elevated in diffuse disease compared
to limited cutaneous disease, there is no further rise in plasma levels in the subset of
patients with diffuse disease who have hypertensive renal crisis or PHT [271, 272]
suggesting that ET is not the trigger provoking transformation of the disease into
these phases, nor is plasma ET a useful marker of the impending transformation. In
vitro work has shown, however, that stimulated alveolar macrophages from
scleroderma patients secrete higher amounts of ET-1 and big ET-1 than normal
controls [273] and that there is a down regulation of ETA receptors in scleroderma
fibroblasts [274]. ET is a powerful fibroblast and smooth muscle cell mitogen and its
role systemic sclerosis may be a more central one in the pathogenesis of the disease
with the elevated plasma levels representing an overproduction and subsequent
overspill of this fibrotic mediator. Indeed, increased levels of ET-1 receptors have
been demonstrated in scleroderma lung tissue, localised to the alveolar epithelium
and the pulmonary interstitium, composed ofmainly fibroblastic cells [275].
Additionally, the recent trials in PHT included patients with systemic sclerosis [268,
269], demonstrating clinical improvement in this group.
1.6.2b Congestive Heart Failure (CHF)
There is considerable evidence for a role of ET-1 in CHF. Experimentally, ET-1
causes hypertrophy of cardiac myocytes [276] and has a direct toxic effect on these
cells [277], In animal models of CHF, increased cardiac and pulmonary ET-1
synthesis has been documented [278-281]; In a Dahl salt-sensitive hypertensive rat
model, the initial compensated left ventricular hypertrophy (LVH) was not
associated with an increase in cardiac ET-1 but a five fold increase was noted after
progression to the stage of left ventricular (LV) dilatation and global hypokinesis
[282], ETA receptors are more numerous than ETB receptors in both the normal and
failing heart, but there may be an upregulation of ETA receptors in the failing heart
[212, 278] suggesting that ETA receptors may be the major therapeutic target. As
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with coronary artery disease, however, some evidence points toward the
enhancement of vascular smooth muscle ETB mediated vasoconstriction in CHF
[283-285]. Also, although an attenuation ofmyocyte contractility in response to ET-
1 in cells from CHF animals and humans has been demonstrated [212, 286, 287],
there is some evidence that endogenous ET-1 is involved in the maintenance of
cardiac function in CHF [278], making cautious blockade of the ET system
necessary.
Animal models of CHF have shown substantially improved survival with both
selective ETA and non-selective ETA/B receptor antagonists. In CHF rats (coronary
artery ligation model) although acute ETA receptor blockade with BQ-123 reduced
myocardial contractility [279], long term treatment resulted in a 90% survival rate,
compared to 40% for the non-treated animals [278]. This improved survival was
associated with an amelioration of LV dysfunction and prevention of ventricular
remodelling. Treatment with the non-selective receptor antagonist bosentan for 9
months in a coronary artery ligation model of CHF resulted in beneficial alterations
in haemodynamics, cardiac geometry and function, and an 18% increase in survival
in the treated group [288], In the Dahl salt-sensitive hypertensive model of CHF,
chronic treatment with bosentan, started at the stage of compensated LVH, did not
alter LV mass but improved survival by 36% [282]. Of note, in a pacing CHF model,
chronic (6 weeks) non-selective receptor antagonism also increased coronary sinus
NO concentrations and improved endothelium-dependent relaxation in coronary
arteries [289].
In man, the increase in circulating big ET-1 or ET-1 seen in patients with CHF
correlates with the severity of symptoms and with prognosis [290, 291]. A series of
trials point towards potential usefulness of ET receptor antagonists in this condition
(Table 1.3), though it is unclear whether selective or non-selective receptor
antagonism would offer the greatest benefit.
Initial studies with the non-selective ET receptor antagonist bosentan reported
marked haemodynamic benefits both acutely and in the short term (2 weeks) [292,
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293]. On the basis of these results, larger, longer-term trials have been undertaken
with bosentan. The REACH study (370 patients followed for 6 months) was
terminated early because of asymptomatic, reversible increases in hepatic
transaminases, but reported improvements in symptoms, and reduced
hospitalisations, in the treatment group in those completing the 6 month protocol
[294]. However, in >1500 patients enrolled into the ENABLE study, bosentan
conferred an early risk of worsening heart failure [295]. Acute studies with the
combined ETA/B receptor antagonist tezosentan suggest that a much lower dose is
required than originally to achieve benefit without significant side-effects [296-298].
The possible theoretical benefits of selective ETA antagonism in CHF have been
explored in small acute studies. BQ-123 [299] and TBC 11251 [300] have produced
significant systemic and pulmonary haemodynamic benefits respectively. Acute ETB
receptor antagonism with BQ-788, caused systemic vasoconstriction in CHF
patients, an effect reversed by the addition of BQ-123, suggesting that ETB receptors
contribute to vasodilator tone in CHF [301], The HEAT study demonstrated for the
first time in a large patient population that 3 weeks of selective ETA receptor
blockade improved CI in patients with CHF [302]. Larger, longer-term studies with
ETA receptors have not, however, confirmed this potential. In a 24 week study,
darusentan did not improve cardiac remodelling, clinical symptoms or outcome
[303],
1.6.2c Coronary Artery Disease (CAD)
Ischaemia and myocardial infarction
Inducing coronary ischaemia in CAD patients results in a significant release of ET-1
of cardiac origin [304], Plasma ET-1 concentrations have been shown to be high in
CAD, particularly in patients with myocardial infarction or coronary vasospasm
[305-308], and elevations of plasma ET-1 and big ET-1 in unstable angina and after
myocardial infarction are correlated with a worse prognosis [309, 310] suggesting
that an activated ET system may contribute to a poor outcome.
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Both ETA and ETB receptors in the coronary circulation contribute to
vasoconstriction [205, 311] and in isolated porcine and canine coronary arteries,
TAK-044 inhibits ET-1 induced coronary vasoconstriction to a greater extent than
BQ-123 [311]. These data might suggest that non-selective receptor blockade would
be more appropriate than selective. In man, acute administration of the non-selective
receptor antagonist bosentan to patients with CAD resulted in an increase in vessel
diameter in coronary epicardial arteries, that was not further augmented by nitrates.
This effect was, however, only clear in normal or mildly diseased arteries and was
shown to correlate inversely with plasma LDL-cholesterol levels [312],
With respect to myocardial infarction, both ETA receptor and non-selective ETA/B
receptor antagonists have been shown to reduce infarct size in coronary ligation
models [313, 314], Though these animal studies are promising, work on man in this
respect has not yet been published.
Atherosclerosis
Plasma ET-1 concentrations are elevated in patients with atherosclerosis [239] and
increased ET-1 had been demonstrated in atherosclerotic lesions [315] and
throughout the vessel walls of patients with CAD [219] suggesting upregulation of
the ET system in atherosclerosis.
In hypercholesterolaemic hamsters, ETA receptor inhibition decreases the
progression of atherosclerosis mainly by reducing the number and size of
macrophage-foam cells [316]. In addition, apolipoprotein E-deficient mice,
genetically susceptible to severe atheroma and endothelial dysfunction, are protected
from atherosclerosis when treated with ETA receptor antagonists and show an
increase in NO-mediated endothelium-dependent relaxation [317]. Similarly,
hypercholesterolaemic pigs treated with chronic ET receptor antagonists, both
selective and non-selective, have improved coronary vascular function [318], In
respect of the failure of bosentan to significantly vasodilate severely diseased
coronary arteries in man [312], it is possible that the lack of effect may relate to
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greater endothelial dysfunction and that this might be respond to longer term ET
receptor antagonism.
Post-angioplasty restenosis
ET-1 is known to have a mitogenic effect on vascular smooth muscle cells in vitro
[319, 320], In animal studies, expression ofmRNA for all of the components of the
ET system is increased at balloon angioplasty sites [321], and intra-arterial
administration of ET-1 post-angioplasty increases neointima formation in vivo [322].
In humans, an increase in plasma ET-1 concentration is seen distal to the angioplasty
site correlating with the duration and pressure of the balloon inflation [241, 323]. In
animals, non-selective receptor antagonism with bosentan [324], SB 209670 [322,
325] or its analogue SB 217242 [326] reduces neointima formation after endothelial
injury by balloon angioplasty whereas ETA receptor antagonism alone with BQ-123
is ineffective [325], This may not indicate a need for combined receptor antagonism,
however, as ETA receptor blockade with the potent, highly selective, oral agent
ABT-627 does reduce restenosis [327]. Thus, targeting restenosis for prevention by
ET antagonists might seem appropriate, although many other potentially useful
agents have failed to fulfil their promise in this condition.
Arrhythmias
In animals, both combined receptor antagonism with SB 209670 and selective ETA
receptor antagonism with LU 135 252 reduced the incidence of arrhythmias induced
by ischaemia or exogenous ET-1 [328-330]. Of note, however, though BQ-123 did
reduce ischaemic arrhythmias in rats at a low dose, a high dose increased mortality,
due to an increase in refractory ventricular fibrillation [331].
1.7 Summary
ET receptor antagonists have been, and continue to be, crucial experimental tools in
elucidating of the role of the ET system in renal and cardiovascular physiology and
pathophysiology. Few studies have yet been performed in man to clarify the role of
ET in renal function in health and disease, and on vascular function in chronic renal
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disease. With the increasing availability of oral antagonists, both selective and non¬
selective, a knowledge of the actions of ET and its receptors is crucial to fully
establish the clinical role of these drugs in renal and cardiovascular disease. If they
live up to their promise, ET receptor antagonists could offer a wide range of benefits
including a renoprotective effect, reduction of systemic and pulmonary blood
pressure, a reduction of cardiac pre- and after-load, an improvement in coronary
blood flow, and, in the longer term, a reduction in abnormal ventricular and vascular
remodelling, and atherosclerosis. Through these effects, they might be useful in the
management of CRF, hypertension, PHT, CAD and CHF.
1.8 Aims and Hypotheses
In a series of acute studies in healthy subjects and renal patients, this thesis explores
the role of ET-1 and its receptors on systemic haemodynamics and renal function in
health and renal disease.
Study 1: (Chapter 3) This study sought to clarify the role of ET-1 acting via the
ETA receptor in the maintenance of normal vascular tone, hypothesising that
previous systemic studies in healthy subjects with ET receptor antagonists have
failed to demonstrate a haemodynamic effect as the doses of antagonists used have
been insufficient to achieve significant ETA receptor blockade. The effect of
incremental doses ofETA receptor antagonists to plasma concentrations sufficient to
significantly block the ETA receptor was studied to ascertain a haemodynamic dose
response curve for ETA receptor blockade. The information from this study was then
used in the choice ofETA receptor antagonist dose in further studies.
Study 2: (Chapter 4) This study examined the interaction between angiotensin II
(ANG II) and ETA receptor antagonism, hypothesising that the acute effects ofANG
II would be mediated through the ETA receptor in healthy subjects.
Study 3: (Chapter 5) This study examined the effects of selective ETA and ETB,
and combined ETA/B receptor antagonism on systemic and renal haemodynamics
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and on renal tubular function in healthy subjects and patients with CRF. It explored
the role of ET-1 in the maintenance of systemic and renal vascular tone in health and
disease, and in renal tubular function. It also provided a direct comparison between
selective ETA and combined ETA/B receptor antagonism. The hypothesis was that
ETA receptor antagonism would produce vasodilatation, ETB receptor antagonism
would produce vasoconstriction, and the addition of ETB to ETA receptor
antagonism would attenuate the vasodilator effects of ETA blockade. It was also
hypothesised that, based on forearm studies, the systemic haemodynamic response to
ET receptor antagonism would be less in CRF patients compared to healthy controls,
and finally that ETA receptor blockade should promote ET-1 induced, ETB receptor
mediated natriuresis.
Study 4: (Chapter 6) This study examined the interaction between ET receptor
antagonism and angiotensin converting enzyme (ACE) inhibition in healthy subjects.
Based on animal data, the hypothesis was that there would be a synergism between
these two agents.
Study 5: (Chapter 7) This study explored the mechanism of the synergy observed
between ETA receptor antagonism and ACE inhibition in healthy subjects,
hypothesising that this synergism would be mediated through NO, and possibly
vasodilator prostaglandins.
Study 6: (Chapter 8) This study explored the actions of the ETB receptor by
examining the effects of exogenous ET-1 in the presence of ETA receptor
antagonism on systemic and renal haemodynamics and tubular function in healthy
volunteers. The hypothesis was that, with the ETA receptor blocked, ET-1 would
produce systemic and renal vasodilatation and natriuresis via the unblocked ETB
receptor.
Study 7: (Chapter 9) This study examined the influence of a high salt diet on the
effects of ETA receptor antagonism in healthy volunteers. The hypothesis was that,
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in individuals whose blood pressure exhibited a high degree of salt sensitivity, the
relative reduction in endothelial NO activity on a high salt diet would result in a
reduced systemic haemodynamic response to BQ-123 compared to salt-resistant
individuals.
Study 8: (Chapter 12) This study examined the effects of a single high dose of
CyA on systemic and renal haemodynamics and tubular function in healthy
volunteers. The purpose of this study was to establish a model of renal
vasoconstriction that could then be used to explore the effects of intervention with
ET receptor antagonists.
Study 9: (Chapter 13) This study sought to explain the systemic vasodilatation and
lack of renal effects of high dose CyA in healthy volunteers by examining the
differences in response to a standard dose of CyA in renal transplant patients
chronically on the drug compared with those nai've to it. The hypothesis was that
chronic exposure to CyA is required to produce the endothelial dysfunction, which






All studies were performed in the University of Edinburgh's Clinical Research
Centre except for two patient studies (Chapter 5), which were performed in
Monkland's Hospital, Airdrie, Lanarkshire, with the approval of the local research
ethics committees and the written informed consent of each subject. The
investigations conformed to the principles outlined in the Declaration of Helsinki.
All subjects abstained from alcohol, nicotine and caffeine-containing products for 24
hours, and had a light breakfast before attending on each study day. All studies were
carried out in a quiet, temperature-controlled room, at 22-24°C, with the subject
recumbent throughout, except when voiding urine.
Healthy subjects taking any medications in the previous 2 weeks were excluded from
the study. Patients continued taking their normal medication up to and including
each study day with the exception of diuretics, which they omitted that morning.
During renal clearance studies, (Chapter 5-13) subjects were asked to adhere to a
standard diet containing 150 mmol sodium for 3 days before each study.
2.1 Drug administration
2.1.1 Locally active doses - intra-arterial administration
The brachial artery of the non-dominant arm was cannulated under local anaesthesia
(1% lignocaine; Astra Pharmaceuticals, Stockholm, Sweden) with a 27 SWG steel
needle (Cooper's Needle Works, Birmingham, UK) attached to a 16G epidural
catheter (Portex Ltd, Hythe, Kent, UK), and patency was maintained by infusion of
physiological saline (0.9%; Baxter Healthcare Ltd, Thetford, UK) at 1 ml/min.
Saline was infused for 30 min prior to the infusion of ET-1.
2.1.2 Systemicaliy active doses - intravenous administration
For systemic intravenous administration, study drugs were infused via an 18 SWG
cannula sited in an antecubital vein. PAH and Inulin were diluted in dextrose (5%;
Baxter Healthcare Ltd, Thetford, UK) and infused intravenously at a constant rate of
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2 ml/min. All other drugs were dissolved in physiological saline and infused
intravenously at a constant rate of 1 ml/min. Saline was administered as placebo.
2.2 Drugs
2.2.1 Endothelin-1
ET-1 (Clinalfa, Laufelfingen, Switzerland) was used as a non-selective ET receptor
agonist. It is a 21 amino acid polypeptide that is highly selective for both the ETA
and the ETB receptor (IC50: ETA = 0.12 nM, ETB = 0.02 nM [96]) Its binding to its
receptors is non-competitive.
In forearm studies (Chapter 3), ET-1 was dissolved in saline 0.9% and infused at a
locally active dose of 5 pmol/min via the brachial artery for 90 min. This dose was
selected from previous studies showing that ET-1 at this dose causes slow onset
vasoconstriction of up to 40% in human resistance vessels [191].
In systemic studies (Chapter 8), it was infused at a dose of 2.5 ng/Kg/min for 60 min
[118, 332]. The systemic effects of this dose are minimal [118]. The renal
haemodynamic effects of this dose (-20% fall in RBF) return to baseline within 30
min of ceasing the infusion [118, 139] and are blocked by low dose BQ-123 [139],
2.2.2 BQ-123
BQ-123 (Clinalfa AG, Laufelfingen, Switzerland) was used as a selective ETA
receptor antagonist (Chapters 3 - 11). It is a synthetic derivative of BE 18257B, a
product of Streptomyces misakiensisis and is a cyclic pentapeptide that is highly
selective for the ETA receptor (IC50: ETA = 7.3 nM, ETB = 18 pM [93]). Studies
with radiolabelled BQ-123 demonstrate that it binds competitively to the ETA
receptor, achieving steady state within 7 minutes of injection and dissociates with a
half-life of 1.4 min [94]. It is extracted from the circulation by the hepatic anion
transport system [97], It does not inhibit the binding of ANG II, calcitonin gene-
related peptide or peptide YY to their respective receptors [93], and has been
specifically shown not to bind to ANG II receptors [333],
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In study 1 (Chapter 3), I sought to establish a dose response curve for BQ-123 in
healthy humans. Doses ranged from 100 - 3000 nmol min"1 for 15 min. The starting
dose was selected from a previous study investigating the local effects of BQ-123,
which suggested that 100 nmol min"1 is the threshold around which systemic effects
might be observed [191].
On the basis of this dose response curve, in subsequent studies (Chapter 4 - 11), a
dose of 100 nmol/min for 15 min was used as a threshold dose for systemic ETA
blockade, and 1000 nmol/min over 15 min as that achieving maximal haemodynamic
effects. The haemodynamic effects of 1000 nmol/min for 15 min are demonstrable
for ~2 hours after injection. BQ-123 is undetectable in the plasma 45 min after the
100 nmol/min dose and 150 min after the 1000 nmol/min dose.
2.2.3 BQ-788
BQ-788 (Clinalfa AG, Laufelfingen, Switzerland) was used as a selective ETB
receptor antagonist (Chapters 5, 6, 10). It is a linear tripeptide that is highly selective
for the ETB receptor (IC50: ETA = 280 nM, ETB = 1.2 nM [96]). It is specific, (it
does not inhibit the binding of ANG II, calcitonin gene-related peptide or peptide
YY to their respective receptors [96]), and is a competitive inhibitor of the ETB
receptor.
BQ-788 was infused at 30 and 300 nmol/min for 15 min, doses shown to be
haemodynamically active in a previous systemic dose-ranging study [210].
2.2.4 Angiotensin II
ANG II (Clinalfa AG, Laufelfingen, Switzerland) (Chapter 4) was administered in
ascending doses of 1, 3 and 6 ng/kg/min for 15 min at each dose. The doses were
chosen from previously published studies [334, 335], and pilot studies in the
department, to achieve a maximum increase in MAP of-20 mmHg.
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2.2.5 Noradrenaline
Noradrenaline (Sanofi Winthrop, Guildford, UK) (Chapter 4) ANG II (Clinalfa AG,
Laufelfmgen, Switzerland) was administered in ascending doses of 60, 120 and 210
ng/kg/min for 15 min at each dose as a control pressor agent. Doses of NE were
selected from a previously published study [336], and confirmed by pilot studies in
the department to give an equivalent pressor response to that achieved with the
chosen doses ofANG II.
2.2.6 Enalapril
Enalapril (Dexcel Pharma Ltd, Daventry, UK) used as an ACE inhibitor (Chapter 6 -
8). It is a non-sulphydryl derivative of the amino acids L-proline and L-alanine. It
reduces concentrations ANG II by inhibiting the conversion of ANG I to ANG II by
ACE. ACE is also identical to kininase II that breaks down bradykinin. Some of the
effects of ACE inhibitors may therefore be mediated by increased concentrations of
bradykinin.
After oral dosing, -60% of the dose of enalapril is absorbed, reaching peak plasma
concentrations at 1 hour. It has low ACE inhibitory activity but is hydrolysed by
liver esterases to form enalaprilat, the active drug (enalaprilat is poorly absorbed
from the GI tract). Enalaprilat reaches peak plasma concentrations -3-4 hours after
administration of enalapril [337] and has a half-life of -11 hours in the circulation.
Excretion is primarily renal, and consequently delayed in renal failure. Steady state
is achieved after 3-4 days administration in healthy volunteers [338],
Haemodynamically, enalapril causes an increase in arterial compliance, a reduction
in systemic vascular resistance and a reduction in blood pressure. In healthy
volunteers, RBF increases and renal vascular resistance falls without significant
changes in GFR. [338], Enalapril also produces a moderate increase in urinary
sodium excretion 6-10 hours after oral administration [339]. In terms of hormonal
effects, acutely, plasma renin activity increases while ANG II and aldosterone
concentrations are reduced [340].
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Plasma ACE inhibition is maximal between 2-10 hours after oral dosing, with 20 mg
producing 80-95% ACE inhibition [339, 341, 342], This ACE inhibition has been
shown to be sustained over extended periods of up to 6 months of chronic dosing
[338]. Elowever, while a single dose of enalapril will still produce substantial ACE
inhibition after 24 hours, ANG II concentrations have returned to baseline by this
time [340]. Maximal increases in urinary sodium excretion, and renal
haemodynamics do not occur until 72 hours of treatment [343].
Thus, I chose to use a dose of 20 mg twice daily for 5 days before each study
because 20 mg ensures maximal achievable ACE inhibition, twice daily dosing
ensures continued ANG II suppression, pre-treatment allows steady state to be
reached and maximal renal changes to develop, and pre treatment does not result in
an attenuation ofACE inhibition. The final dose of 20 mg was given at 0830 in each
study day. Baseline measurements are therefore 2.5 - 3.5 hrs after administration,
and the study measurements are made from 3.5 - 7.5 hr after administration. Thus,
ACE inhibition was maximal throughout the period under study.
2.2.7 L-NMMA
L-A^-monomethyl-arginine (L-NMMA) (Clinalfa AG, Laufelfingen, Switzerland)
was used as an inhibitor of nitric oxide synthase (NOS) activity (Chapter 7). It is a
specific substrate analogue that acts as a competitive inhibitor NOS in humans.
A dose of 3 mg/Kg over 5 min was used in the studies. Based on previous studies,
this dose is sufficient to cause a small transient increase in blood pressure (7-10%)
and decrease in RBF (-10%) with no adverse effects noted. After a 5 min infusion,
blood pressure returns to baseline by 30 min and RBF returns to baseline by 60 min.
The plasma half life of L-NMMA given in this form is 75 min [191, 193, 344].
2.2.8 Indomethacin
Indomethacin (Cox Pharmaceuticals, Devon, UK) is a cyclooxygenase (COX)
inhibitor that prevents prostaglandin formation (Chapter 7). It was administered as a
single 100 mg dose at study start. This is sufficient to significantly reduce urinary
prostaglandin formation [345]. Subjects were specifically instructed to eat breakfast
on each study day, therefore, it has not been given on an empty stomach. None of the
subjects recruited had dyspepsia or a history of peptic ulcer disease.
2.2.9 Slow sodium
Slow Sodium tablets (Novartis Pharmaceuticals, Frimley, UK), each containing 10
mmol of sodium, were used to supplement dietary sodium intake in high salt studies
(Chapter 9).
2.2.10 PAH
Para-aminohippurate sodium (PAH, Clinalfa AG) was used for the measurement of
renal plasma flow by standard clearance techniques [346] (Chapter 5-9, 12, 13). It
is an inert and non-toxic compound that is both filtered at the glomerulus and
actively secreted by the proximal tubules, reaching the kidney only via the blood
stream. The extraction by the kidneys in a single transit is not complete (the full
criteria for a marker of RBF by clearance) but about 80-90%, thus measurements are
quoted as "effective" renal plasma flow (ERPF). This extraction rate is not affected
by BQ-123, BQ-788 or ET-1 in man [141].
PAH was administered as a bolus loading dose of 0.4 g in 100 ml dextrose 5 over 15
min, and a maintenance infusion of 6.6 g/L at a rate of 2 ml/min. For subjects with a
calculated GFR <40 ml/min, doses were reduced by a third.
2.2.11 Inulin
Inutest (Fresenius Pharma, Austria GmbH) was used for the measurement ofGFR by
standard clearance techniques [346] (Chapter 5 - 10, 12, 13). Inulin is an inert and
non-toxic complex polyfructose with a molecular weight of 5,200 daltons. It is not
protein bound, is freely filtered at the glomerulus, is neither secreted not reabsorbed
within the tubules, nor metabolised within the kidney and hence fulfils the criteria
for the measurement of GFR by clearance measurements. Its problems with
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solubility have been overcome by the introduction of Sinistrin (Inutest) a related
polysaccharide with identical clearance.
Inutest was administered as a bolus loading dose of 3.5 g in 100 ml dextrose 5 over
15 min, and a maintenance infusion of 10 g/L at a rate of 2 ml/min. For subjects with
a calculated GFR <40 ml/min, doses were reduced by a third.
2.2.12 Cyclosporin
Cyclosporin Neoral (Novartis Pharmaceuticals, Frimley, UK) is a fungal peptide
whose main target is the T lymphocyte, producing immunosuppressive activity. It is
also known to have significant effects on blood pressure via actions on the
sympathetic nervous system and the vascular endothelium and smooth muscle cells.
To study its vascular effects, healthy subjects CyA liquid, 10 mg/kg, or placebo
(olive oil) administered in orange juice to disguise the taste (Chapter 12). This dose
was chosen from a previous study demonstrating an acute, but transient decline in
GFR after oral administration [347]. In patients, CyA was administered as a single
dose of 100 mg (Chapter 13). This dose was chosen to be in line with standard doses
taken by transplant patients on chronic therapy.
2.3 Haemodynamic measurements
2.3.1 Forearm blood flow
Blood flow was measured in both forearms by venous occlusion plethysmography
using mercury-in-silastic gauges [348] that were securely applied to the widest part
of each forearm. The hands were excluded from the circulation during each
measurement period by inflation of a wrist cuff to 220 mm Hg. Upper arm cuffs
were intermittently inflated to 40 mm Hg for 10 in every 15 sec to temporarily
prevent venous outflow from the forearm and thus obtain plethysmographic
recordings. Recordings of forearm blood flow were made repeatedly at 10 min
intervals over 3-minute periods. Voltage output from a dual-channel Vasculab SPG
16 strain gauge plethysmograph (Medasonics Inc) was transferred to a Macintosh
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personal computer (Performa 475, Apple Computer Inc, Cupertino, CA, USA) using
a MacLab analogue digital converter and Chart software (v. 3.2.8; both from AD
Instruments, Castle Hill, NSW, Australia). Calibration was achieved using the
internal standard of the Vasculab plethysmography units.
2.3.2 Blood pressure
Blood pressure was recorded in duplicate at each time-point using a well-validated
semi-automated non-invasive oscillometric sphygmomanometer (Takeda UA-751
sphygmomanometer, Takeda Medical Inc) [349]. Recordings were required to be
within 10 mmHg of each other (systolic and diastolic). If not, blood pressure was
repeated until two consecutive readings did fulfil these criteria. During forearm
studies (Chapter 3), blood pressure was recorded in the dominant arm (ie. not in the
arm with intra-arterial cannulation.)
2.3.3 Cardiac output and heart rate
Cardiac output (CO, L/min) and heart rate (HR, bpm) were recorded using a well
validated non-invasive bioimpedance technique (NCCOM3; BoMed Medical
Manufacturer Ltd, Irvine, California, USA) [350, 351]. This non-invasive technique
measures CO by transthoracic bioimpedance. A constant sinusoidal current is
applied through dual electrodes situated at the root of the neck bilaterally and to the
lateral aspect of the trunk at the level of the xiphisternum. These electrodes then
detect changes in bioimpedance related to the cardiac cycle and blood flow. CO is
estimated from the measures of bioimpedance by the Sramek-Bernstein formula,
adapted from the original formula of Kubicek [351]. HR is counted directly from
detection of the cardiac electrical cycle. Each reading is the average of 15
consecutive beats. Four such readings were recorded for each measurement of CI
and HR.
Bioimpedance is useful for the measurement of changes in CO in an individual in
acute interventional studies [352] and is best expressed as percentage change from
baseline [351]. However, bioimpedance derived CO does not correlate well with CO
measured by invasive methods. I have demonstrated, against thermodilution as a
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gold standard, that it is least accurate at high CO values or when the % change from
baseline is high. In these circumstances, it tends to underestimate the degree of
change. As such it produces conservative estimates of changes in CO (Fig 2.1).
Fig 2.1 Comparison of cardiac output measured by thermodilution and
bioimpedance




Data presented from a study performed in the Clinical Research Centre in patients with heart failure treated with
endothelin antagonists (Study by S. Leslie). Subjects had CO measured by thermodilution during right heart
catheterisation and by bioimpedance. Comparison of these two measures demonstrated good correlation over a
wide range of CO. Bioimpedance did, however, underestimate high CO values when compared to Swan Ganz
thermodilution measurements. A similar pattern was seen when change from baseline was compared. Again
bioimpedance underestimated large changes in CO. Thus, in providing a conservative esitmate, bioimpedance is
less likely to produce false positive results when examining changes in CO after vasoactive agents.
2.3.4 Clearance Studies
ERPF and GFR were measured by standard clearance techniques [346] (Chapter 5 -
10, 12, 13). On each study day, an 18 standard wire gauge (SWG) cannulae was sited
in an antecubital vein in each arm. Diuresis was induced by 500 ml 5% dextrose over
30 min through the left arm cannula. After 15 min, the loading doses of PAH &
inutest were administered through the same cannula. Thereafter, maintenance
infusions of PAH and inutest, and 5% dextrose at 260 ml/hr continued throughout
the study. Urine was collected by spontaneous voiding every 30 min. A two hour
period was allowed for water, inutest and PAH equilibration before baseline
measurements, made over two 30 min urine collection periods. Blood pressure, CO
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and HR were recorded every 15 min. At the mid-point of each 30 min collection
period, blood was sampled from the right antecubital cannula for PAH, inulin, and
haematocrit measurements.
2.4 Assays
At pre-specified time points, venous blood was collected via an 18 SWG cannula for
plasma measurements. Blood was collected into plain tubes (Sarstedt) for the
measurement of serum sodium, and into EDTA tubes (Sarstedt) for all other plasma
measurements. 20 ml aliquots of urine from each voiding were collected into plain
tubes for the urinary measurements. At pre-specified time points, 20ml aliquots of
urine were also collected into plain tubes containing 2.5ml of 50% acetic acid for the
measurement of urinary ET-1.
Haematocrit (Hct) was measured on whole blood. All other blood samples were
centrifuged immediately at 1000 g at 4°C for 20 min, and plasma and urine stored in
plain tubes at -80°C until assay.
2.4.1 Plasma and urinary inulin
Inulin was determined by spectrophotometry after hydrolysis to fructose. Plasma
samples were deproteinised with equal volumes of 6% perchloric acid and, after
centrifugation at 1000 g for 10 min, supernatant was decanted. Urine was diluted
1/20 with 3% perchloric acid. Resorcinol (1.5 g dissolved in 1 1 of ethanol) and
HCl/FeCb solution (7.5 mg FeCh dissolved in 1 1 of molar hydrochloric acid) were
added in a 6:6:1 ratio to the plasma/urine. The samples were then vortexed and
incubated at 80°C for 40 min. Inulin concentrations were then determined against
standard curves by absorption spectrophotometry at 480 nm.
2.4.2 Plasma and urinary PAH
PAH was determined by high performance liquid chromatography (HPLC) with
fluorescence detection. Plasma samples were deproteinised with equal volumes of
6% perchloric acid and, after centrifugation at 1000 g for 10 min, supernatant was
56
diluted by 1/40 with deionised water. Urine samples were diluted by 1/4000.
Dihydroxybenzylamine hydrobromide (DHBA) was used as an internal standard.
Samples were injected into the HPLC column. The HPLC system consisted of a
Waters 510 HPLC pump, WISP (Waters Intelligent Sample Processor) and
Spherisorb S5 ODS column (Waters Ltd, Watford, Herts. UK) with detection by an
LS-5 fluorometric detector (Perkin-Elmer Ltd, Beaconsfield, Bucks, UK), with
excitation and emission wavelengths of 280 nm and 360 nm respectively. The
mobile phase consisted of 0.1 molar citrate acetate buffer containing 100 mg/L
octane sulphonic acid.
2.4.3 BQ-123
BQ-123 concentrations in plasma were measured by HPLC with fluorescence
detection. One volume of plasma was precipitated with 4 volumes of ethanol,
ultracentrifuged at 4°C for 15 min at 10,000 g, and the resulting supernatant injected
into the HPLC column. The HPLC system consisted of a Waters 510 HPLC pump,
WISP (Waters Intelligent Sample Processor) and Spherisorb S5 ODS column
(Waters Ltd, Watford, Herts. UK) with detection by an LS-5 fluorometric detector
(Perkin-Elmer Ltd, Beaconsfield, Bucks, UK), with excitation and emission
wavelengths of 284 nm and 348 nm respectively. The mobile phase consisted of
60:40 acetonitrile: de-ionised water with tri-fluoroacetic acid at a concentration of
0.1%. The peptide TAK-044 was found to fluoresce at identical wavelengths to BQ-
123 and was eluted from the column with a retention time similar to but not identical
with BQ-123, allowing its separate measurement. Hence, TAK-044 was used as a
standard in this assay. Recovery of BQ-123 from plasma was found to be 107% and
the intra- and inter-assay variations were 5.8% and 9.6% respectively.
2.4.4 Haematocrit
Hct was measured using a Coulter counter.
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2.4.5 Hormone measurements
After extraction with acetic acid using Bond ElutTE columns (Varian, harbour City,
CA, USA), [353] plasma ET-1 and ANG II concentrations were determined by
standard radioimmunoassay (Peninsula Laboratories Europe, St Helens, UK), as
previously described [354-356]. Plasma renin activity (PRA) was measured under
standard conditions through the generation of ANG I as determined by
radioimmunoassay [357]. Plasma aldosterone concentrations were measured by
radioimmunoassay [358].
2.4.6 Serum ACE activity
Serum ACE activity was determined spectrophotometrically using a Sigma
Diagnostics kit (Sigma Diagnostics St Louis, US). ACE hydrolyses the synthetic
tripeptide N-[3-(2-furyl)acrylotl]-L-phenylalanylglygylglycine (FAPGG) to
furylacryloylphenylalanine (FAP). This conversion results in a decrease in
absorbance at 340 nm that can be calibrated against a standard sample to determine
ACE activity. One unit of ACE activity is defined as that amount of enzyme that will
catalyse the formation of one micromole of FAP from FAPGG per minute at 37°C.
[359]
2.4.7 Plasma and urinary sodium
Urinary and plasma sodium concentrations were measured by flame photometry.
Concentrations were determined against standard curves described by a quadratic
equation. Plasma samples were diluted by 1/100 and compared against a standard
curve ranging from 0-2 mmol/L. Urine samples were compared against a standard
curve ranging from 0-40 mmol/L. Concentrated urine samples were diluted into this
range as required.
2.4.8 Piasma and urinary osmolality




Urinary albumin concentrations were measured using a double antibody technique
(EURO/DPC Ltd, Llanberis, Gwynedd, UK) where 125I labelled albumin competes
with albumin in the sample for antibody sites. Separation of bound from free
albumin is then achieved with a second antibody and the antibody bound fraction
precipitated and radioactivity counted. Samples were compared against standard
curves ranging from 5-60 pg/ml. Concentrated urine samples were diluted into this
range as required. The assay has a detection limit of 0.3 pg/ml.
2.5 Data analysis
All results are expressed as mean ± standard error of the mean (SEM).
2.5.1 Forearm Blood Flow
Plethysmographic data listings were extracted from the chart data files and forearm
blood flows calculated for individual venous occlusion cuff inflations using a
template spreadsheet (Excel 4.0; Microsoft Ltd). As flow only stabilises after 60 sec
of wrist cuff inflation, recordings made in the first 60 sec were not used for analysis.
The last 5 flow recordings in each measurement period were calculated and averaged
for the infused and non-infused arms [360]. To reduce the variability of blood flow
data, the ratio of flows in the 2 arms was calculated for each time point, in effect
using the non-infused arm as a contemporaneous control for the active treatment arm
[348]. Forearm blood flow results are shown as the percentage change from basal
values in the ratio of blood flow between infused and non-infused arm. Data were
examined by repeated measures analysis of variance (ANOVA) and Bonferroni
correction was applied to examine significance at each time point. Statistical
significance was taken at the 5% level.
2.5.2 Systemic and Renal Data
Data were stored and analysed using the Microsoft Excel data analysis package
(Excel 5.0, Microsoft Ltd). Blood pressure at each time point was calculated as the
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mean of 2 recordings and represented as mean arterial pressure (MAP).
Biompedance data at each time point were calculated as the mean of four recordings,
each the average of 15 consecutive heart beats. Data were corrected using body
surface area to give cardiac index (CI) for direct comparison of subjects, and
systemic vascular resistance index (SVRI) derived from blood pressure and CI data
(Table 2.1). GFR and ERPF were calculated from inulin and PAH clearances
respectively. Effective renal blood flow (ERBF), effective renal vascular resistance
(ERVR) and effective filtration fraction (EFF) were derived from these indices
(Table 2.1). Urinary sodium excretion and fractional excretion were calculated from
plasma and urinary sodium and inulin concentration and urinary flow rates.
Demographic data are expressed as mean ± standard error of the mean (SEM) and
comparisons between groups examined by unpaired Student's /-tests. Baseline data
were calculated as the mean of the 2 time points immediately preceding
administration of the first study drug. Haemodynamic results are expressed as mean
± SEM placebo-corrected maximum (%) change from baseline. Statistical analysis
was performed on untransformed data. Responses were examined by repeated
measures analysis of variance (ANOVA) and Bonferroni correction was used to
assess significance at specific time points. Area under the curve was calculated as a
summary statistic of each curve and comparisons analysed by paired Student's /-




Mean Arterial Pressure dBP + (sBP-dBP) mmHg
(MAP) 3
Systemic Vascular Resistance Index MAP x 80 dyne.s /m2/cm5.
(SVRI) CI
Glomerular Filtration Rate Uln x UFR ml/min
(GFR) Pin
Effective Renal Plasma Flow UPAH xUFR ml/min
(ERPF) PPAH
Effective Renal Blood Flow ERPF ml/min
(ERBF) 1-Hct
Effective Renal Vascular Resistance MAP mmHg.min/L
(ERVR) ERBF
Effective Filtration Fraction GFR x 100%. %
(EFF) ERPF
Urinary Flow Rate Urinarv Volume ml/min
(UFR) Time of collection
Urinary Sodium Excretion UNa x UFR (ftmol/min)
(UNaV)
Fractional Excretion of Sodium UNa x Pin
(FeNa) PNa Uin
Free water clearance UFR x 11 - UOsm) ml/min
(FWC) POsm
dBP - diastolic blood pressure, sBP - systolic blood pressure, U - urine, P - plasma, In - Inulin, PAH -
para-amino hippuric acid, Hct - haematocrit, Na - sodium, Osm - osmolality
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Chapter 3
Investigation of the effects of systemic ETA
receptor antagonism in healthy volunteers
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3.1 Introduction
Local studies in human forearm resistance vessels using phosphoramidon, an ECE
inhibitor, and BQ-123, a selective ETA receptor antagonist, first demonstrated the
importance of ET-1 in maintaining basal resistance vessel tone, in large part through
an action on the ETA receptor [191]. These observations have since been confirmed
by others [192, 194], Responses in the forearm resistance vessels are usually
predictive of those in the systemic circulation [360], so these data suggested that
systemic ETA receptor antagonism would produce systemic vasodilatation.
However, acute systemic administration of the selective ETA antagonist, BQ-123,
was reported to have no effect on basal systemic haemodynamics [139, 199].
It is possible that a systemic haemodynamic effect of ETA receptor antagonism was
not seen in these studies because the doses of BQ-123 used provided insufficient
ETA receptor blockade to affect blood pressure. In addition, because healthy
subjects have a number of reflex mechanisms that serve to defend blood pressure, it
is possible that an important effect on systemic vascular resistance might have been
missed by measurement of blood pressure alone. This chapter therefore describes
two studies in healthy volunteers designed to address the issue of the role of the ETA
receptor in the maintenance of vascular tone in healthy human subjects. The first
study examines the haemodynamic effects of increasing doses of BQ-123, using
bioimpedance cardiography to allow measurement of SVRI, with the aim of
achieving a high degree of ETA selective receptor blockade. The second examines
whether haemodynamically active doses of BQ-123 would antagonise the response
to exogenous ET-1, by infusion of local doses of ET-1 into the forearm circulation,
after administration of BQ-123 systemically, and measuring responses using forearm
plethysmography.
3.2 Study design
3.2.1 Systemic haemcdynamic study
This was a double-blind, placebo-controlled, balanced 5-way crossover study in 5
subjects, investigating the responses to four doses of BQ-123 (100, 300, 1000 and
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3000 nmol/min for 15 min) and placebo. An ascending dose regimen was followed,
allowing safety and tolerability of lower doses to be assessed before proceeding.
Total doses of BQ-123 administered were 1.5, 4.5, 15 and 45 pmol (or 0.95, 2.84,
9.5 and 28.4 mg). The order of the placebo dose was randomly allocated so that each
subject received it on a different visit (Table 3.1). Each visit was separated by at
least 5 days. Subjects rested supine for 20 min, and baseline measures were then
made in the 30 min before study drug administration. Haemodynamic measurements
were made at 10 min intervals from 30 min pre-dose until 60 min post-dose, then at
30 min intervals until 2 h, then hourly until 4 h post-dose. Venous blood was
obtained at 5, 15 and 240 min after BQ-123 infusion for measurement of plasma ET-
1 and big ET-1. During the 300 and 1000 nmol/min phases, sub-aliquots of the
samples were used for plasma BQ-123 assay.
Table 3.1 Systemic haemodynamic study randomisation
Period 1 Period 2 Period 3 Period 4 Period 5
Volunteer I Placebo 100 nmol/min 300 nmol/min 1000 nmol/min 3000 nmol/min
Volunteer 2 100 nmol/min Placebo 300 nmol/min 1000 nmol/min 3000 nmol/min
Volunteer 3 100 nmol/min 300 nmol/min Placebo 1000 nmol/min 3000 nmol/min
Volunteer 4 100 nmol/min 300 nmol/min 1000 nmol/min Placebo 3000 nmol/min
Volunteer 5 100 nmol/min 300 nmol/min 1000 nmol/min 3000 nmol/min Placebo
Using MAP & SVRI measurements from a previous placebo-controlled study over 4
h [210], the study was calculated to have a power of -90% to detect a 15% change in
MAP and 20% change in SVRI (p=0.05) with 5 subjects.
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3.2.2 ET-1 challenge study
This was a double-blind, placebo-controlled, 3-way crossover study in 5 subjects (3
of whom participated in the systemic study), investigating the effects of intra-arterial
ET-1 on forearm blood flow (FBF), after treatment with either 300 or 1000
nmol/min of BQ-123 or placebo. After baseline infusion of saline for 30 min,
subjects received a 15 min intravenous infusion of BQ-123 (300 or 1000 nmol/min)
or placebo via a cannula in the right forearm, followed immediately by an intra¬
arterial infusion of ET-1 at a dose of 5 pmol/min for a total of 90 min via a left
brachial artery cannula. Recordings of FBF by venous occlusion plethysmography
were made repeatedly at 10 min intervals over 3-minute periods.
From FBF measurements in a previous study using ET-1 at 5 pmol/min [361], the
study was calculated to have a power of 99% to detect abolition of the
vasoconstriction response to ET-1 by BQ-123, and a power of -80% to detect a 66%
attenuation of this response (p=0.05) with 5 subjects.
3.3 Results
3.3.1 Systemic haemodynamic study
All 5 subjects (mean age 26 ± 2 yr, range 18-30 yr) completed all parts of the study.
No adverse effects of treatment were reported.
Plasma ET-1 and big ET-1
Baseline values of plasma ET-1 and big ET-1 concentrations ranged from 4.4 to 5.2
pg/ml and 25 to 42 pg/ml respectively. There were no significant differences
between baseline plasma ET-1 or big ET-1 concentrations in any phase of the study.
Neither ET-1 nor big ET-1 changed significantly following treatment with any dose
ofBQ-123 or placebo (Table 3.2 & 3.3).
Plasma BQ-123 concentrations
Plasma concentrations of BQ-123 were undetectable with both doses at baseline. For
300 nmol/min, mean plasma concentrations were 126 ± 11 nmol/1 at 5 min rising to
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174 ± 20 nmol/1 at 15 min. For 1000 nmol/min, they were 424 ± 33 nmol/1 and 510 ±
64 nmol/1 respectively (ETA receptor IC50 7.3 nM; ETB receptor IC50 18 |±M) [93].
BQ-123 was no longer detectable in the plasma by 4 h at either dose.
Table 3.2 Plasma concentrations of ET-1 (pg/ml) after administration of
BQ-123
BQ-123 Placebo 100 300 1000 3000
(nmol/min)
4.91 ±0.69 4.57 ±0.48 5.23 ± 0.52 4.43 ± 0.28 2.88 ±0.10
Baseline
5 min 5.16 ±0.74 4.08 ± 0.39 5.29 ±0.49 6.07 ±0.49 4.08 ± 0.49
15 min 5.81 ±0.50 3.95 ± 0.65 5.49 ± 0.95 5.56 ±0.95 4.03 ± 0.63
240 min 5.77 ±0.75 4.44 ± 0.29 5.88 ± 0.65 5.80 ±0.65 4.22 ±0.41
Table 3.3 Plasma concentrations of big ET-1 (pg/ml) after
administration of BQ-123
BQ-123 Placebo 100 300 1000 3000
(nmol/min)
Baseline 45.7 ± 14.4 37.8 ± 7.4 40.2 ± 6.5 57.5 ±9.1 26.6 ± 6.7
5 min 49.3 ±10.7 29.2 ±1.9 38.5 ± 6.3 51.9 ± 8.5 34.7 ± 0.6
15 min 66.2 ± 14.4 26.0 ± 2.4 49.5 ±14.1 51.4 ±9.4 30.7 ±3.1
240 min 38.8 ±7.1 35.8 ± 5.2 48.4 ±6.0 51.5 ±9.2 30.1 ±4.6
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Haemodynamic parameters
Baseline measurements for haemodynamic parameters were similar during all
treatment periods (Table 3.4). After BQ-123 administration, changes were apparent
in all parameters by the first measurement at 10 min. Maximal changes occurred
between 40 and 60 min, with a prolonged effect occurring at the 2 highest doses,
excepting changes ofHR, which were maximal at 15 min.
Table 3.4 Baseline haemodynamic measurements
BQ-123 Placebo 100 300 1000 3000 ANOVA
(nmol/min) baseline
data
MAP 78.9 ±1.5 79.2 ± 2.3 80.8±3.5 78.2 ±2.1 78.6±3.3 p=0.96
(mmHg)
SVRI 1816 ± 104 1752 ± 136 1774 ±144 1800 ±232 1880 ±176 p=0.98
(dyne.sec/cm5/m2)
CI 3.52 ±0.21 3.69 ±0.25 3.80 ±0.31 3.63 ± 0.38 3.45 ± 0.35 p=0.89
(L/min/m2)
HR 64.2 ± 6.6 57.1 ± 5.2 63.9 ±6.6 54.5 ±4.8 57.3 ± 5.9 p=0.69
(bpm)
MAP decreased in a dose-dependent fashion. This was statistically significant at 300,
1000 and 3000 nmol/min BQ-123 (300 nmol/min: ANOVA p<0.05 vs. placebo,
1000 & 3000 nmol/min: p<0.01 vs. placebo) with a maximum mean placebo-
corrected reduction of 12.4 ± 3.5% after 3000 nmol/min. Placebo corrected SVRI
also decreased in a dose dependent fashion. This decrease was significant for all
doses of BQ-123 (ANOVA p<0.01 vs. placebo). The maximum decrease in SVRI
(23.3 ± 4.3%) occurred with 3000 nmol/min of BQ-123 (Table 3.5 & Fig 3.1). CI
and HR increased significantly at all doses (p<0.01; ANOVA, Table 3.5 & Fig 3.1).
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Table 3.5 Systemic haemodynamic responses to BQ-123
BQ-123 100 300 1000 3000
(nmol/min)
MAP
-4.8 ± 2.6% -6.8 ± 3.6% -8.2 ± 3.1%f -12.4±3.5%f




-20.6± 3.0% -22.7 ± 5.2%+ 23.3 ± 4.3%+
(dyne.sec/cm5/m2) (-312 ± 168) (-360 ± 56) (-432 ± 152) (-448 ± 208)
CI
14.3 ±8.9% 13.0 ± 2.2%* 17.9 ± 5.7%t 12.7 ± 1.6%
(L/min/m2) (0.49 ± 0.32) (0.47 ± 0.07) (0.59 ±0.16) (0.43 ± 0.04)
HR
23.8 ± 13.4%+ 11,8± 4.4% 20.0 ± 5.9%f
*
18.7 ±6.8%
(bpm) (12.1 ±6.5) (6.8 ± 2.4) (11.6 ±3.0) (10.7± 3.1)
*
Results given are maximum placebo corrected percentage change from baseline ± SEM p<0.05 vs.
t
placebo, p<0.01 vs. placebo: ANOVA + Bonferroni correction
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3.3.2 ET-1 challenge study
Subjects who received placebo followed by local infusion of ET-1 developed a slow
onset progressive vasoconstriction in the infused arm compared to the non-infused
arm (maximum reduction in FBF: -48 ± 10% at 90 min). This response was
attenuated by 300 nmol/min BQ-123 (-27 ± 8% at 90 min p>0.5 vs. placebo) and
abolished by 1000 nmol/min BQ-123 (-8% ± 3%, p<0.01 vs. placebo, Fig 3.2).
Figure 3.2 Response in forearm blood flow to intra-arterial ET-1, when




























This study demonstrates that, in healthy humans, BQ-123 causes substantial
systemic vasodilatation, associated with a small but significant reduction in arterial
blood pressure. A dose-dependent effect was observed, with little additional effect
occurring above 1000 nmol/min. This work confirms the importance of the ET
system, and of the vascular ETA receptor in controlling vascular tone and blood
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pressure [36], and is in accord with the results of previous local forearm infusion
studies [191, 192, 194],
There are several reasons for concluding that the effects on vascular tone and blood
pressure are mediated by the ETA receptor. Measured BQ-123 concentrations in
plasma at both 300 and 1000 nmol/min were substantially greater than the IC50 for
BQ-123 at the ETA receptor. Even so, at 1000 nmol/min the plasma concentration of
510 nmol 1" , was more than 35 fold lower than the IC50 for the ETB receptor (18
pM), consistent with effective but selective ETA receptor blockade [93], In addition,
there is a substantial body of evidence that the ETB receptor is a clearance receptor
for ET-1 [362-364] and that agents that block the ETB receptor in vivo cause
increases in plasma ET-1 concentrations [201, 202, 210, 293]. In contrast, in this
study, there was no significant increase in either big ET or ET-1 plasma
concentration at any dose of BQ-123. Finally, it has previously been shown that the
net effect of systemic ETB receptor blockade is to cause systemic vasoconstriction
[210], which would suggest that any ETB blockade would attenuate the
vasodilatation associated with ETA blockade. Indeed, this effect may contribute to
the lack of further vasodilatation at the highest dose of BQ-123, which was
associated with a tendency for a rise in plasma ET-1 concentration, also consistent
with a threshold effect on the ETB receptor at this dose.
Doses sufficient to lower blood pressure (300 & 1000 nmol/min) also antagonised
the forearm vasoconstriction to brachial artery administration of ET-1 and, in
keeping with its submaximal effect on SVRI, the lower dose of BQ-123 (300
nmol/min) only partially antagonised forearm vasoconstriction to ET-1. Of note,
however, in the presence of a higher degree of ETA blockade, exogenous ET-1
failed to produce vasodilatation via the unblocked ETB receptor. This possibly
reflects the local balance of dilator and constrictor effects mediated by endothelial
and vascular smooth muscle ETB receptors. However it is also possible that the
locally administered ET-1 was washed out by an increase in forearm blood flow
consequent upon the vasodilatation induced by systemic BQ-123. Comparison with a
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constrictor agent unaffected by ET-A antagonism would be needed to clarify this
further.
Previous studies in healthy men [139, 199] failed to demonstrate a significant effect
of BQ-123 on basal haemodynamics. However, the doses used were substantially
lower, at 23.7 nmol/min for 60 min, followed by 94.8 nmol/min for 60 min [139] and
~9 nmol/min for 90 min [199]. These should be compared with 100 nmol/min BQ-
123 for 15 min as the threshold dose for a systemic haemodynamic effect in our
studies. In addition, both other studies measured blood pressure but not systemic
vascular resistance, whereas, from the current study, the latter was a more powerful
measure of the vascular effect of BQ-123, underlining the importance of this
measurement in detecting modest haemodynamic influences. In this regard, other
published studies in humans with ET antagonists do appear to show modest (~10
mmHg) reductions in blood pressure, with both bosentan (mixed ETA/ETB) [202]
and ABT-627 (ETA selective) [200], In the latter study, although systemic
haemodynamics were only recorded at 30 min and 8 hours after dosing, systemic
vascular resistance was measured and significant effects on this parameter were
found in both acute and chronic dosing.
It should be noted that our research group has also previously failed to detect
significant systemic effects, as measured by blood pressure and HR, at our lowest
dose of BQ-123 (100 nmol/min) when administered into the brachial artery [191].
These current results suggest that 100 nmol/min does have a small systemic action,
most apparent in its effects on systemic vascular resistance, that was not detected in
forearm studies, perhaps because the major vasodilatation is in other vascular beds.
In recognition of this potential problem, our research group has more recently used a
10-fold lower dose of 10 nmol/min BQ-123 [194], as a local dose for forearm
studies. The study confirms the rationale for this approach.
It is also interesting to note that a 15 min infusion of BQ-123 produces
haemodynamic effects for up to 4 hours at the higher doses. Although, in this study,
there are measurements of BQ-123 concentrations only at 0, 15 and 240 min,
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subsequent experiments, with identical dosing schedules of BQ-123, demonstrate
that the peak concentration is achieved at the end of the infusion, falls to -10% by 30
min and is undetectable by 75 min post infusion (Studies 3 & 4, Chapters 5 & 6).
This suggests that the observed responses are a pharmacodynamic effect rather that a
reflection of the plasma half-life of BQ-123. This is similar to our group's experience
with the non-selective ET antagonist TAK 044 where the systemic haemodynamic
effects of a 15 min bolus were still observable at 24 hours, whereas the peptide had a
plasma half-life of 30-60 min [201].
In the current study, there was an increase in HR similar to that observed in other
acute studies [202, 312], These effects are not generally seen in chronic dosing
studies with ET antagonists in patients with either hypertension or heart failure [224,
293], For this reason, the effects are probably mediated through the activation of a
cardiopulmonary reflex response to systemic vasodilatation rather a direct
chronotropic effect on the heart.
Although the total number of subjects studied was low (n=5), the power of the study
was sufficient to allow clear conclusions to be drawn. Given the limited experience
with BQ-123 at these systemic doses, there were safety reasons for keeping the
number of subjects to a minimum. In this regard, it is reassuring to note that, despite
substantial systemic vasodilatation, and significant lowering of the mean arterial
pressure, no side effects were observed or reported by the subjects.
In conclusion, this study with BQ-123 demonstrates that systemic ETA receptor
antagonism causes substantial peripheral vasodilatation and modest lowering of
blood pressure, consistent with an important role for the ET system in the
maintenance of vascular tone in man.
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Chapter 4
Actions of ETA receptor antagonism on the




ANG II is a powerful vasoconstrictor substance formed from its inactive precursor
ANG I by the actions of the endothelial cell ecto-enzyme, ACE [365]. The success
of ACE inhibitors in treating conditions such as hypertension and congestive heart
failure underlines the importance of ANG II in pathophysiological situations
involving vasoconstriction [366-368]. Recently, several lines of evidence have
suggested that the effects ofANG II on vascular structure and function are at least in
part mediated by ET-1. Studies in rats have demonstrated that chronic administration
of, [369-373] or pre-treatment with [374] ET receptor antagonists can attenuate
[370-372] or even abolish [369, 373, 374] the pressor response to chronic ANG II
infusion. In contrast, acute administration of ET receptor antagonists show no effect
on, [375, 376] or at best only partial blunting of [377-379] the pressor response to
acute ANG II infusions.
This study investigates the effects of acute ETA receptor blockade with BQ-123 on
the acute pressor response to ANG II in man, using a dose ofBQ-123 known to have
maximal haemodynamic actions and to block the vasoconstrictor effects of
exogenous ET-1 (Chapter 3). To allow for any non-specific hypotensive and
vasodilatory effects of BQ-123 on the response to ANG II, norepinephrine (NE) was
used as a control pressor agent.
4.2 Study design
This was a double-blind, placebo-controlled study in eight subjects, who attended for
a total of 4 visits. On two study days they received ANG II, and on two NE. The
subjects were randomly assigned to receive ANG II or NE first and, for each pressor
agent, subjects received BQ-123 or placebo in random order. A pilot study was
performed in 2 subjects receiving ANG II and NE in incremental doses to confirm
the equivalent pressor effect of the chosen study doses of these agents (Fig 4.1).
On each study day, subjects rested supine for 15 min before beginning the study.
Saline was then infused intravenously for 30 min, followed by BQ-123 or placebo
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for 15 min, then saline for a further 15 min. ANG II or NE was then administered in
three incremental ascending doses for 15 min at each dose. The timing of the pressor
infusions was chosen to correspond to the period of maximal vasodilatation, and
hence inhibition of ETA receptor function, to this dose of BQ-123 (Chapter 3).
Blood pressure and HR and CI were recorded in duplicate at 15 min intervals from
45 min before administration of BQ-123 or placebo until completion of the ANG II
or NE infusions. Blood was taken from the left forearm cannula for the measurement
of ET-1 and ANG II before administration of BQ-123/placebo, at 30 min after BQ-
123/placebo infusion and after each dose increment ofANG II/NE.
Figure 4.1 Pilot study (n=2 subjects) to confirm equivalence of
pressor effect
Doses for study: ANG II - 1,3 and 6 ng/kg/min for 15 min at each dose, NE -




All 8 subjects (age 28 ± 4 yr, body mass index 24.6 ±1.0 kg/m ) completed all parts
of the study. No adverse events were reported.
4.3.1 Haemodynamic parameters
Baseline haemodynamic measurements were similar on all four study days (Table
4.1).
Table 4.1 Baseline haemodynamic data
ANG II ANGII NE NE ANOVA
+ Placebo + BQ-123 + Placebo + BQ-123
MAP 81.5 ± 2.5 83.5 ±2.5 84.5 ±2.8 83.1 ±3.5 p=0.897
(mmHg)
SVRI 1712 ±240 1736 ±248 1744 ±256 1792 ±272 p=0.997
(dyne.s /m2/cm5)
HR 60.3 ±1.8 61.3 ±2.3 65.7 ± 1.9 63 ± 1.8 p=0.279
(bpm)
CI 4.3 ±0.4 4.2 ±0.4 4.2 ± 0.4 4.1 ±0.3 p=0.986
(L/min/m2)
After pre-treatment with placebo, ANG II and NE both increased blood pressure in a
dose-related manner and to a similar extent (maximum increase in MAP: ANG
II+placebo: 25.3 ± 2.8 mmHg, NE+placebo: 31.4 ± 5.1 mmHg, p<0.01 vs. baseline
for ANG II and NE, p=0.12, ANG II vs. NE), though the mechanism of the pressor
effect appeared different for ANG II and NE. The increase in MAP with ANG II was
associated mainly with an increase in SVRI, whereas NE significantly increased CI,
as well as SVRI.
Administration of BQ-123 was associated with a small reduction in MAP at 30 min
and a subsequent significant attenuation of the observed pressor effect of both ANG
II and NE (maximum response to ANG II+BQ-123: 18.8 ± 1.5 mmHg, p=0.02 vs.
77
placebo, NE+BQ-123: 23.0 ± 4.7 mmHg, p=0.04 vs. placebo). This attenuation was
of a similar magnitude for both agents (P=0.28) (Fig 4.2). BQ-123 reduced SVRI
compared to placebo (% change from baseline at 30 min; BQ-123: -3.1 ± 2.8%,
Placebo: +4.9 ± 1.6%, p=0.02). The increase in SVRI observed with the pressor
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agents was also significantly attenuated by BQ-123 in the case of ANG II (-5.7 ±
2.0: p=0.019) but not for NE (-3.2 ± 2.1: p=0.090) (Fig 4.2). However, the
magnitude of the BQ-123 effect was not significantly different for the two agents
(p=0.875). HR decreased during both ANG II and NE infusions (maximum reduction
ANG II+placebo: -3.1 ± 2.1 bpm, NE+placebo: -11.0 ± 3.3 bpm), and was not
altered by pre-treatment with BQ-123 (maximum reduction ANG II+BQ-123: -2.6 ±
1.9 bpm, p=0.57 vs. placebo, NE+BQ-123: -9.9 ± 3.4 bpm, p=0.13 vs. placebo).
4.3.2 Plasma ET-1 and ANG II
Plasma concentrations of ET-1 were not affected by ANG II or NE infusion at any
time point (Table 4.2). Plasma ANG II concentrations increased with each
successive ANG II dose increment, but there were no significant differences in the
plasma ANG II levels between the BQ-123 and placebo phases (Table 4.3).
Table 4.2 Plasma ET-1 concentrations (pg/ml)
ANG II ANG II NE NE
+ Placebo + BQ-123 + Placebo + BQ-123
Baseline 2.41 ± 0.35 3.81 ±0.51 2.72 ±0.41 2.32 ± 0.23
30 min post BQ-123 3.07 ±0.12 3.05 ± 0.28 2.67 ±0.55 2.40 ±0.44
Post ANG II (1 ng/Kg/min)/ 2.74 ± 0.42 3.47 ±0.49 2.88 ± 0.38 3.06 ±0.28
NE (60 ng/Kg/min)
Post ANG II (3 ng/Kg/min)/ 3.10±0.27 3.21 ± 0.33 3.38 ± 0.68 3.13±0.43
NE (120 ng/Kg/min)
Post ANG II (6 ng/Kg/min)/ 3.04 ±0.26 3.60 ±0.43 3.89 ±0.79 3.12 ±0.44
NE (210 ng/Kg/min)
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Table 4.3 Plasma ANG II concentrations (pg/ml)
ANG II ANG II
+ Placebo + BQ-123
Baseline 21.8 ±7.1 12.0 ±1.6
30 min post BQ-123 23.4 ±8.6 11.8 ±2.2
Post ANG II (1 ng/Kg/min)/ 34.7 ±4.5 27.2 ±4.7
NE (60 ng/Kg/min)
Post ANG II (3 ng/Kg/min)/ 67.8 ± 8.5 83.2 ± 20.4
NE (120 ng/Kg/min)
Post ANG II (6 ng/Kg/min)/ 97.8 ±9.5 121.6 ±20.8
NE (210 ng/Kg/min)
4.4 Discussion
These studies demonstrate that the blunting effect of acute ETA antagonism on the
pressor actions of ANG II in man is modest and non-specific, having a similar effect
on the pressor response to NE. This response is similar to that seen with BQ-123
alone (Chapter 3). This suggests that ET-1, acting through the ETA receptor, does
not contribute importantly to the acute pressor response to ANG II in man.
Animal evidence suggests that ANG II can interact with the ET system. ANG II
stimulates ET-1 gene transcription [21, 22, 380] and peptide secretion [33, 381] in
vitro in a variety of cell types, including endothelial and vascular smooth muscle
cells, probably via the AT-1 receptor [382], In vivo, (Table 4.4) a series of studies in
rats have demonstrated that pre-treatment with, or concomitant administration of,
either selective ETA [374] or combined ETA/B [369, 373] receptor antagonists can
abolish the pressor effects of chronically administered ANG II, although this effect is
blunted [370-372] or lost [383] at higher ANG II doses. By contrast, after acute
administration of ANG II, concomitant administration of both selective ETA [379]
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and combined ETA/B [375, 377-379] antagonists have demonstrated either no effect
on, [375] or at best only partial blunting of [377-379], the pressor response.
Table 4.4 Animal in vivo studies ANG II + ET receptor antagonism
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Indeed, in dogs, selective ETA antagonism has been shown to have no effects on the
rise in blood pressure during acutely administered ANG II at doses of the pressor
agent ten-fold lower than those used in chronic studies [376]. However, it should be
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noted that none of these studies included an ET-independent pressor agent as a
control, and thus it is possible that any effects observed could be non-specific,
relating to the direct vasodilatory properties of ETA and ETA/B receptor
antagonists.
This interaction was explored in this study using the ETA selective receptor
antagonist, BQ-123, because of evidence from systemic studies supporting the role
of ETA receptors in the maintenance of vasoconstrictor tone [194] (Chapter 3) and of
ETB receptors in vasodilator tone [194, 210]. Study 1 (Chapter 3) has shown that the
dose of BQ-123 used in this study, 1000 nmol/min for 15 min, gives maximal
functional ETA receptor blockade in healthy volunteers. As this earlier study has
demonstrated that this dose of BQ-123 has a significant effect on blood pressure and
systemic vascular resistance, confirmed in this study by a reduction in SVRI 15 min
after the end of the BQ-123 infusion of -8% compared to placebo, a control pressor
agent was used to identify any non-specific hypotensive and vasodilatory effects of
BQ-123 at this dose. NE was used as a control pressor agent because previous
animal studies have shown that, while ET receptor antagonists can reduce ventricular
hypertrophy induced by chronic NE infusion [384], in the acute setting, while
inhibiting ANG II induced aortic ring contractions, they do not affect NE induced
contractions [333], Additionally, while ET and ANG II have been shown to act
synergistically to increase blood pressure in vivo, this is not so for the combination
of ET-1 and NE [385], These data tend to support the use of NE as an ET-
independent pressor agent in this acute study. As such, the similar efficacy of BQ-
123 in attenuating equivalent rises in blood pressure induced by ANG II and NE
suggests that the modest effect of acute ETA blockade on the pressor actions of
ANG II is non-specific. Wenzel et al have recently demonstrated that BQ-123 can
attenuate both ANG II and NE induced vasoconstriction in the skin microcirculation
of healthy volunteers and postulate an acute ET-1 interaction with both ANG I and
NE [386], As with this study, however, the dose of BQ-123 used itself produced
vasodilatation, and as such, it is equally likely that the attenuation of ANG II or NE
induced vasoconstriction seen after ETA receptor inhibition is non-specific.
Additionally, although the essentially paracrine nature of the ET system may makes
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interpretations of changes in plasma ET-1 concentrations difficult, the failure of
ANG II or NE to increase plasma ET-1 concentrations in this study also suggests
that neither ANG II nor NE achieve their acute pressor effect by stimulating ET-1
generation. However, it is possible that ET-1 secretion may occur with chronic
elevation of plasma ANG II and that this may influence vascular structure rather than
function.
In conclusion, this study demonstrates a modest and non-specific inhibition by BQ-
123 of the pressor response to ANG II in man suggesting that ANG II does not
achieve its acute pressor effect via ET-1. It must be noted that this study looks only
at acute effects, and further chronic interaction studies are needed in man,
particularly in relation to vessel structure. Nevertheless, the lack of an acute ETA-
ANG II interaction on vascular tone is consistent with clinical studies showing an
added haemodynamic benefit of both selective ETA and non-selective ETA/b in
patients with heart failure already treated with ACE inhibitors [293, 299]. This




Actions of ET-A and ET-B receptor antagonism
on systemic and renal haemodynamics and
tubular function in hypertensive patients with
chronic renal failure and healthy controls
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5.1 Introduction
Previous ET receptor antagonist studies in man have failed to demonstrate any role
for ET-1 in the maintenance of normal renal vascular tone [120, 139-141, 199]. To
date, the effects of ET receptor antagonists on either basal systemic or renal
haemodynamics in CRF have not been investigated. CRF is characterised by
systemic and renal vasoconstriction, and commonly associated with hypertension.
Given that ET receptor antagonists cause vasodilatation [191, 201], lower blood
pressure [201, 224], and also ameliorate renal dysfunction in experimental models of
kidney disease [387], they may be useful in the treatment ofCRF.
The first aim of this study was to investigate whether ET receptor antagonists at
doses known to be maximally systemically active (Study 1, Chapter 3) would have
effects in the renal circulation in healthy volunteers. Secondly, it investigates
whether ET receptor blockade can produce alterations in systemic or renal
haemodynamics in CRF. Because of the potential opposing effects at ETA and ETB
receptors, and to establish which pattern of ET receptor blockade may be the more
beneficial therapeutic combination, this study also directly compared the effects of
regimens involving ETA and ETB receptor blockade separately, and in combination
in CRF patients and matched healthy controls.
5.2 Study design
This was a randomised, double-blind, placebo-controlled study in 8 patients with
CRF and 8 matched healthy controls. Subjects attended for 4 visits, each separated
by >7 days, receiving placebo, BQ-123, BQ-788 or the combination of BQ-123 and
BQ-788. Four comparisons of interest were pre-identified as placebo vs. BQ-123, vs.
BQ-788 and vs. BQ-123/788, and BQ-123 vs. BQ-123/788.
On each study day, subjects underwent a standard clearance study. After baseline
measurements, the low dose of antagonist was then administered followed by three
30 min collection periods. The higher dose of antagonist was then administered
followed by 5 further 30 min collection periods. (Fig 5.1)
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Fig 5.1 Study protocol
Placebo or Placebo or
BQ-123/788 BQ-123/788
100/30 nmol/min 1000/300 nmol/min
t=0 t=90 min
1100 1200 1330
BP & bioimpedance measurements every 15 min
Urinary collection periods every 30 min
At 0, 60 & 90 min after the start of low and high dose antagonist, and at the end of
the study, blood samples were taken for the measurement of plasma ET-1,
aldosterone, ANG II concentrations and PRA. BQ-123 was measured before and at
15, 45 & 90 minutes after the start of each dose of antagonist, and at the end of the
study.
5.2.1 Subjects
8 patients with stable CRF and 8 matched controls were recruited into the study. To
enhance homogeneity and avoid other influences on vascular reactivity, patients with
vasculitis, other systemic inflammatory disease, polycystic kidney disease, nephrotic
syndrome or obstructive uropathy were excluded. Additionally, patients with
significant co-morbid disease including diabetes mellitus, heart or lung disease,
peripheral vascular disease or hypercholesterolaemia were excluded. The two study
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groups were matched for age, weight, serum cholesterol and blood pressure (Table
5.1). Further patient characteristics are given in Table 5.2.
Table 5.1 Subject demographic data
Healthy Volunteers Renal Patients f-test
Age (yr) 47 ± 5 (23 - 64) 46 ± 5 (25 - 67) NS
Body mass index (kg/m2) 26 ± 2 (18 - 31) 27 ±1 (24-33) NS
MAP (mmHg) 92.8 ±3.1 (83.0- 103.6) 98.8 ±3.5 (78.8- 109.5) NS
Creatinine (gmol/L) 85 ±5 (62- 111) 255 ±41 (122-434) p<0.01
Urinary Na excretion (mmol/24 hr) 136 ±14 (56- 199) 150 ± 14(74-246) NS
Cholesterol (mmol/L) 5.3 ±0.3 (3.9-6.1) 5.6 ±0.2 (4.5-6.7) NS
Urinary protein excretion (mg/24 hr) 0+ 476 ± 110 (27-2033)
(n=7)
p<0.01
+values below limit of laboratory assay
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Table 5.2 Patient characteristics






Renal calculi, single Enalapril, bicarbonate, HT, Secondary
kidney 1-a calcidol
40 31 IgA nephropathy Enalapril
Tpth
NK - late presentation Lisinopril, bicarbonate, HT
omeprazole, frusemide
HT
44 61 IgA nephropathy Ranitidine HT, PUD





IgA nephropathy Enalapril, doxazosin,
bicarbonate, omeprazole




67 59 IgA nephropathy/HSP Labetalol HT
CrCl - creatinine clearance, GN - glomerulonephritis, HSP - Henoch-Schonlein Purpura, HT -
hypertension, NK - not known, tPTH - hyperparathyroidism, PUD - peptic ulcer disease, TPTH -
hyperparathyroidism, UPE - urinary protein excretion
5.3 Results
Twelve renal patients were initially recruited: 1 developed nausea after receiving
BQ-123, and 1 was unable to void urine at 30 min intervals. Two others withdrew
for reasons unrelated to the study. Eight patients, and all healthy controls, completed
the study without adverse events. Baseline study data are given in Table 5.3.
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Table 5.3: Baseline data
Healthy Volunteers Renal Patients f-test
MAP (mmHg) 94.0 ±2.2 (86.5- 104.9) 100.5 ±4.0 (76.9-110.1) NS
SVRI (dyne.sec/cm5/m2) 3089 ±269 (1558-4068) 3479 ± 270 (2296 - 4478) NS
CI (L/min/m2) 2.6 ±0.3 (1.9-4.6) 2.4 ±0.2 (2.0-3.2) NS
HR (bpm) 58.2 ±2.3 (47.2-67.4) 56.6 ± 1.8(49.1 -62.4) NS
ERBF (ml/min) 683 ±41 (534 - 844) 295 ± 58 (81 - 571) p<0.01
ERVR (mmHg.min/L) 148 ± 12(108- 191) 489 ± 101 (208 -973) p<0.01
EFF (%) 25.4 ±2.0 (17.8-36.3) 20.8 ± 1.8(13.5-30.7) NS
GFR (ml/min/1.73m2) 116 ± 11 (80 - 164) 39 ±6 (19-67) p<0.01
FWC (ml/min) 5.0 ±0.5 (3.0- 7.5) 3.1 ±0.5(1.4-6.0) P<0.05
UNaV (pmol/min) 143 ± 11 (56-215) 180 ±31 (70 - 341) NS
Urinary protein (mg/L) 0* 453 ± 82 (101 - 1435)§ p<0.01
Plasma ET-1 (pg/ml) 4.2 ±0.3 (2.9-5.3) 5.6 ±0.3 (4.6-7.3) p<0.01
PRA (pg/ml/hr) 3.6 ±0.5 (2.2-6.4) 10.5 ±2.3 (3.3-20.6) p<0.05
Plasma ANG II (pg/ml) 7.7 ± 1.0 (4.4-12.6) 7.6 ± 1.1 (4.2-13.8) NS
Plasma aldosterone (pg/ml) 61 ±4 (45-81) 88 ±28 (33 -274) NS
♦Values are given as the mean of the two baseline periods over the four study days ± SEM with the
range of values given in brackets. NS = not significant Values below limit of laboratory assay, §n= 7
one value below limit of detection.
Fluid balance was calculated for each subject during each phase of the study. Not
accounting for insensible losses, subjects were in a small positive fluid balance by
the end of the 7.5 hr study (+51±21ml/hr for healthy subjects, +69±26 ml/hr for renal
patients, p=0.58 healthy subjects vs. CRF). This did not differ with different phases
of the study (placebo, BQ-123, BQ-123/788 or BQ-788) and was not different
between the healthy subjects and patients with renal failure.
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5.3.1 Systemic haemodynamics (Fig 5.2)
In CRF patients, placebo was associated with increases in SVRI to study end
(3478±240 dyne.s m2/cm5 vs. 3797±301 dyne.s m2/cm5, p<0.05) and MAP
(100.7±3.8 mmHg vs. 108.0±4.1 mmHg, p<0.01), consistent with the waning effects
of anti-hypertensive medication. BQ-123 and BQ-123/788 reduced SVRI to a similar
extent (BQ-123 (maximum placebo corrected change from baseline) -630±145
dyne.s m2/cm5, BQ-123/788: -617±158 dyne.s m2/cm5, both p<0.01 vs. placebo).
MAP was reduced in CRF patients after BQ-123/788 (-7.4±1.6 mmHg, p<0.01 vs.
placebo), but to a greater extent after BQ-123 alone (BQ-123: -12.9±1.7 mmHg,
p<0.01 vs. placebo and BQ-123/788). The systemic haemodynamic response
observed in individual patients was not related to baseline blood pressure.
In healthy controls, placebo did not alter systemic haemodynamics. Both BQ-123
and BQ-123/788 reduced SVRI to a similar extent, and equivalent to that seen in
CRF (BQ-123: -591±104 dyne.s m2/cm5, BQ-123/788: -498±159 dyne.s m2/cm5,
both p<0.01 vs. placebo). The reductions in MAP after BQ-123 & BQ-123/788 were
equal (BQ-123: -3.6±1.4 mmHg, BQ-123/788: -3.7±1.6 mmHg, both p<0.01 vs.
placebo), and less than those seen in CRF (p<0.05).
BQ-788 alone increased MAP (CRF: +7.0±1.6 mmHg, HC: +5.8±1.5 mmHg, both
p<0.01 vs. placebo) and SVRI (CRF: +454±114 dyne.s m2/cm5, p<0.01 vs. placebo,
healthy controls: +390±76 dyne.s m2/cm5, p<0.05 vs. placebo) to a similar extent in
CRF patients and controls.
Increases in HR and CI were observed with selective ETA and combined ETA/B
receptor antagonism, while decreases in these indices were observed following ETB
receptor antagonism. While HR responses were similar between healthy volunteers
and patients, the increases in CI with the dilator drugs were less, particularly for
ETA receptor antagonism, and the reductions in CI following ETB receptor
antagonism greater in patients compared to healthy volunteers.
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5.3.2 Renal haemodynamics (Fig 5.3)
In CRF patients, BQ-123, but not BQ-123/788, produced striking increases in ERBF,
and reductions in ERVR and EFF (ERBF: +102±74 ml/min, ERVR: -243±91
mmHg.min/L, EFF: -4.2±2.9%, all p<0.01 vs. placebo and vs. BQ-123/788). GFR
did not change. By contrast, in healthy controls, BQ-123 and BQ-123/788 were
neutral in respect ofERBF, ERVR, EFF and GFR.
In both groups, BQ-788 reduced ERBF (CRF -77±72 ml/min, HC -134±47 ml/min;
both p<0.05 vs. placebo) and increased ERVR (CRF 112±63 mmHg.min/L, HC
39±12 mmHg.min/L; both p<0.05 vs. placebo). These changes were apparent even at
low dose, and associated with a reduction in GFR and an increase in EFF.
5.3.3 Urinary free water clearance and sodium excretion (Fig 5.4)
Free water clearance was modestly increased by BQ-123/788 (p<0.05 vs. placebo) in
healthy controls. A similar trend was seen after BQ-123 in healthy controls and after
BQ-123 and BQ-123/788 in CRF, particularly after administration of the low dose of
ET receptor antagonist, though this did not reach statistical significance. FWC was,
however, reduced after BQ-788 administration in 7 out of 8 CRF patients. No
changes in sodium excretion were observed in either CRF or healthy controls.
5.3.4 Urinary protein excretion (Fig 5.4)
Urinary protein excretion was undetectable for one CRF subject and all healthy
controls. In the remaining 7 CRF patients, after correcting for GFR, BQ-788 and
BQ-123/788 did not affect proteinuria, but BQ-123 reduced protein leak by 46%
(-8.1±4.9 pg/ml) at 210 min (p<0.01 vs. placebo), an effect most apparent in
subjects with higher baseline urinary protein excretion.
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Figure 5.4 Free water clearance, urinary sodium excretion and
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5.3.5 Plasma BQ-123 (Fig 5.5)
BQ-123 was detectable in plasma at 15 min post low dose and at 15 & 45 min post
high dose administration. There was no difference in the plasma concentrations of
BQ-123 between healthy controls and renal patients (CRF 1.52±0.36 pg/ml, HC
1.21 ±0.17 pg/ml at 15 min post high dose), nor between study days when BQ-123
was given alone compared with when given with BQ-788 (CRT 1.62±0.20 pg/ml,
HC 1.26±0.20 pg/ml).
Figure 5.5 Plasma BQ-123 concentrations after BQ-123 administration
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5.3.6 Plasma hormone concentrations (Fig 5.6)
Baseline ET-1 concentrations were slightly higher in renal patients compared to
healthy volunteers (Table 5.3). Plasma ET-1 concentrations were increased o a
similar extent after high dose BQ-788 (Healthy controls baseline: 4.1 ± 0.4 pg/ml,
120 min: 6.6 ± 1.0 pg/ml, CRF baseline: 5.6 ± 0.4 pg/ml, 120 min: 8.3 ± 0.5 pg/ml)
and BQ-123/788 (Healthy controls baseline: 3.9 ± 0.5 pg/ml, 120 min: 8.5 ± 1.1
pg/ml, CRF baseline: 5.4 ± 0.3 pg/ml, 120 min: 7.9 ± 0.4 pg/ml), but unaltered by
placebo or BQ-123. Plasma renin activity, aldosterone and ANG II concentrations
were unchanged by the administration of placebo, BQ-123 and/or BQ-788.
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This is the first clinical study to directly compare ETA, ETB and combined ETA &
ETB receptor antagonism at systemic doses in man. It demonstrates that, in CRF
patients, that selective ETA receptor antagonism produces substantial reductions in
blood pressure that are associated with renal vasodilatation, without changes in GFR.
Combined ETA/B receptor blockade was less effective in lowering blood pressure,
had no effect on renal haemodynamics and reduced ET-1 clearance. Selective ETB
receptor antagonism alone produced substantial systemic and renal vasoconstriction.
By contrast, in healthy subjects the effects of ETA and ETA/B receptor blockade on
blood pressure were similar to each other, but less than those seen in CRF, and there
were no effects on renal haemodynamics.
These data confirm the physiological importance of ET- 1, through activation of the
ETA receptor, in the maintenance of basal systemic but not renal vascular resistance
[140]. They also show that ET-1 plays a major role in regulating blood pressure and
renal vascular resistance in CRF, consistent with activation of the ET system in this
condition. Additionally, the reduction in EFF suggests an effect primarily on efferent
arteriolar tone, which may serve to reduce glomerular pressure, and thus be
renoprotective.
The effects of BQ-788, whether in the presence of BQ-123 or not, suggest the net
effect of ETB receptor activation on the circulation, in health and renal disease, is to
produce vasodilatation. Therefore, similar to observations in healthy subjects [194,
210] and patients with heart failure [388], any enhanced effects of constrictor ETB
receptors in CRF is outweighed by ETB receptor mediated vasodilatation. Of
interest, ETB receptor antagonism increased renal vascular resistance twice as much
(—20-30%) as systemic vascular resistance (—10-15%), suggesting that tonic ETB
receptor mediated renal vasodilatation plays a key role in maintenance of renal
vascular tone. This is likely to be of particular importance in CRF, where baseline
renal vascular resistance is high.
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This study has demonstrated a reduction in SVRI after BQ-123 or BQ-123/788 that
is similar in patients and healthy volunteers. Using a nitric oxide clamp, Verhaar et
al demonstrated that the vasodilatory response of the forearm circulation to ETA
receptor antagonism was dependent on NO production [194], As many
cardiovascular disease states including CRF are characterised by a reduction in NO
activity [389-391], this finding would suggest that ETA receptor blockade should be
less effective in disease. Consistent with this, forearm studies in renal failure patients
[195], heart failure patients [388], and hypertensives [222] have demonstrated a
reduced vasodilatory response to BQ-123 when compared to healthy controls. This
was clearly not the case in this study.
BQ-123 concentrations were the same in the CRF patients and the healthy controls,
suggesting that altered pharmacokinetics does not account for this difference. Indeed
as BQ-123 is metabolised by the liver [97] one would not expect altered
pharmacokinetics in renal patients (see Chapter 11 for further exploration of BQ-123
pharmacokinetics). It is possible that the medications taken by renal patients may be
responsible for this finding. As the duration of the study was a minimum of four
weeks plus one week washout period for each individual, withdrawal of medications
was felt not only to be ethically unjustified, but it also introduced another unmatched
variable, hypertension, compared to the healthy controls that might have affected the
response to ET antagonists. Given the prevalence of hypertension in renal disease, it
was felt that the option chosen (to maintain patients on their medication) was a
clinically relevant one and in keeping with previous studies in heart failure patients
[293, 294, 299], In this respect, it is important to note that six of the eight patients
were taking ACE inhibitors. These drugs, in addition to blocking the conversion of
ANG I to ANG II, also increase NO activity via inhibition of bradykinin breakdown
[392], It is possible therefore that ACE inhibitors and ETA antagonists, both acting
through NO, somehow interact to increase the haemodynamic response observed. An
acute synergism between ETA receptor antagonism and ACE inhibitors has been
demonstrated in animals in respect of systemic and renal haemodynamics [393] but
has yet to be studied in man. In Chapter 6 and 7, this issue is addressed in healthy
volunteers.
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However, despite similar changes in SVRI, blood pressure fell significantly in renal
patients, while healthy volunteers defended their blood pressure. Reductions in MAP
in the healthy volunteers are small and similar to those seen in Chapter 3 and in other
studies [140, 200, 202], Our experience is that healthy subjects defend their blood
pressure via reflex alterations in HR and CI, and that MAP is usually the last
cardiovascular measurement to change, an observation supported by this study. It is
potentially one reason why studies with ET receptor antagonists in healthy
volunteers that only measure mean arterial pressure, and do not look at vascular
resistance, have failed to show significant effects [139, 202]. In the renal patients,
the larger reduction in blood pressure is accompanied by a lesser increase in CI in
patients compared healthy volunteers, suggesting that the hypertensive renal heart
less able to compensate for changes in SVRI. The greater reduction in MAP in
patients after ETA receptor antagonists and corresponds with a smaller increase in
CI with ETA compared to ETA/B receptor antagonism. It is interesting to speculate
whether this is a direct cardiac effect of ETA receptor blockade, though this study
was not designed to answer this question.
Consistent with previous studies [120, 139-141, 199], selective ETA and non¬
selective ETA/B receptor antagonists had little effect on ERBF or ERVR in healthy
subjects. As the higher dose of BQ-123 is at the top of the dose response curve for
systemic haemodynamics (Chapter 3) insufficient dose is an unlikely explanation for
the lack of effect of ETA and non-selective antagonism on the renal circulation of
healthy volunteers. It is possible that the ETA receptor is not an important mediator
of renal vasoconstriction in health. However, the circumstances of this study mean
that this is an unchallenged renal circulation and therefore likely to be maximally
dilated. It is possible therefore that no effect is seen as no further dilatation can
occur.
In patients however, ETA blockade produces a clear reduction in ERVR and increase
in ERBF. The increased ERVR at baseline compared to healthy controls is a good
indicator that, in the renal circulation in patients, even unchallenged, the balance
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between constrictors and dilators is shifted towards the constrictors. Blockade of one
of these constrictor systems i.e. ET-1 will, therefore, produce a dilatation. The
response in renal patients to selective ETA receptor would suggest that the ETA
receptor mediates ET-1 induced renal vasoconstriction. The neutral effect of non¬
selective receptor antagonism on ERBF and ERVR underlines the importance of the
vasodilatory action of the ETB receptor in the renal circulation of CRF patients. Loss
of this vasodilatory action, in contrast to the systemic circulation, reduces the
effectiveness of ETA receptor blockade. Again this study provides no evidence to
support an upregulation of vasoconstrictor ETB receptors in the renal circulation.
The renal vasoconstriction produced by selective ETB receptor antagonism is
accompanied, not surprisingly, by a reduction in GFR. EFF is moderately increased,
suggesting, in the absence of changes in filtration coefficient, an increase in efferent
arteriolar tone. The reduction in EFF observed with ETA receptor antagonists in
renal patients is also suggestive of a preferential efferent arteriolar effect. If this is
real, it implies that the observed increase in RBF is not associated with increases in
glomerular capillary perfusion. This is important as an increase in ERBF
accompanied by increases in glomerular capillary perfusion pressure could be
deleterious to long term renal function, conversely a fall in glomerular capillary
perfusion pressure would result in a situation analogous to ACE inhibitors, and
might be expected to improve long term renal outcome. Consistent with our
observations, an ETA receptor selective antagonist has been shown to reduce
proteinuria in type 1 diabetics [190], However, it would mean that ETA receptor
blockade would need to be approached with caution in situations of low renal
perfusion pressure e.g. congestive heart failure and renovascular disease. Because of
the importance of this issue to rational prescribing of ET receptor antagonists,
Larger, chronic studies are needed to confirm or refute this finding.
Perhaps surprisingly, given the evidence for ETB receptor mediated natriuresis
shown in animal studies [394], no changes in sodium excretion were observed in this
study. However, the urinary sodium data in this study were the most variable and
failed to achieve significance. Larger studies are required to adequately define the
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renal tubular actions of ET receptor antagonists. Despite this, during ETA receptor
blockade, in the face of substantial systemic and renal vasodilatation, sodium
retention did not occur, which is important if these drugs are to be safely prescribed
to patients with CRF.
Based on the data from study 1 and earlier work, this study was designed to achieve
effective and selective blockade of the ETA and ETB receptor ([194, 210, 395] and
Chapter 3) and not specifically to reproduce the effects of existing ET receptor
antagonists, which all block ETA to a greater extent than ETB receptors [396].
Therefore, although the main effects of therapeutic interest in our study appear to
derive from ETA receptor blockade, and are countered by ETB blockade, drugs
causing only modest ETB receptor inhibition might produce similar effects. As a
limitation, ours were acute studies. However, based on studies in heart failure, [293]
haemodynamic effects would be sustained, or even greater, with continued
treatment. Also, a relatively homogeneous CRT population were recruited to this
study. Therefore, further work is now needed in a broader population of patients with
kidney disease, including those with low renal perfusion pressure. In particular, as
ACE inhibitors are most effective as renoprotective agents in patients with >3g/24hr
of proteinuria, studies are needed in patients with higher degrees of urinary protein
leak to address what may be a major benefit of these agents.
In conclusion, this study suggests that selective ETA receptor antagonists may be
valuable anti-hypertensive drugs in patients with CRF as well as offering additional
benefits, including renoprotection. ET receptor antagonists also improve endothelial
function [397], reduce inflammation and fibrosis [398], and reverse cardiac [399]
and vascular remodelling [400] and so may offer additional benefits to renal patients,
who are at high cardiovascular risk. On this basis, longer term studies in patients
with CRF are justified, paying particular attention to effects on proteinuria as a
surrogate marker for the progression of renal disease.
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Chapter 6
An examination of the interaction between ACE




ET-1 and ANG II are both powerful vasoconstrictors involved in the regulation of
vascular tone, and there is considerable evidence for an interaction between the ET
and renin-angiotensin-aldosterone systems [401], ANG II increases ET-1
transcription and secretion in vitro in a variety of cell types, including endothelial
and vascular smooth muscle cells [21, 402], and ET-1 can increase ACE activity [73,
403]. As discussed in Chapter 4, ET receptor antagonists attenuate the acute
haemodynamic effects of ANG II in rats in vivo [377, 379], although this is by no
means a uniform finding [375], and has not been replicated in acute studies in dogs
[376] or in local [404] or systemic studies in man (Chapter 4). Animal data have,
however, demonstrated that ACE inhibition can attenuate ET-1 induced hypertension
[405, 406] and suggested that concomitant blockade of the renin-angiotensin and ET
systems produces changes greater than those seen with blockade of either system
alone [393, 407-409]. In man, synergism between ETA receptor antagonists and
angiotensin receptor type 1 antagonists has been demonstrated [410], Also, many
clinical studies with ET receptor antagonists demonstrating clear haemodynamic
effects [293, 299] have been performed in patients already receiving ACE inhibitors.
In contrast to forearm studies that have suggested that ETA receptor blockade would
be less effective in patient groups compared to healthy controls [195, 222, 388],
study 3 (Chapter 5) demonstrated that, despite a greater reduction in blood pressure
in CRF patients, reductions in SVRI were similar in CRF patients and healthy
volunteers. In light of the above evidence, a possible explanation for the augmented
response in CRF, as six of the eight patients were or ACE inhibitors, might be due to
an interaction between ET receptor antagonism and ACE inhibition.
The aim of this study was, therefore, to explore the possible systemic and renal
interaction between ET receptor antagonism and ACE inhibition, hypothesising that
pre-treatment with ACE inhibition would augment the systemic and renal
haemodynamic response to ETA receptor antagonism.
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6.2 Study design
This was a randomised, double-blind, placebo-controlled study in 6 healthy subjects.
For demographic data, see Table 6.1. Subjects attended for 6 visits, each separated
by >7 days. On visits 1-3, they received either placebo, BQ-123, or the combination
of BQ-123 & BQ-788 in a randomised order. They then followed and identical study
protocol on visits 4-6, after pre-treatment with enalapril (E). The response to BQ-123
and BQ-123/788 in the presence or absence of E was pre-identified as the
comparison of interest.
For 5 days before each study, subjects took enalapril at a dose of 20 mg twice daily
(see methods for justification of dosing schedule) taking the last dose at 0830 on the
study day. Subjects then underwent a standard clearance study. After baseline
measurements, the low dose of antagonist was then administered followed by three
30 min collection periods. The higher dose of antagonist was then administered
followed by 5 further 30 min collection periods.
Table 6.1 Subject demographic data
Age (yr) 47 ± 5 (23 - 64)
Body mass index (kg/m2) 25 ±2(18-31)
MAP (mmHg) 88.5 ± 2.7 (71.4 - 99.4)
Creatinine (fimol/L) 89 ± 7 (62 - 119)
Urinary Na excretion (mmol/24 hr) 118 ± 15 (64 - 185)
Cholesterol (mmol/L) 5.2 ±0.3 (3.9 — 6.1)
At 0, 60 & 90 min after the start of low and high dose antagonist, and at the end of
the study, blood samples were taken for the measurement of plasma ET-1,
aldosterone, ANG II concentrations and PRA. BQ-123 was measured before and at
15, 45 & 90 minutes after the start of each dose of antagonist, and at the end of the
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study and serum ACE activity was determined at 0830 am and at 1430 (60 min after
the start of the higher dose antagonist).
6.3 Results
All subjects completed all phases of the study without adverse events. Baseline study
data (Table 6.2) were not different for any of the 6 individual phases of the study
except for plasma aldosterone concentrations which were reduced during the phases
when BQ-788 was administered by pre-treatment with enalapril.
Table 6.2: Baseline data
Placebo BQ-123 BQ-123/ Enalapril+ E+BQ-123 E+BQ-123 No E vs.
788 Placebo /788 E t-test
MAP 96.2±2.5 92.6±4.1 94.0±3.2 87.2±1.7 89.2±3.8 90.6±5.0 p<0.01
(mmHg)
SVRI 2868±318 3157±435 3157±410 2726±305 283U358 2616±353 p<0.01
(dyne.s rrr/cm5)
CI 2.94±0.47 2.64±0.43 2.60±0.38 2.77±0.39 2.73±0.36 2.99±0.36 NS
(L/min/m2)
HR 61.2±1.5 60.8±1.5 61.3±2.2 60.3±2.5 59.1±3.6 61.8±2.0 NS
(bpm)
ERBF 587±53 705±66 703±84 795±89 723±138 945±101 p<0.05
(ml/min)
ERVR 173±19 139±15 142±21 119±16 142±22 108±18 p<0.05
(mmHg.min/L)
EFF 28±4 23±2 23±3 21 ±2 24±3 19±2 NS
(%)
GFR 106±9 110±14 103±13 106±7 103±6 107±9 NS
(ml/min/1,73m2)
UNaV 157±19 150±32 134±29 154±13 142±22 157±28 NS
(gmol/min)
Plasma ET-1 4.7±0.5 4.7±0.3 3.5±0.2 3.8±0.3 3.6±0.3 3.9±0.1 NS
(pg/ml)
Plasma Aldosterone 61±14 53±8 76±12 42±4 43±4 29±3* p<0.05
(pg/ml)
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However comparing the 18 visits where subjects received pre-treatment with
enalapril to those where they did not, MAP, SVRI, ERVR and aldosterone were
significantly reduced and ERBF was significantly increased.
6.3.1 Systemic haemodynamics
Administration of placebo, either alone or in the presence of pre-treatment with
enalapril, did not alter systemic haemodynamics. Both selective ETA receptor
antagonism with BQ-123, and combined ETA/B receptor antagonism with BQ-123
& BQ-788, reduced MAP (maximum placebo corrected change from baseline: BQ-
123: -4.2 ± 1.6 mmHg, ANOVA p<0.05 vs. placebo; BQ-123/788: -4.4 ± 2.0
mmHg). After pre-treatment with E, the effect of BQ-123 on blood pressure was
almost doubled (-8.3 ±3.0 mmHg, p<0.01 vs. BQ-123 alone). However, this
synergy was not seen when BQ-788 was co-administered with BQ-123 (-4.4 ± 2.9
mmHg) (Fig 6.1). SVRI followed a similar pattern (Fig 6.2). Pre-treatment with E
was associated with a trend towards a smaller increase in HR after BQ-123 or BQ-
123/788. No significant changes in CI were noted.
6.3.2 Renal haemodynamics
Placebo, E alone, BQ-123 and BQ-123/788 were all neutral in respect of ERBF,
ERVR, EFF and GFR. After pre-treatment with E, BQ-123 increased ERBF (+146 ±
41 ml/min, p<0.01 vs. placebo and vs. BQ-123 alone), reduced ERVR (-32 ± 15
mmHg.min/L, p<0.01 vs. placebo and vs. BQ-123 alone) and reduced EFF (-3.4 ±
2.5%, p<0.05 vs. placebo, p<0.01 vs. BQ-123 alone). By contrast, after pre-
treatment with E, BQ-123/788 increased ERBF (-224 ± 31 ml/min, p<0.01 vs.
placebo and vs. BQ-123/788 alone) and reduced ERVR (26 ± 6 mmHg.min/L,
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6.3.3 Urinary sodium excretion
No significant changes in natriuresis were observed after placebo, E alone and both
BQ-123 or BQ-123/788 alone. However, after pre-treatment with E, BQ-123
produced a striking increase in urinary sodium excretion (UNaV: +58 ± 27
pmol/min, p<0.01 vs. placebo and BQ-123 alone). Fractional excretion of sodium
followed a similar pattern. As with renal haemodynamics this increase was not
observed with BQ-123/788. (Fig 6.7)
6.3.4 Serum ACE activity
Pre-treatment with E reduced serum ACE activity by 75% at baseline compared to
no pre-treatment (9.1 ± 2.3 vs. 36.4 ± 4.3 U, p<0.01), and by 79% at 150 min (5.4 ±
1.7 vs. 26.5 ±2.1 U, p<0.01). ET-receptor antagonist administration did not alter
ACE activity (Table 6.3)
Table 6.3 Serum ACE activity after ET receptor antagonist
administration
Placebo BQ-123 BQ-123/788
t=0 min 36.1 ±3.2 39.0 ± 11.5 34.1 ± 6.5
t=210 min 27.4 ±3.5 27.5 ± 2.7 24.6 ± 5.2
Enalapril Enalapril +BQ-123 Enalapril +BQ-123/788
t=0 min 10.6 ±3.0 8.6 ±3.0 11.7 ±6.6
t=210 min 8.0 ±3.2 3.7 ±2.0 7.0 ±3.9
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BQ-123 was detectable in plasma at 15 min post low dose and at 15 & 45 min post
high dose administration. Peak BQ-123 concentrations were higher after pre-
treatment with E, though the difference was not statistically significant (BQ-123:
1.26 ± 0.18 pg/ml, BQ-123/788:1.32 ± 0.23, BQ-123 + E: 2.06 ± 0.65, BQ-123/788
+ E: 2.32 ± 0.53) (Fig 6.8).
Figure 6.8 Plasma BQ-123 concentrations
6.3.6 Plasma ET-1 concentrations
Baseline plasma ET-1 concentrations were not altered by pre-treatment with
enalapril (Table 6.2). They were increased following administration of BQ-788
whether administered in the presence of enalapril (+1.7 ± 0.6 pg/ml, 43 ± 16%
p<0.05 vs. baseline) or not (4.4 ±1.3 pg/ml, 132 ± 33%, p<0.05 vs. baseline), but
unaffected by placebo or BQ-123 alone.
6.3.7 Plasma aldosterone concentrations
Baseline plasma aldosterone concentrations were lowered by pre-treatment with
enalapril (pre treatment with enalapril 37.8±2.8 pg/ml, no pre-treatment 63.6±7.7
pg/ml, p<0.05) (Table 6.2). After administration of BQ-788, plasma aldosterone
concentrations tell whether administered in the presence of enalapril (-10.6 ± 3.5
pg/ml, -38 ± 14% p<0.05 vs. baseline) or not (-33.3 ± 9.3 pg/ml, -40 ± 6%, p<0.05
vs. baseline), but unaffected by placebo or BQ-123 alone.
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6.4 Discussion
This study demonstrates a synergy between ACE inhibition and ETA receptor
antagonism, both on systemic and renal haemodynamics, and on renal tubular
function that is lost when the ETB receptor is concomitantly blocked.
The renin-angiotensin and ET systems are known to interact [401] and an in vivo
synergistic effect between ACE inhibition and ETA receptor antagonism has been
demonstrated in animals [393], and in man between ERAs and angiotensin receptor
antagonists [410], This study has shown that, in healthy volunteers subjected to a
high degree of ACE inhibition, the effects of ETA receptor blockade on systemic
haemodynamics are enhanced. In respect of blood pressure, ACE inhibition almost
doubles the effect of ETA receptor blockade. Additionally, in contrast to the absence
of an effect of ETA receptor antagonism alone on the renal circulation, the
combination with ACE inhibition increased renal perfusion, with an associated fall
in EFF, and thus, by inference, a preferential vasodilatation of the efferent arteriole
and a fall in glomerular capillary pressure. These alterations in glomerular
haemodynamics have the potential to be renoprotective in a manner analogous to the
effect of ACE inhibition alone. Additionally, a striking natriuresis was observed that
was still developing at the end of the study, 4 hours after initial administration of
BQ-123. If sustained over 24 hrs, this would be equivalent to 80 mmol of sodium
excreted, a clinically important degree of sodium loss.
These results also demonstrated that, while maximal haemodynamic changes
occurred after the higher dose of BQ-123, useful systemic and renal haemodynamic
changes were achieved after the lower dose of BQ-123 in the presence of ACE
inhibition. As adverse effects in clinical trials with ET receptor antagonists appear to
be largely dose related [295], this combination might allow the use of a lower dose of
ETA receptor antagonist without losing efficacy.
Montanari and colleagues [410] have demonstrated that ETA receptor antagonism
can produce renal haemodynamic changes under conditions of ANG II receptor-1
blockade. This study demonstrates a similar synergy between ETA receptor
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antagonism and ACE inhibition. Recently, enalapril has been shown to attenuate ET-
1 induced hypertension (but not the reduction in GFR) in rats via increased
bradykinin [406]. However, the loss of this synergistic effect in this study on all
indices when BQ-788 is also given suggests that the ETB receptor is crucial to the
mechanism of this BQ-123-enalapril interaction. In an experimental rat model of
interstitial renal fibrosis, enalapril treatment has been shown to increases ETB
mRNA expression [411], providing a possible mechanism for this ET-l/ACE
interaction. It is possible that ETA receptor antagonism then results in displacement
of endogenous ET-1 from the ETA receptor onto the unblocked, upregulated ETB
receptor.
As BQ-788 is a vasoconstrictor, it is possible that its ability to abolish the vasodilator
effect of enalapril and BQ-123 is non-specific. However, the previous study in
healthy volunteers and CRF patients (Chapter 6) has demonstrated that, while this
dose of BQ-788 alone produces systemic and renal vasoconstriction, it does not
abolish the vasodilator effects of BQ-123 suggesting the effect seen here is specific
to the interaction between ACE inhibition and ETA receptor antagonism.
These studies were performed in subjects in a salt replete state (mean 24 hr urine
excretion 119 ± 6mmol). A recent study has suggested that ET-1 plays a role in
angiotensin-dependent hypertension in humans [412] particularly in respect of blood
pressure and proteinuria. Salt depletion, with enhancement of renin-angiotensin
activity, might therefore further enhance the synergy seen between ETA receptor
antagonism and ACE inhibition.
In this study, in the presence of ACE inhibition, combined ETA/B receptor
antagonism actually ERVR and ERBF, underlining the importance of this ETB
mediated vasodilatation. This finding has important implications for the therapeutic
use of ET receptor antagonists, suggesting that, in conjunction with ACE inhibitors,
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ETA will be superior to ETA/B receptor antagonists in respect of haemodynamic
benefits. This demonstration of an ETB receptor dependent, synergistic interaction in
healthy subjects between ETA receptor antagonism and ACE inhibition suggests
these differences observed in renal patients in chapter 5 may be, at least in part, due
to concomitant chronic treatment with ACE inhibitors.
It is important to note that BQ-123 concentrations were higher when subjects were
pre-treated with ACE inhibition. The number of subjects studied was small and this
difference did not reach significance, but it is interesting to note that in Chapter 5,
CRT patients also had higher BQ-123 plasma concentrations that healthy volunteers
(again, however, not significant). In light of this, a pharmacokinetic interaction
between enalapril and BQ-123 cannot be fully excluded without larger studies.
In summary, this mechanistic study demonstrates, in healthy men, that pre-treatment
with ACE inhibition increases the systemic haemodynamic effects of ETA receptor
antagonism and unmasks a renal haemodynamic and renal tubular effect, and that
this synergy is requires an unblocked ETB receptor. These findings would support
the use of ETA but not combined ETA/B receptor antagonists as useful adjunctive
treatments to ACE inhibitors in the treatment of the systemic and renal vascular
consequences of diseases characterised by vasoconstriction particularly in
circumstances where sodium loss would also be beneficial such as heart failure or
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ACE inhibitors, by preventing the breakdown of bradykinin [392], and ET-1, acting
on endothelial ETB receptors [413], both increase endothelium-dependent
vasodilatation. Having demonstrated a synergism between ETA receptor antagonism
and ACE inhibitors that is dependent upon an unblocked ETB receptor (Chapter 6),
the aim of this study was to explore the possible the mechanisms by which this
interaction might occur. During co-administration of ACE inhibition and ETA
receptor antagonism, subjects underwent selective blockade of NO production with
L-NMMA and prostaglandin production with indomethacin.
7.2 Study design
This was a randomised, double-blind, placebo-controlled study 6 healthy subjects.
For demographic data, see Table 7.1. Subjects attended for 4 visits, each separated
by >7 days. For each visit, they received pre-treatment with enalapril. During the
study day they then received placebo, BQ-123, BQ-123 + indomethacin or BQ-123 +
L-NMMA, in a randomised order (Table 7.1). Comparisons of interest were pre-
identified as placebo vs. BQ-123 and vs. BQ-123 + indomethacin/L-NMMA, and
BQ-123 vs. BQ-123 + indomethacin/L-NMMA. This study ran concurrently with the
study described in Chapter 8 (ie. 5 randomised visits in total). Placebo and BQ-123
phases are the same in the two studies.
Table 7.1 Subject demographic data
Age (yr) 47 ±2 (30 -59)
Body mass index (kg/m2) 23 ±2 (18-29)
MAP (mmHg) 84.9 ± 3.1 (70.8 - 98.7)
Creatinine (gmol/L) 86 ±8 (62-119)
Urinary Na excretion (mmol/24 hr) 103 ± 15 (61 - 162)
Cholesterol (mmol/'L) 5.1 ± 0.3 (3.9 — 6.1)
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For 5 days before each study, subjects took enalapril at a dose of 20 mg twice daily
(see methods for justification of dosing schedule) taking the last dose at 0830 on the
study day, along with indomethacin or a placebo capsule. Subjects then underwent a
standard clearance study. After baseline measurements, the low dose of antagonist
and L-NMMA or placebo was then administered followed by three 30 min collection
periods. The higher dose of antagonist and L-NMMA or placebo was then
administered followed by 5 further 30 min collection periods. To ensure blinding
with ET-1 (Chapter 8 study), L-NMMA infusion was followed by saline for 55 min,
and placebo was administered in 2 stages, over 5 min and 55 min after each dose of
antagonist (Fig 8.1).
At 0, 60 & 90 min after the start of low and high dose antagonist, and at the end of
the study, blood samples were taken for the measurement of plasma ET-1
concentrations. Serum ACE activity was determined at 0830 am and at 1430 (60 min
after the start of the higher dose antagonist).
7.3 Results
One subject experienced an increase in mean arterial blood pressure of 50 mmHg
following indomethacin administration and before receiving BQ-123, and was
withdrawn from the study and replaced. Baseline measurements were not different in
any phase of the study (Table 7.2).
7.3.1 Systemic haemodynamics (Fig 7.1)
The reduction in blood pressure observed after BQ-123 in the presence of enalapril
(maximum placebo-corrected change from baseline -6.0 ±1.7 mmHg, ANOVA
p<0.01 vs. placebo) was abolished by L-NMMA (-2.0 ± 2.7 mmHg, p <0.01 vs. BQ-
123+E), and moderately augmented by indomethacin, an effect most evident towards
the end of the study (-11.0 ± 2.3 mmHg, p<0.01 vs. placebo and vs. BQ-123+E).
SVRI was reduced by E+BQ-123 (-541 ± 119 dyne.s m2/cm5, p<0.01 vs. placebo),
and HR and CI increased. These changes were unaffected by indomethacin
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administration (SVRI -706 ± 148 dyne.s m2/cm5, p<0.01 vs. placebo), and abolished
by L-NMMA (SVRI -194 ± 116 dyne.smW, p<0.01 vs. BQ-123+E).











MAP (mmHg) 82.4±2.6 84.2±3.5 90.7±1.8 80.5±2.4
SVRI (dyne.s m2/cm5) 2291±275 2340±279 2679±348 2108±281
CI (L/min/m2) 3.1 ±0.4 3.0±0.3 2.9±0.4 3.3±0.3
HR (bpm) 59.6±2.8 60.1 ±3.2 54.7±2.3 60.1±2.3
ERBF (ml/min) 760±108 759±134 574±87 862±98
ERVR (mmHg.min/L) 124±22 126±18 177±25 105±18
EFF (%) 24±2 25±3 26±1 22±3
GFR (ml/min/1.73m2) 106±7 106±12 93±13 110±12
UNaV (pmol/min) 132±16 121±21 60±16 124±24
Plasma ET-1 (pg/ml) 3.9±0.5 3.4±0.6 5.2±0.6 5.0±0.6
7.3.2 Renal haemodynamics (Fig 7.2)
The effects of BQ-123+E were abolished by NOS inhibition (ERBF: BQ-123+E 179
± 63 ml/min; BQ-123+E+LNMMA -217 ± 98 ml/min, p<0.01 vs. BQ-123+E.
ERVR: BQ-123+E -61 ± 23 mmHg.min/L; BQ-123+E+LNMMA -14 ± 26
mmHg.min/L, p<0.01 vs. BQ-123+E), but unaffected by indomethacin (ERBF: 121
± 37 ml/min; ERVR: -42 ± 16 mmHg.min/L).
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Figure 7.1 Systemic haemodynamics
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7.3.3 Urinary sodium excretion (Fig 7.2)
The natriuresis produced by the combination of BQ-123+E (UNaV: 29.3 ± 7.4
pmol/min) was abolished by L-NMMA (-27.4± 20.3 pmol/min, p<0.01 vs. BQ-
123+E) and attenuated by indomethacin (-13.6 ± 11.7 pmol/min, p<0.01 vs. BQ-
123+E).
7.3.4 Serum ACE activity
Serum ACE activity at t = 0 and 180 min confirmed inhibition of ACE at the start of
and throughout each study day. There was no difference in ACE activity during any
phase of the study (Table 7.3).
Table 7.3 Serum ACE activity (AU)
Serum ACE E + Placebo E + BQ-123 E + BQ123 + E +BQ-123 +
activity (AU) Indomethacin L-NMMA
t = 0 min 6.1±3.3 12.6±4.0 11.2±4.1 12.6±4.4
t= 180 min 12.4±4.9 4.8±2.0 5.7±3.0 2.1±2.1
0 vs. 180 min p=0.36 p=0.15 p=0.34 p=0.09
7.3.5 Plasma ET-1 concentrations
Plasma ET-1 concentrations were not affected by pre-treatment with enalapril alone,
or by subsequent treatment with BQ-123, indomethacin or L-NMMA (Table 7.4).
Table 7.4 Plasma ET-1 concentrations (pg/ml)
Plasma ET-1 E + Placebo E + BQ-123 E + BQ123 + E +BQ-123 +
(pg/ml) Indomethacin L-NMMA
t = 0 min 3.9±0.5 3.4±0.6 5.2±0.6 5.0±0.6
t= 120 min 3.8±0.5 4.7±0.3 4.5±0.7 5.1±0.5
ANOVA* p=0.91 p=0.55 p=0.53 p=0.46
* for 0, 30, 90, 120, 180 & 240 min measurements
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7.4 Discussion
This study has demonstrated that synergy between ACE inhibition and ETA receptor
antagonism is abolished by NOS inhibition but largely unaffected by prostaglandin
inhibition, leading us to conclude that ETA receptor antagonism and ACE inhibition
act synergistically through an ETB receptor-mediated, NO-dependent and COX-
independent mechanism. This systemic data is in keeping with previous forearm
work demonstrating that the dilatory effects ofBQ-123 are mediated through NO but
not prostaglandins [194].
As L-NMMA is a vasoconstrictor, it is possible that its ability to abolish the
vasodilator effect of enalapril and BQ-123 is non-specific. However, indomethacin
has also been shown to produce renal vasoconstriction in healthy subjects [414] but
it had no effect on the renal vasodilatation seen in this study after enalapril and BQ-
123, suggesting the effect of L-NMMA seen here is specific to the interaction
between ACE inhibition and ETA receptor antagonism.
While prostacyclin is the major COX product of macrovascular endothelium in vitro,
COX activity can produce both vasoconstrictor and vasodilator arachadonic acid
derivatives. Prostaglandins stimulate renin release [415], Thus indomethacin may
produce both vasodilatation, by inhibition of renin-mediated ANG II generation and
COX-1-mediated thromboxane A2 synthesis, and vasoconstriction, by blocking
synthesis of vasodilator prostanoids. Studies in animals also suggest that
vasoconstrictor COX products, such as thromboxane A2 and prostaglandin H2,
might be implicated in ET-1 induced vasoconstriction, particularly in disease models
[416-420]. The greater fall in blood pressure when indomethacin was co¬
administered with enalapril and BQ-123 may represent blockade of the action of
these constrictor COX products. Additionally, there is animal evidence that
vasodilator prostaglandins may also be involved in the actions of ET in the renal
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circulation, particularly the renal medulla [418, 421], This study did not, however,
demonstrate any inhibitory effect of indomethacin on the systemic and renal
haemodynamic effects of the combination of ACE inhibition and ETA receptor
antagonism. In respect of RBF, however, clearance studies only measure total RBF.
It is possible, therefore, that opposite changes are occurring in the renal cortex and
medulla.
In respect of natriuresis, knockout and antagonist studies in animals have implicated
ETB receptors, in association with NO production, in ET mediated sodium excretion
[135]. COX inhibition however, augments big ET mediated natriuresis, suggesting
the involvement of prostaglandins, in an anti-natriuretic role [422], This study
demonstrates, in the presence of ACE inhibition, an ETB dependent natriuresis that
is mediated by both NO and, to a lesser extent, prostanoids.
In summary, this mechanistic study demonstrates, in healthy men, that the systemic
and renal haemodynamic synergy between ACE inhibition and ETA receptor
antagonism operates largely via a NO dependent mechanism.
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Chapter 8
Effects of exogenous ET-1 administration in the
presence of ET-A receptor antagonism and ACE
inhibition in healthy volunteers
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8.1 Introduction
The ETB receptor appears to have a natriuretic role at least in animals. ETB knockout
mice, and ETB antagonist treated rats, develop a sodium dependent hypertension [134,
135], Dogs subjected to high-grade ETA blockade demonstrate a vasodilatation and
natriuresis in response to administration of exogenous low dose ET-1[123], However,
ET-l/ETB induced natriuresis has not been demonstrated in man. In this study
exogenous ET-1 was administered in the presence of ACE inhibition and ETA blockade
to examine the effects of ETB receptor activation on systemic and renal
haemodynamics
8.2 Study design
This was a randomised, double-blind, placebo-controlled study 6 healthy subjects.
Subjects attended for 3 visits, each separated by >7 days. For each visit, they
received pre-treatment with enalapril. During the study day they then received
placebo, BQ-123, or BQ-123 + ET-1 in a randomised order (Fig 8.1). Comparisons
of interest were pre-identified as placebo vs. BQ-123 and vs. BQ-123 + ET-1, and
BQ-123 vs. BQ-123 + ET-1. This study ran concurrently with the study described in
Chapter 7 on the same subjects (ie. 5 randomised visits in total). Placebo and BQ-
123 phases are the same in the two studies.
For 5 days before each study, subjects took enalapril at a dose of 20 mg twice daily
(see methods for justification of dosing schedule) taking the last dose at 0830 on the
study day. At 0830 they also received a placebo capsule to allow indomethacin
administration (Chapter 7 study) to be blinded. Subjects then underwent a standard
clearance study. After baseline measurements, the low dose of antagonist was
administered over 15 min and ET-1 or placebo over 60 min followed by three 30 min
collection periods. The higher dose of antagonist and ET-1 or placebo was then
administered followed by 5 further 30 min collection periods. To ensure blinding for
L-NMMA administration (Chapter 7 study), ET-1 and saline placebo were
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administered in 2 stages, over 5 min and 55 min after each dose of antagonist (Fig
8.1).


















BP & bioimpedance measurements every 15 min
Urinary collection periods every 30 min
At 0, 60 & 90 min after the start of low and high dose antagonist, and at the end of
the study, blood samples were taken for the measurement of plasma ET-1
concentrations. BQ-123 plasma concentrations were measured before and at 15, 45
& 90 minutes after the start of each dose of antagonist, and at the end of the study.
Serum ACE activity was determined at 0830 am and at 1430 (60 min after the start
of the higher dose antagonist).
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8.3 Results
All subjects completed the study without adverse effects. Baseline measurements
were not different in any phase of the study (Table 8.1).
Table 8.1 Baseline data
E+Placebo E+BQ-123 E+BQ-123+ET-1
MAP (mmHg) 82.4±2.6 84.2±3.5 82.1+3.9
SVRI (dyne.s m2/cm5) 2291±275 2340+279 2238+297
CI (L/min/m2) 3.1±0.4 3.0+0.3 3.1+0.2
HR (bpm) 59.6±2.8 60.1+3.2 61.9+2.9
ERBF (ml/min) 760±108 759+134 675+69
ERVR (mmHg.min/L) 124±22 126+18 132+14
EFF (%) 24±2 25+3 24+2
GFR (ml/min/1.73m2) 106±7 106+12 102+8
UNaV (pmol/min) 132±16 121+21 137+36
Plasma ET-1 (pg/ml) 3.9±0.5 3.4+0.6 5.5+0.7
8.3.1 Systemic haemodynamics (Fig 8.2)
The reduction in blood pressure observed after BQ-123 in the presence of enalapril
(maximum placebo-corrected change from baseline -6.0 ± 1.7 mmHg) was
abolished by ET-1 (-6.0 ±1.7 mmHg). SVRI was reduced by E+BQ-123, and HR
and CI increased. Administration of exogenous ET-1 abolished all systemic
haemodynamic changes produced by BQ-123 except for the increase in HR.
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Figure 8.2 Systemic haemodynamics
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Figure 8.3 Renal indices
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8.3.2 Renal haemodynamics (Fig 8.3)
ET-1 administration abolished all renal haemodynamic changes produced by BQ-
123. (ERBF: BQ-123+E 179 ± 63 ml/min; BQ-123+E+ET-1 -213 ± 56 ml/min,
p<0.01 vs. BQ-123+E. ERVR: BQ-123+E-61 ± 23 mmHg.min/L; BQ-123+E+ET-1
+54 ±1.5 mmHg.min/L, p<0.01 vs. BQ-123+E).
8.3.3 Urinary sodium excretion (Fig 8.3)
The natriuresis produced by the combination of ACE inhibition and ETA receptor
antagonism (UNaV: 29.3 ± 7.4 pmol/min) was abolished by exogenous ET-1
infusion (UNaV: -38.2±23.6, p<0.01 vs. BQ-123+E).
8.3.4 Serum ACE activity
Serum ACE activity at t = 0 and 180 min confirmed inhibition of ACE at the start of
and throughout each study day. There was no difference in ACE activity during any
phase of the study (Table 8.2).
Table 8.2 Serum ACE activity (AU)
Serum ACE E + Placebo E + BQ-123 E + BQ-123 +
activity (AU) ET-1
t = 0 min 6.1+3.3 12.6±4.0 6.2±3.1
t = 180 min 12.4±4.9 4.8±2.0 5.6±2.5
0 vs. 180 min p=0.36 p=0.15 p=0.76
8.3.5 Plasma ET-1 concentrations
Administration of exogenous ET-1 resulted in a threefold rise in plasma ET-1
concentrations 30 min after commencing each ET-1 infusion (t=0 min, 5.5±0.7
pg/ml; t=30 min, 12.5±2.8 pg/ml; t=120 min, 15.1±3.6 pg/ml, p<0.05 vs. placebo).
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Plasma concentrations had reduced back to baseline 90 min after commencing ET-1
infusion (t=90 min, 5.4±0.5 pg/ml; t=l80 min, 6.5±0.8 pg/ml)
8.3.6 Plasma BQ-123 (Fig 8.4)
Plasma BQ-123 concentrations were not altered by infusion of exogenous ET-1



















This study demonstrates that that ET-1 abolishes the systemic and renal
vasodilatation and natriuresis produced by combined ACE inhibition and ETA
receptor antagonism.
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Studies in dogs have used ETA receptor blockade to unmask a renal vasodilatory and
natriuretic effect of ET-1, presumed to be due to ETB receptor activation [123]. In
administering exogenous ET-1 during combined ACE inhibition and ETA receptor
blockade, the aim had been to demonstrate an effect of direct ETB receptor
stimulation in man. However, administration of exogenous ET-1 in this study served
only to abolish the systemic and renal effects of combined ACE inhibition and ETA
receptor blockade. BQ-123 is a competitive antagonist at the ETA receptor [93]
whereas ET-1 is a non-competitive agonist [413]. It would be important therefore to
ensure that plasma ET-1 concentrations do not achieve levels sufficient to displace
BQ-123 from the ETA receptor. A previous study has demonstrated that an
equivalent dose of BQ-123 to our low dose is sufficient to abolish the systemic and
renal vasoconstriction produced by this dose of ET-1 [139]. Therefore, in designing
the study, it was hoped that the high dose of BQ-123, an order ofmagnitude greater,
would be sufficient to sustain ETA blockade in the presence of this dose of ET-1.
The abolition of vasodilatation and natriuresis does suggest that a degree of ETA
receptor activation is occurring by displacement of BQ-123 by exogenous ET-
1.However, no increases in plasma BQ-123 concentrations were observed in the
presence of ET-1 to suggest any displacement from its receptor. It is possible,
therefore, that the ETB receptor does not play a role in renal vasodilatory tone and
sodium regulation in healthy volunteers. However, all studies so far presented
(Chapter 5 & 6) and previous work from the department [194, 210] suggests that the
net result of ETB receptor activation is to produce vasodilatation in man. This needs
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Chapter 9
The systemic haemodynamic and renal
response to acute ETA antagonism after a high
salt intake in healthy volunteers
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9.1 Introduction
Animal models of salt-sensitive hypertension have suggested an important pathogenic
role for ET-1 [423] and the therapeutic potential for ETA receptor antagonism in this
condition [424-426], In man, plasma and urinary ET concentrations have been shown to
be elevated in salt-sensitive individuals [427, 428], though this is not a uniform finding
[215],
A high salt intake has also been shown to increase vascular NO activity in man [429]
and the response to NOS inhibition increases on a high salt diet suggesting a greater
dependence on the dilatory actions of NO when salt loaded [429, 430], This
upregulation of NO is likely to represent an important adaptation to increased salt
intake and studies suggest that a relative deficiency of endothelial NO activity may
contribute to the development of salt-sensitive hypertension [426, 431, 432],
ETA antagonism with BQ-123 decreases vascular tone in healthy volunteers and
patient groups (Chapters 3 & 5). Forearm studies suggest these dilator effects are
largely mediated though nitric oxide (NO) [194], The hypothesis for this study was,
therefore, that in individuals whose blood pressure exhibited a high degree of salt
sensitivity, the relative reduction in endothelial NO activity would result in a reduced
systemic haemodynamic response to BQ-123 compared to salt-resistant individuals.
9.2 Study design
This was a randomised, double-blind, placebo-controlled study 6 healthy subjects. For
demographic data, see Table 9.1. Subjects attended for 4 visits, each separated by >7
days receiving placebo or BQ-123 in a randomised order in the presence or absence of
sodium supplementation. For 3 days before each study subjects adhered to a
standardised diet restricting salty foods (restricted salt: RS). On two of the four visits,
subjects also took 15 slow sodium tablets a day (10 mmol each) to achieve a high salt
(HS) intake. Comparisons of interest were pre-identified as placebo vs. BQ-123 on a RS
diet, placebo vs. BQ-123 on a HS diet and BQ-123 on a RS vs. a HS diet. Salt sensitivity
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index (SSI) was calculated as the percentage difference between baseline MAP on a high
salt compared to a routine salt diet.
Table 9.1 Subject demographic data
Age (yr) 51 ±3 (41 - 64)
Body mass index (kg/m2) 24 ±2 (19 -33)
MAP (mmHg) 98.2 ±8.8 (88.6- 108.5)
Creatinine (|imol/L) 93 ± 8 (62 - 119)
Cholesteroi (mmol/L) 5.2±0.2
On each study day, subjects underwent a standard clearance study. After baseline
measurements, the low dose of BQ-123 was administered followed by three 30 min
collection periods. The higher dose of BQ-123 was then administered followed by 5
further 30 min collection periods.
At 0, 60 & 90 min after the start of low and high dose of BQ-123, and at the end of the
study, blood samples were taken for the measurement of plasma ET-1, and urine samples
for the measurement of urinary ET-1 excretion rates.
9.3 Results
One subject was unable to tolerate salt tablets, withdrew from the study and was
replaced. Six subjects completed the study without adverse events. 24 hr urinary sodium
excretion on the third day of a RS diet was 130±19 mmol/24 hrs. After the HS diet, this
increased to 279±36 mmol/24 hrs (p<0.01 vs. RS). Baseline data are shown in Table 9.2.
Blood pressure at baseline was higher after the HS diet (RS both visits: 93.2±2.2, HS
both visits: 101.0±3.2 p<0.01) but ERBF and GFR were unchanged. Plasma ET-1
concentrations were not increased (RS both visits: 4.8±0.3 pg/ml, HS both visits: 5.1±0.2
pg/ml) but urinary ET-1 excretion rates were higher after the HS diet (RS both visits:
10.6±1.2 pg/min, HS both visits: 13.7±1.4 pg/min p<0.05).
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MAP (mmHg) 94.5±2.8 93.4±3.7 100.7±4.9 101.4±4.6 p<0.01
SVRI (dyne.s m2/cm5) 2527±297 2842±453 3009±512 2787±385 NS
CI (L/min/m2) 3.2±0.4 2.9±0.4 3.0±0.4 3.1±0.4 NS
HR (bpm) 60.8±0.9 58.4±1.1 55.3±1.4* 55.6±1.3* p<0.01
ERBF (ml/min) 695±78 703±75 732±118 737±96 NS
ERVR (mmHg.min/L) 150±13 144±17 159±32 153±25 NS
EFF (%) 24±2 22±2 23±2 22±2 NS
GFR (ml/min/1.73m2) 99±11 102±13 105±10 104±10 NS
UNaV (pmol/min) 165±11 166±25 253±17 221±24 p<0.01
Plasma ET-1 (pg/ml) 4.7±0.5 4.9±0.4 5.2±0.2 5.0±0.2 NS
Urinary ET-1 11.3±1.5 10.0±1.8 12.3±2.2 15.1±1.5 p<0.05
excretion (pg/min)
*p<0.05 vs. Placebo RS diet
9.3.1 Systemic haemodynamics (Figs 9.1 & 9.2)
BQ-123 significantly reduced MAP and SVRI, and increased HR and CI on both a RS
and a HS diet to an equal degree (p<0.01 vs. placebo) (Fig 9.1). However, the increase in
baseline MAP on a high salt diet for each individual (SSI) did correlate with the extent
to which he responded to ETA antagonism (R2=0.76 p=0.02) (Fig 9.2). There was no
correlation observed between the reduction in MAP after BQ-123 and baseline MAP
(R2<0.001 p=0.98), or 24 hour urinary sodium excretion (R2<0.001 p=0.99) for that
study day.
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Figure 9.2 Salt sensitivity index vs response to BQ-123 - MAP
9.3.2 Renal haemodynamics (Figs 9.3 & 9.4)
Consistent with previous studies in healthy volunteers (Chapter 5) BQ-123 did not
significantly alter ERBF, ERVR or GFR and no correlations were noted between SSI
and ERVR (R2=0.59 p=0.27), or ERBF (R2=0.28 p=0.08).
9.3.3 Urinary sodium excretion
While BQ-123 modestly increased urinary sodium excretion on both diets (RS:
+7.9±11.1%; HS: +10.7±12.0%, p<0.05 vs. HS placebo), there was no correlation
2 • • 2between SSI and sodium excretion (R <0.001 p=1.00), or fractional excretion (R <0.001
p=0.96).
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Figure 9.3 Salt sensitivity index vs response to BQ-123 - ERBF
Figure 9.4 Salt sensitivity index vs response to BQ-123 - ERVR
9.3.4 ET-1 concentrations
Plasma ET-1 concentrations were not altered by any treatment (Table 9.3). Urinary
ET-1 excretion rates were higher at baseline on a HS diet (Table 9.2) but did not
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correlate with 24hr urinary sodium excretion or SSI. Urinary ET-1 excretion was not
altered by administration of placebo or BQ-123 on either diet (Table 9.3).
Table 9.3 Plasma ET-1 concentrations (pg/ml) and urinary excretion
rates (pg/min)
Plasma ET-1 Placebo BQ-123 Placebo BQ-123
concentrations RS diet RS diet HS diet HS diet
(pg/ml)
t = 0 min 4.7±0.5 4.9±0.4 5.2±0.2 5.0±0.2
t = 120 min 4.8±0.5 4.1±0.3 4.9±0.3 5.1±0.5
ANOVA* p=0.97 p=0.41 p=0.53 p=0.99
Urinary ET-1 Placebo BQ-123 Placebo BQ-123
excretion RS diet RS diet HS diet HS diet
(pg/min)
t = 0 min 11,3±1.5 10.0±1.8 12.3±2.2 15.l±1.5
t= 120 min 10.2±1.2 11.7±2.5 9.8±1.3 14.2±1.6
ANOVA* p=0.85 p=0.91 p=0.72 p=0.72
* for 0, 30, 90, 120, 180 & 240 min measurements
9.4 Discussion
While this study did not demonstrate a difference, in the group as a whole, in the effect
of BQ-123 on systemic and renal haemodynamics on a HS diet compared to the RS diet,
individuals with higher degrees of salt sensitivity of their blood pressure appear to have
a blunted blood pressure response to ETA receptor antagonism on a high salt intake.
This suggests that ETA antagonists would be more effective as treatments for
hypertension in salt-sensitive individuals when such patients are salt restricted.
The role of ET in the response to salt and salt-sensitivity has been supported by a series
of studies. Salt loading causes rats to develop greater hypertension on a high salt diet
under conditions of chronic ETB receptor blockade [433], and the DOCA-salt
hypertensive rat, a salt-sensitive strain demonstrates increased ET-1 production,
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upregulation of ETB receptors and hypertension that is blocked by ETA receptor
antagonism [434, 435]. Renal ET-1 in particular is important in the response to salt.
Urinary ET-1 is increased by a high salt diet [433], and a high salt intake also augments
the ETB receptor mediated medullary vasodilatation induced by big-ET-1 [133], A high
salt intake is known to increase renal NO activity [430]. However, salt-sensitive rats fail,
unlike salt-resistant strains, to increase renal NOS activity in response to salt loading
[426]. Taken together, these studies suggest that the response to an increased salt
ingestion is to increase in ETB and NO mediated vasodilatation particularly in the renal
medulla where it promotes natriuresis (that may be in part related to this increase in
blood flow or direct tubular effect) as an adaptive response to limit hypertension, and
that in salt-sensitive individuals, there is a failure to increase NO sufficiently and a
consequent reduced sodium excretion and increased systemic vasoconstriction.
It has previously been demonstrated in forearm studies that ETA receptor antagonists
achieve their haemodynamic effects through NO [194], presumed due to binding of ET-
1 under conditions of ETA receptor blockade to the ETB receptor. It is possible that the
lesser response to BQ-123 in salt-sensitive subjects seen in this study is a consequence
of reduced endothelial NO activity in such individuals compared to salt-resistant
individuals. However, if the lesser response to BQ-123 in salt-sensitive subjects is a
consequence of reduced endothelial NO activity, concomitant ETB blockade will be less
important in salt-sensitive individuals on a high-salt diet with loss of endothelial NO.
This must be borne in mind in comparing the clinical effects of selective ETA and
combined ETA/B receptors in unscreened subjects, as a high salt diet in salt-sensitive
individuals may limit any differences between these two therapeutic approaches.
In this study, a high salt diet increased baseline blood pressure without an alteration in
plasma ET-1 concentrations to suggest an upregulation of the ET system. However, due
to the largely paracrine action of vascular endothelial ET-1, plasma ET-1 is not a good
marker of the activity of the vascular ET system. Urinary ET-1, a marker of increased
renal production [436], was, however, increased on a high salt diet consistent with
increased renal ET-1 in response to salt loading. Despite this, no clear changes in renal
blood flow or vascular tone could be demonstrated in this study either in the group as a
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whole, or relating the changes observed in individuals to their salt-sensitivity, though the
subject with the highest degree of salt-sensitivity did exhibit the greatest increase in
ERVR and fall in ERBF on a high salt diet. PAH clearances can only measure total renal
blood flow so changes in medullary or cortical blood flow may be missed. Nevertheless,
SSI, however, had no influence on sodium excretion either in this study.
However, this study is limited by the small number of subjects studied and the fact that 4
out of the 6 subjects had very similar and small increases in blood pressure in response
to increased salt intake. While a trend was observed in respect of a correlation between
SSI and ERBF and ERVR, this did not reach significance. Further studies are needed in
healthy volunteers and patients with a range of SSIs, particularly subjects with a high
degree of salt sensitivity to explore this further.
In conclusion, the effectiveness of ETA receptor blockade may be limited in salt-
sensitive individuals who continue to take a high salt diet. Identification of such
individuals is therefore important, as pharmacological intervention for hypertension
must be instituted in conjunction with dietary advice.
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Chapter 10
Urinary excretion of endothelin-1
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10.1 Introduction
ET-1 is largely removed from the circulation by receptor (ETB) mediated mechanisms,
primarily in the pulmonary circulation [86-88]. Renal clearance, however, does account
for -10% of plasma ET-1 clearance in man [86]. ET-1 is a small polypeptide and plasma
ET-1 will thus be filtered at the glomerulus, and, because it is dependent upon filtration,
this renal clearance does not require receptor-mediated mechanisms. After filtration, in
common with most polypeptides, ET-1 is likely to be hydrolysed at the brush border and
the constituent peptides and amino acids reabsorbed in the tubules and metabolised. In
rats, though up to 15% of plasma ET-1 is extracted across the renal bed [88] less than
1% of injected radiolabelled ET-1 is recovered in the urine [92], The failure of plasma
ET-1 in these isotope studies to appear in the urine implies that neither glomerular
filtration nor tubular secretion of plasma ET-1 accounts for urinary ET-1, which is
therefore assumed to be primarily of renal origin, and, hence, independent of plasma ET-
1 concentrations.
In CRF, the consequence of a reduced filtration rate is a reduced filtered load of ET-1
delivered to the tubules. Thus renal ET-1 clearance will fall as renal function is lost,
leading to increases in plasma concentrations of ET-1 [216]. Renal ET-1 production, and
hence urinary ET-1 excretion, is, however, also increased in CRF [92, 188]. Therefore,
while plasma ET-1 concentrations and urinary ET-1 excretion should be independent of
each other [436], both will correlate inversely with GFR, and may, thus, appear to
correlate with each other.
There is also recent animal evidence to suggest that ETB receptors may participate in the
movement of proteins across the renal tubular epithelium [437], Peri-tubular ET-B
receptors are abundant in the human kidney [52], However, their possible role in urinary
ET-1 excretion has not been studied.
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Using paired plasma and urine samples from the studies described in studies 3-7
(Chapter 5-9), this chapter compares plasma ET-1 concentrations and ET-1 excretion
rates to establish if any relationship exists between these two measurements.
Additionally, using measurements from study 3 (Chapter 5), the effect of ET receptor
blockade on urinary excretion of ET-1 has been examined.
10.2 Protocol
During all of the clearance studies (studies 3-7), paired plasma and urine samples were
taken at 0, 60 & 90 min after the start of both low and high dose antagonist
administration, and at the end of the study, for the measurement of plasma and urinary
ET-1 concentrations. Urinary excretion rate was calculated by multiplying urinary ET-1
concentration by urine flow rate.
10.3 Results
10.3.1 Correlation of plasma and urinary ET-1
Analysing the results from study 3 (Chapter 5) in isolation, at baseline (t=0), before
administration of ET receptor antagonist, a limited correlation between plasma and
urinary ET-1 excretion was observed (R2=0.09, p=0.02). However, both plasma ET-1
concentration and urinary ET-1 excretion correlated inversely with baseline GFR (Fig
10.1). Fractional excretion of ET-1 also correlated inversely with baseline GFR
(R2=0.44, p<0.01) and only exceeded unity in patients with CRF (Fig 10.2).
Analysis of paired plasma and urine samples from all the phases of study 3 (384 paired
samples) did not demonstrate a relationship between plasma ET-1 concentration and
urinary ET-1 excretion (R2=0.001, p=0.50) (Fig 10.3).
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Figure 10.1 Plasma & urinary ET-1 in baseline samples
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Fig 10.3 Plasma ET-1 concentrations vs. Urinary ET-1
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Plasma ET-1 concentrations were significantly increased acutely in two studies. In study
6 (Chapter 8), administration of exogenous ET-1 achieved a ~ threefold increase in
plasma ET-1 concentrations but did not alter urinary ET-1 excretion rates (R2=0.009,
p=0.58) (Fig 10.4).
Fig 10.4 Plasma ET-1 concentrations vs. Urinary ET-1 excretion
rate during exogenous ET-1 administration
40-,
Plasma ET-1 concentration (pg/ml)
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In study 3, plasma ET-1 concentrations increased at 30 min after administration of the
high dose of BQ-788 alone (+2.6±0.5, p<0.01), or in combination with BQ-123
(+3.5±0.6 pg/ml, p<0.01). Again, these alterations in plasma ET-1 after ET receptor
antagonism were not reflected by changes in urinary ET-1 excretion (R2=0.009, p=0.11)
(Fig 10.5).
Fig 10.5 Plasma ET-1 concentrations vs. Urinary ET-1 excretion
rate during ETB receptor blockade
Plasma ET-1 (pg/ml)
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10.3.2 Effect of ET receptor antagonism on ET-1 excretion
In study 3, following administration of BQ-788 alone urinary ET-1 excretion decreased
(-4.7±1.5 pg/min, p<0.05) (Fig 10.6) but was not altered by placebo, BQ-123 or BQ-
123/788. Because GFR was also reduced by ETB receptor antagonism (-11.4±3.4%,
p<0.01 vs. placebo), fractional urinary excretion of ET-1 was calculated. This was
reduced after both BQ-788 alone (-41±6%, p<0.01) and in combination with BQ-123 (-
40±7%, p<0.01), but not by placebo (+6±12%) or BQ-123 alone (-12±8%) (Fig 10.4).
No difference was observed in the pattern of responses to ET receptor antagonism
between healthy volunteers and CRF patients. In study 4 (Chapter 6), when healthy
volunteers were pre-treated with ACE inhibitor, again a reduction in fractional excretion
of ET-1 was observed when BQ-123/788 (-23±13%) but not BQ-123 (-6±18%) was
given.
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Figure 10.6 Plasma ET-1 concentrations and urinary ET-1 excretion
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10.4 Discussion
The lack of correlation between plasma ET-1 concentrations and urinary ET-1 excretion
rates, particularly when drug manoeuvres acutely increase plasma ET-1 concentrations,
demonstrates the independence of plasma and urinary ET-1 concentrations, consistent
with two separate ET systems in the circulation and the kidney. Additionally, because
urinary ET-1 is dramatically and acutely reduced by ETB blockade, these data also
suggest a role for ETB receptors in the excretion of ET-1 of renal origin.
Baseline data from study 3 (Chapter 5), before pharmacological manoeuvres to change
plasma ET-1, confirm an inverse correlation between plasma ET-1 concentration and
GFR, consistent with reduced renal clearance, and between urine ET-1 excretion and
GFR, consistent with increased renal production of ET-1 in CRF. Because both plasma
ET-1 concentrations and urine ET-1 excretion are related to GFR, a weak correlation
does exist between these two measurements at baseline. Additionally, baseline data from
study 3 demonstrate that fractional excretion of ET-1 only exceeds unity in patients with
CRF. For this to occur more ET-1 must be excreted than filtered. If, as suggested by
isotope studies [92], plasma ET-1 does not account for urinary ET-1, a fractional
excretion exceeding unity demands renal ET-1 synthesis. Hence our finding supports
urinary ET-1 excretion as being a marker of the increased renal ET-1 production in CRF.
There are few data, however, to suggest how renal ET-1 reaches the tubules. A recent
study in fish has localised ETB receptors to the basolateral aspect of proximal tubular
cells and has demonstrated that low concentrations of ET-1 are able to reduce cell to
tubular lumen transport ofmethotrexate and CyA derivatives. This effect was inhibited
by ETB receptor antagonists [437], suggesting a role for ETB receptors in tubular
transport mechanisms.
In study 3 and 4, after correcting for changes in GFR by calculating FeET-1, it was
evident that urinary ET-1 excretion is reduced specifically by blockade of the ETB
receptor either alone or when combined with ETA receptor blockade. Because the acute
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nature of our studies make it unlikely that ET receptor blockade had significant effects
on renal ET-1 production, these data suggest that the renal tubular excretion of ET-1
appears also to be at least partly mediated through the ETB receptor.
In conclusion, these data provide confirmatory evidence in man for two independent ET
systems in the circulation and in the kidney, both related to GFR, and suggest, for the
first time, that ETB receptors may be involved in the urinary excretion of renal ET-1.
This has implications for the use of ET antagonists that block both the ETA and the ETB
receptor. ET-1 is associated with renal fibrosis [438], and therefore failure to excrete
renal ET-1 may be detrimental to the kidney, limiting the use of combined ETA/B
receptor antagonists. As ET receptor antagonists are in Phase III clinical trials, this
important observation warrants further attention.
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Chapter 11
Renal Clearance of BQ-123
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11.1 Introduction
BQ-123 is a cyclic pentapeptide that is cleared by hepatic anion transport mechanisms
[97]. However, though non-significant, renal patients had higher plasma concentrations
after BQ-123 infusion than healthy volunteers for the same dosing schedule of BQ-123
(study 3). Concentrations of BQ-123 were therefore measured in the urine in a subgroup
of subjects to ascertain if any BQ-123 was excreted renally, and, if so, whether this renal
clearance was significantly reduced in CRF to account for the higher plasma
concentrations observed in CRF patients.
Urinary concentrations of BQ-123 were therefore measured after BQ-123 administration
(alone or with BQ-788) during 10 healthy volunteer visits and 5 patient visits from the
study described in Chapter 5.
11.2 Results
BQ-123 was recoverable in the urine after intravenous administration. The profile of
BQ-123 appearance in the urine mirrored exactly the profile in the plasma (Fig 11.1).
Fig 11.1 BQ-123 plasma concentrations and urinary excretion rates
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It fell to zero and remains there by 2 hours after the high dose infusion. In the group as a
whole, the total excreted was 3.7 ± 0.5% (0.3 - 6.2%) of the total given.
An inverse correlation between peak plasma concentrations of BQ-123 at 105 min (at
end of high dose BQ-123 infusion) and urinary BQ-123 excretion rate between 90 and
120 min was noted (R2=0.35, p=0.04). Additionally, a correlation between the total BQ-
123 excreted by an individual and their GFR was noted (R2=0.31, p=0.03) (Fig 11.2).
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11.3 Discussion
BQ-123 is subject to renal clearance and this clearance reduces as GFR falls. However,
this renal excretion is of minor importance in respect of overall clearance of BQ-123
from the circulation. A reduced urinary excretion rate of BQ-123 is, nevertheless,
associated with higher plasma concentrations, and must be taken into consideration in
interpreting the effects of BQ-123 in renal patients. Looking at individual plasma








CyA is a fungal derived peptide that is a widely used immunosuppressive agent that
inhibits the immune system by suppressing T-helper cell activation via inhibition of the
intracellular enzyme calcineurin. The introduction of CyA in the transplant field in the
1980s has significantly improved graft survival [439-441]. Unfortunately, though it is an
effective immunosuppressive drug, it has a wide range of side effects including
hypertension and nephrotoxicity. It is estimated that 60 - 90% of patients on chronic
CyA therapy requiring anti-hypertensive medication [441-443].
The precise mechanisms of CyA induced hypertension and nephrotoxicity however,
remain unclear. Impaired vasodilator responsiveness [444] or enhanced vasoconstrictor
tone, either as a direct CyA effect [445] or as a consequence of increased sympathetic
nervous system (SNS) activity [445-447] and renal vasoconstriction, with salt and water
retention and consequent extravascular volume expansion [448], have all been proposed,
and it is probable that more than one mechanism is acting to increase blood pressure.
Animal models and patient studies have both demonstrated increases in systemic
vascular resistance and reductions in CO in response to CyA [449-452], CyA is also well
documented as causing acute renal vasoconstriction in patients on chronic CyA
treatment [453-456]. However, while acute studies in healthy volunteers have
demonstrated renal hypoperfusion after a single high dose ofCyA [347, 457-459], this is
not a uniformly reproducible effect [460, 461], and experimental data suggests that, in
both healthy subjects and patients, systemic and renal vasoconstriction may only
develop after days to weeks of CyA treatment [462-465]. Additionally, forearm studies
have suggested that acute CyA administration might, paradoxically, increase the activity
of endothelial vasodilators in healthy subjects naive to the drug [466],
The purpose of this study was, therefore, to examine the systemic and renal
haemodynamic effects of a single, oral, high dose of CyA in healthy volunteers to
ascertain if the pattern of systemic and renal haemodynamic changes produced differed
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from those documented in patients on chronic CyA therapy, and thus ascertain if this is a
relevant model for the investigation of chronic CyA induced systemic vasoconstriction
and renal hypoperfusion.
12.2 Study design
The study was a randomised, double-blind, placebo-controlled, crossover study. Subjects
attended for 2 visits, separated by >5 days. Twelve healthy volunteers were recruited to
the study. For subject demographic data see Table 12.1
On each day, subjects then underwent an adapted clearance study. After baseline
measurements over three 20 min collection periods, subjects then received placebo
(olive oil) or CyA (Neoral) liquid (Novartis), 10 mg/kg. Measurements then continued at
20 min intervals for 4 hours. At 0, 60, 120, 180 and 240 min, blood was collected for the
measurement of plasma CyA and ET-1.
Table 12.1 Subject demographic data
Age (yr) 33±2 (22 - 44)
Body mass index (kg/m2) 24 ± 1 (20 - 26)
MAP(mmHg) 90.3 ± 1.8 (80.0 - 99.3)
Creatinine (|amol/L) 84 ±3 (71 - 104)
12.3 Results
6 subjects completed the CyA arm of the study and 9 completed the placebo arm. The
most common reason (in 5 of 24 studies) for non-completion was emesis. Other reasons
were not study related. Data was only analysed from those subjects completing a study
day. Baseline data did not differ between CyA and placebo phases (Table 12.2).
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12.3.1 Systemic haemodynamics
Mean arterial pressure rose in the CyA group by 6.7 ± 1.9% from 92.9 to 99.6 mmHg
(p<0.001 compared to placebo). This was accompanied by an increase in HR of 26.2 ±
3.5% (p<0.001), an increase in CI of 20.6 ±3.1% (p<0.001) and a fall in SVRI of 13.5 ±
1.4% (p<0.001). Changes were maximal at 80 min but persisted throughout the 4 hours
of the study (Fig 12.1).
Table 12.2: Baseline data
CyA Placebo CyA vs. Placebo
t-test
MAP (mmHg) 92.9±2.1 89.9±3.0 NS
SVRI (dyne.s rrf/cm5) 2432±152 2448±232 NS
CI (L/min/m2) 3.1±0.2 2.9±0.2 NS
HR (bpm) 57.3±3.4 54.3±2.6 NS
ERBF (ml/min) 914±90 862±103 NS
ERVR (mmHg.min/L) 116±16 122±17 NS
EFF (%) 27±2 24±3 NS
GFR (ml/min/1,73m2) 120±8 103±7 NS
UNaV (gmol/min) 130±41 106±17 NS
12.3.2 Renal haemodynamics
A moderate fall in GFR was seen (-9.0 ± 4.8%, p<0.01), maximal at 180 min. ERBF
after CyA was not different from placebo. However, ERBF as a proportion of CO did
fall from 14.8 to 11.6% (p<0.01) (Fig 12.2).
12.3.3 Urinary sodium excretion
There were no differences in urinary sodium excretion between the two groups.
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12.3.4 Plasma ET-1 concentrations
Plasma ET-1 concentrations were not altered by CyA administration (Placebo baseline:
3.5 ± 0.9 pg/ml, t=4 hrs 2.7 ± 0.5; CyA baseline 4.8 ± 2.8 t=4 hrs: 3.9 ± 0.6)
12.3.5 Plasma CyA concentrations
CyA concentrations were maximal at 60 minutes post administration and remained at
this level for a further 60 minutes reaching peak values of 1630 ± 169 nmol/L (Fig
12.3).
Fig 12.3 Plasma cyclosporin concentrations after administration
of 12 mg/Kg oral neoral
Time post CyA administration (hrs)
12.4 Discussion
Single, high dose CyA in healthy volunteers caused the expected increase in blood
pressure, together with in a striking increase in HR. However it was also associated with
a decrease in SVRI and an increase in CI. This contrasts with the reported
haemodynamics in patients on chronic CyA therapy where an increase in SVRI and a
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reduction in CI are commonly seen [451, 452], Additionally, the renal vasoconstriction
reported in patients on treatment [347, 453, 454, 456] was not seen though there was a
fall in RBF relative to CO.
Recent forearm studies in healthy volunteers have shown that acute administration of
CyA results in increased basal and stimulated NO activity and NOS gene expression
[466]. Conversely, renal transplant patients on chronic CyA show reduced basal and
stimulated NO activity compared to healthy volunteers [467]. CyA is also known to
increase gene transcription and secretion of ET-1 from endothelial and smooth muscle
cells [171]. Increased activity of the ET system is also indicated by the ability of ET
receptor antagonism to attenuate CyA induced smooth muscle cell contraction [171] and
CyA induced renal vasoconstriction [145]. Changes in gene transcription will not be
manifest immediately, but will take some days to develop fully. Hence, while CyA
acutely upregulates endothelial NO activity, chronic exposure to CyA will cause
endothelial dysfunction due to both reduced NO activity and increased ET-1 activity,
altering the balance of vasoactive compounds in the endothelium in favour of
vasoconstriction. Rat models suggests that this switch in endothelial balance to favour
vasoconstriction happens early, with 1-3 weeks being sufficient for reduction in urinary
NO metabolites and alterations in vessel responses suggestive of reduced NO activity to
occur [468, 469], Such data suggest the mechanisms behind the hypertensive and renal
haemodynamic changes of a single high dose of CyA will be different from those found
in chronic CyA administration. The results from this study are consistent with this
hypothesis.
The most striking change in this study was the increase in HR after CyA. This study was
not designed to look the sympathetic nervous system (SNS), however, it is known that
CyA can increase SNS activity [446, 447]. The increase observed in this study was
observed in subjects who did not experience nausea after CyA, suggesting this was a
direct CyA effect. Such large increases have also been observed after lOmg/kg CyA
(Hansen). In the study presented in Chapter 13, subjects given 1-2 mg/kg exhibited small
169
increases in HR, more consistent with the published literature. This would suggest that
the marked increase seen in this study is probably related to the large size of the dose
given. Such SNS stimulation will have haemodynamic consequences. As the systemic
vasodilatation observed in this study would normally reduce blood pressure, and given
that the time course of the study is too short for significant salt and water retention to
occur, it is possible that the increase in MAP after CyA in this study is due to this
increase in SNS activity. This is provides a second reason why an acute single high dose
model of CyA administration might be inappropriate for the investigation of chronic
CyA induced changes.
Finally, subjects experienced nausea and vomiting in 5/24 studies and had to discontinue
the protocol. Water loading undoubtedly contributed to the nausea as one subject
vomited in the placebo phase and before drug dosing. However, 4/5 subjects vomited
during the CyA arm of the study with the time course of the vomiting correlating with
peak plasma CyA concentrations. This high incidence of emesis renders this model both
ethically and physiologically unsound.
In summary therefore, the systemic vasodilatation and lack of changes in RBF in healthy
volunteers given single high dose CyA concurs with forearm studies suggesting an
initial upregulation ofNO in the endothelium in response to CyA. It is at variance with
the reported haemodynamic changes in subjects receiving chronic CyA treatment,
namely systemic and renal vasoconstriction. This makes an acute single high dose model
is an inappropriate one for the assessment potential therapeutic treatments for CyA
induced hypertension and nephrotoxicity. The time course of the switch from dilatation
to constriction, and its correlation with the induction of endothelial dysfunction by CyA
needs more detailed investigation in man.
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Chapter 13




Study 8 (chapter 12) demonstrated that in healthy subjects receiving a single large dose
of CyA, the acute increase in MAP seen is associated with an increase in CO and a
decrease in SVR. In animal models, short-term administration of CyA leads to an
increase in SVR and MAP and a decrease in CO [449, 450]. Similar haemodynamic
changes have been reported in heart transplant patients when compared with essential
hypertensives matched for blood pressure [451]. These different responses to CyA in
heart transplant patients compared to healthy subjects might be explained by the altered
cardiac responses of a denervated transplanted heart, or the long-term exposure to CyA
in these patients. However, vasoconstriction to a single dose of intravenous CyA has
also been reported in renal patients on dialysis, but not on chronic CyA treatment [452],
suggesting other factors, such as renal impairment, might be involved in CyA induced
vasoconstriction.
The purpose of this study was, therefore, to explore the effects of a single standard oral
dose of CyA on systemic haemodynamics renal transplant patients to observe if
chronicity of CyA treatment was important in the generation of systemic haemodynamic
responses and hypertension. To asses this, the systemic haemodynamic responses of
renal transplant patients on chronic immunosuppressive therapy including CyA was
compared with matched renal transplant patients on long-term immunosuppressive
regimes consisting of prednisolone and/or azathioprine (Pred/Aza) but not including
CyA. The study hypothesis was that a single dose ofCyA would induce vasoconstriction
in patients on long-term CyA but not in patients previously naive to CyA.
13.2 Study design
The study was a randomised, single-blind, placebo-controlled, crossover study in 22 renal
transplant patients. Subjects attended for 2 visits, separated by >5 days. Subjects continued
to take all their normal medications except for CyA, where relevant, which was omitted on
the morning of the study only. Subjects received CyA 100 mg on one visit and placebo
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(icing sugar) on the other. Both CyA and placebo were placed within gelatin capsules to
ensure that the subjects remained blinded to the treatment received on each study day. On
each study day, an 18 SWG cannula was sited in the left antecubital vein. Subjects then
rested supine for 40 min before study drug administration. Subjects remained recumbent
throughout the study. Haemodynamic measurements were made at 10 min intervals from 30
min pre-dose until CyA administration, then at 20 min intervals until 3 hours after dosing.
At 0 and 3 hours, blood samples were taken for the measurement of plasma ET-1
13.2.1 Subjects
Eleven renal transplant patients on chronic immunosuppressive therapy including CyA, Pred
and Aza (Group I) and eleven patients maintained on immunosuppressive therapy with
Pred/Aza but not including CyA (Group II), all under long term follow-up by Edinburgh
Renal Unit, were recruited to the study. Patients on immunosuppressive agents other than
Pred, Aza or CyA were not recruited to the study. Additionally, patients with known
ischaemic heart disease, clinical evidence of heart failure, heart transplantation, diabetes
mellitus, or other significant cardiac or vascular history were excluded from recruitment.






Number 11: 6M5F 11: 9M2F
Age (yr) 51 ±4 48 ±3 NS
Body mass index (kg/m2) 27.5 ±.9 26.9 ± 1.2 NS
MAP (mmHg) 100.6 ±3.1 92.6 ±2.6 NS
Creatinine (pmol/L) 137 ± 13 140 ±34 NS
Duration of transplant (months) 55 ± 8 194 ±20 p<0.01
CyA dose - chronic (mg/dose) 2.64 ± 0.27
CyA given (mg/kg) 1.34 ±0.06 1.36 ±0.07 NS
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Groups were matched for creatinine, age and weight. However, mean arterial pressure was
slightly higher in group I, 9 of the 11 patients in group I, and 8 of the 11 patients in group II
were also on anti-hypertensive medication, and the mean duration of immunosuppressive
therapy (= duration of transplant) was significantly shorter for this group compared to the
patients on long-term Pred/Aza only (Table 13.1). For subject demographics and patient
characteristics, see Tables 13.1 & 2
Table 13.2a Subject characteristics







1 M 32 Congenital 2.30 No 28 132
2 F 52 CPN 1.03 No 103 258
3 M 61 GN 1.58 Yes Nifedipine 53 140 COAD
4 F 62 PKD 1.59 Yes Amlodipine 91 133 OA
5 F 64 HT 0.89 Yes Doxazosin 36 112
6 F 66 PKD 0.77 Yes Metoprolol 44 Gout
7 M 27 Alport's 1.92 Yes Doxazosin
Nifedipine
21 180
8 M 28 Congenital 1.39 Yes Atenolol
Nifedipine
80 92
9 M 62 GN 1.18 Yes Atenolol
Diltiazem
64 111
10 M 62 NK 0.93 Yes Enalapril
Nifedipine
63 133





Table 13.2b Subject characteristics







12 M 50 NK No 195 83
13 M 51 Congenital No 215 129
14 M 67 NK No 240 89 COAD
15 F 29 Congenital Yes Nifedipine 117 108 ROD
16 M 33 PKD Yes Atenolol 222 90 OP
17 M 45 GN Yes Labetalol 118 141
18 M 48 GN Yes Atenolol 295 91 Psoriasis, OP
19 F 49 GN Yes Nifedipine 240 96
20 M 42 GN Yes Doxazosin
Enalapril
263 121 OP
21 M 59 GN Yes Bisoprolol
Nifedipine
117 120






M - male, F - female, CPN - chronic pyelonephritis, GN - glomerulonephritis, HT - hypertension, NK - not
known, PKD - polycystic kidney disease, COAD - chronic obstructive airways disease, OA - osteoarthritis, OP
- osteoporosis, ROD - renal osteodystrophy, Tx - transplant
13.3 Results
All 22 subjects completed the study. No adverse events were reported. Baseline
haemodynamic data did not differ on each of the study phases (Table 13.3).
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MAP (mmHg) 98.1±3.3 101,2±3.8 93.1±3.7 92.2±2.1
SVRI (dyne.s rrf/cm5) 2846±347 2996±298 2726±136 2755±167
CI (L/min/m2) 3.07±0.24 3.05±0.28 2.81±0.21 2.81±0.24
HR (bpm) 61.1±2.8 61.7±2.5 66.6±2.8 66.8±2.8
13.3.1 Systemic haemodynamics
There was a small increase in MAP in both groups after acute CyA administration
(maximum placebo-corrected change from baseline, group I: + 7.4 ± 3.3 mmHg,
ANOVA p<0.01 vs. placebo, group II: +6.7 ± 2.5 mmHg, p<0.01). HR was unchanged
after CyA administration in both groups relative to baseline values, though increased in
group II relative to placebo (group I: +2.3 ± 1.2 bpm, p>0.5 vs. placebo, group II: +3.9 ±
2.1 bpm, p<0.01) (Fig 13.1).
A significant decrease in CI was observed in group 1 (-0.2 ± 0.11 L/min/m2, p<0.05).
This contrasted with an increase in CI in group II (+0.27 ±0.10 L/min/m2, P<0.05).
SVRI increased in group I both in absolute terms and relative to placebo (+460 ±128
dyne.sec/cm5/m2, p<0.01) (Fig 13.1). By contrast, in group II SVRI was unchanged
relative to baseline and placebo (-257 ± 137 dyne.sec/cm5/m2, p>0.1) (Fig 13.1). Both CI
and SVRI responses were significantly different (p<0.01) when group I was compared
with group II (Fig 13.2).
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Figure 13.1 Effect of 100 mg CyA or placebo on systemic
haemodynamics
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P >0.1
i 1 1 1 1 1 1 1 1
P >0.5
1 1 1 1 1 1 1 1 l 1 1 r
Grp I: CyA O— Grp II:CyA
Grp I: Placebo A— Grp II:Placebo
0
-0.3
Time (min) Time (min)
P <0.05





20 40 60 80 100 120 140 160 180
177
Figure 13.2 Effect of 100 mg CyA or placebo on systemic haemodynamics.




Plasma ET-1 concentrations were not significantly altered in either group compared to
placebo after CyA administration (Table 13.4).
Table 13.4 Plasma ET-1 concentrations (pg/ml) after acute CyA
administration
Group I: Patients on long-term CyA Group II: Patients naive to CyA
Study drug CyA Placebo CyA Placebo
Baseline 2.78 ±0.59 3.85 ±0.29 5.17 ± 0.21 4.07 ±0.47
3 hr post administration 4.47 ±0.41 4.43 ± 0.74 4.32 ±0.33 4.77 ±0.16
13.4 Discussion
This study demonstrated that the pattern of the haemodynamic response to acute CyA
administration differs between renal transplant patients on chronic CyA therapy and
those naive to it. Patients on chronic immunosuppression with CyA demonstrate an
increase in blood pressure associated with an increase in vascular resistance and a
reduction in CI after acute CyA administration. By contrast, matched patients
maintained on drug regimes without CyA increase both blood pressure and CI and do
not vasoconstrict after acute CyA administration. These findings in transplant patients
on long-term CyA are consistent with published literature in heart transplant patients and
chronic dialysis patients [451, 452]. The patients na'ive to CyA, however, followed the
pattern previously observed in healthy subjects given a large single dose of CyA
(Chapter 12) with a small vasodilatation and an increase in CI.
CyA can induce smooth muscle cell contraction [171], and cause increased contractile
responsiveness of blood vessels in vitro [445]. However, in healthy subjects with
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presumed normal endothelial function, acute administration of CyA into the brachial
artery only causes vasoconstriction in the presence of a nitric oxide clamp, and, in the
presence of stimulated endothelial NO release, in fact, increased forearm blood flow,
suggesting that nitric oxide is an important regulating mechanism protecting against
CyA-associated vasoconstriction in vivo [466]. Morris et al. have demonstrated that
renal transplant patients on chronic CyA have reduced basal and stimulated NO activity
compared to those on Pred/Aza and to healthy volunteers [467]. Hence, chronic
exposure to CyA is associated with reduced NO activity, and thus a loss of protection
against further CyA associated vasoconstriction. Rat models suggests that this switch in
the balance of endothelial vasomotor tone to favour vasoconstriction during CyA
administration happens early, with 1-3 weeks being sufficient to see a reduction in
urinary NO metabolites and alterations in vessel responses, consistent with reduced NO
activity [468, 469],
The results from this study would be consistent with this loss of NO activity in long-
term CyA administration. The observed vasoconstriction after acute CyA suggests that
chronic exposure to CyA has resulted in endothelial dysfunction with reduced NO
activity, and loss of an NO related protective mechanism. The lack of vasoconstriction to
acute CyA in the Pred/Aza patients suggests that endothelial function in this group is
comparatively well preserved and thus NO activity is protecting against CyA induced
increases in vascular tone.
It is possible that, in addition to reduced NO activity during chronic CyA treatment,
increased activity of vasoconstrictor systems also occurs. In respect of ET-1, CyA is
known to stimulate ET release from endothelial and smooth muscle cells and activates
ET-1 gene expression [171]. ET receptor antagonism attenuates CyA induced renal
vasoconstriction [145] and CyA induced smooth muscle cell contraction [171]. If ET-1
is upregulated in patients on chronic CyA treatment, and further augmented cyclically by
twice daily CyA ingestion, then ET receptor antagonists, which improve endothelial
function, might provide a therapeutic option for CyA induced hypertension and renal
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dysfunction. Indeed, Binet et al. have recently demonstrated that the ET receptor
antagonist bosentan can attenuate CyA associated renal vasoconstriction, though not
hypertension in healthy subjects treated with 7 days of CyA [177]. This study does not
show any convincing alterations either in baseline plasma ET-1 concentrations between
the two groups studied, or after single dose CyA within each group. However the
secretion of ET-1 from endothelial cells is mainly abluminal and plasma concentrations
may not be truly reflective of alterations in the activity of the ET system. Further studies
in patients with ET receptor antagonists are needed to clarify this issue.
It must be noted, however, that, despite differences in SVRI and CI, similar rises in
MAP occurred in both groups, thus blood pressure changes cannot be wholly attributed
to alterations in vessel tone. Increased SNS activity [446, 447], and salt and water
retention [448] have also been proposed as mediators of CyA associated hypertension.
This study was not designed to look at either of these possibilities. However, in respect
of salt and eater retention, it is highly unlikely that, given the short time course, this can
account for the acute blood pressure response seen here. Previous studies have suggested
that hypertension precedes the onset of antinatriuresis by some hours [347] to days [461,
464, 465] supporting the hypothesis that hypertension on CyA is unlikely to be initiated
by renal vasoconstriction and consequent sodium retention.
The groups studied were well matched except for the length of time that they had been
transplanted. It is important to note, given the association of renal impairment with
endothelial dysfunction [470], and the finding that acute administration of CyA to
dialysis patients naive to CyA causes vasoconstriction [452], that they have similar
creatinines. The different responses between the groups to CyA observed in this study
are therefore not associated with differences in renal function. The two groups do differ,
however, in the duration of immunosuppressive treatment. Since the introduction of
CyA in the early 1980s, dual therapy with Pred/Aza has become rare, with most
immunosuppressive regimens containing a calcineurin inhibitor. As such, the Pred/Aza
treated patients represent an historical group. Hence it is not possible to match for
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duration of transplant with CyA treated patients. However, one would anticipate greater
not less endothelial dysfunction with increasing time as a renal patient.
In summary, the observed haemodynamic response of renal transplant patients to CyA is
altered by previous long-term exposure to CyA from mild vasodilatation to
vasoconstriction, consistent with CyA associated endothelial dysfunction. Identification
of such a chronic CyA induced endothelial dysfunction is important, as restoration of
endothelial balance in favour of vasodilatation might help protect against both
hypertension and the renal vasoconstriction common in CyA treated patients. Further
work is needed to clarify the time course over which this endothelial dysfunction
develops in man, and its relative contribution to the overall elevations in blood pressure





The acute studies presented in this thesis explore the acute actions and interactions of
ET-1 and its receptors in the systemic and renal circulations in health and disease. These
studies have helped to establish a clearer picture of ET physiology and pathophysiology.
Such observations suggest there is clinical potential for ET receptor antagonists in the
treatment of renal dysfunction. As indicated in Chapter 1, in vitro and in vivo
observations suggest a pathogenic role for ET-1 and a possible therapeutic role for ET
receptor blockade in a number of cardiovascular and renal diseases. In this respect, the
observations in this thesis in respect of ETA receptor antagonism, particularly in
conjunction with ACE inhibition are promising. However, the observations of these
acute studies need to be borne out by long-term clinical intervention studies.
14.1 Role of ET-1 and ETA in the maintenance of normal vascular tone
These studies suggest a role for ET-1 acting via the ETA receptor in the systemic but not
renal vascular tone in health.
Though initial studies with ET-1 and ECE inhibitors or ET receptor antagonists
suggested a role for ET-1 in the maintenance of normal vascular tone [191, 192, 194.
195, 201], further local [197, 471] and systemic studies [139, 142, 199, 202] with ET
receptor antagonists have been conflicting in respect of this function ofET-1.
The studies in this thesis in healthy subjects repeatedly demonstrate systemic
vasodilatation with ETA receptor antagonism when this is used at doses sufficient to
produce significant ETA receptor blockade, consistent with a role for ET-1 acting via
the ETA receptor in the maintenance of normal vascular tone. However, consistent with
previous studies, these data suggests that ET-1 does not play a role in the maintenance of
renovascular tone in the "unchallenged1 renal circulation in health [120, 139-141, 199].
It is important to remember that ETA receptor antagonism can cause vasodilatation not
only by blocking ETA mediated vasoconstriction but also by allowing endogenous ET-1
to bind preferentially to the unblocked endothelial ETB receptor promoting ETB
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receptor mediated vasodilatation. However, concomitant ETB blockade in healthy
volunteers does not alter the systemic haemodynamic effects of ETA receptor
antagonism suggesting that it is blockade of ETA mediated vasoconstriction rather than
promotion of ETB mediated vasodilatation that is responsible for the major part of the
decrease in vascular tone observed after ETA receptor antagonism.
14.2 Role of endothelial ETB receptor mediated vasodilatation and
vascular smooth muscle ETB receptor mediated vasoconstriction in the
maintenance of normal vascular tone
These studies suggest that the net effect of ETB receptor activation in health is to
produce vasodilatation, evident in both systemic and renal circulations.
Local studies with ET receptor agonists and antagonists [207, 208] have suggested that
ETB receptors also play a vasoconstrictor role in the maintenance of normal vascular
tone. However, there may be a difference depending upon vessel type in respect of the
presence and clinical significance of vasoconstrictor ETB receptors.
Local forearm [194] and systemic [210] administration of ETB receptor antagonist in
this department has been shown to produce vasoconstriction. The studies in this thesis
have confirmed this finding in healthy subjects, suggesting that endothelial vasodilator
ETB receptors have a role in maintaining a basal vasodilatation in the systemic
circulation, and that the balance of the constrictor and dilator functions of ETB receptors
is, in these circulations at least, in favour of vasodilatation in health.
As with ETA receptor antagonism however, ETB receptor blockade may produce
vasoconstriction not only by loss of ETB mediated vasodilatation but also by
disproportionate binding of endogenous ET-1 to the unblocked ETA receptor producing
ETA mediated vasoconstriction. Additionally, loss of the clearance function of the ETB
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receptor will increase circulating levels of ET-1 that may further augment ETA receptor
activation.
In this respect it is important to note that, contrary to expectations if the clinical effect of
ETB receptor activation is vasodilatation, concomitant administration of ETB to ETA
receptor antagonism does not affect the systemic vasodilatation produced by ETA
receptor antagonism alone. This is in contrast to previous forearm studies when ETB
receptor antagonism attenuated the vasodilatation produced by ETA receptor blockade
[194]. There are a number of possible reasons for this discordance. Firstly, the forearm
circulation is not necessarily indicative of total peripheral vascular resistance. The
measurement of SVR may include local circulations where ETB mediated
vasoconstriction is important. Secondly, the vasodilatation produced by ETA receptor
antagonism may produce reflex neurohormonal mechanisms that act to limit any
changes in the circulation. In forearm studies, this is avoided by using concentrations of
drugs that are only locally active and so should not activate systemic compensatory
mechanisms [365], Thirdly, the role of ETB mediated vasodilatation in health may be
minor by comparison to ETA mediated vasoconstriction and so loss of this
vasodilatation in healthy blood vessels in an "unchallenged" state may be clinically
insignificant in the presence of blockade of the constrictor ETA receptor. Therefore, the
vasoconstriction produced by ETB receptor antagonism alone, and the failure of ETB
receptor blockade to augment ETA receptor mediated vasodilatation does not support a
role for constrictor ETB receptors in health, but is consistent with a role for ETB in the
maintenance of systemic vasodilator tone.
Within the renal circulation, the lack of effect of ETA receptor blockade suggests that
ETA mediated tone in not important in the kidney in health. The absence of dilatation
after ETA receptor blockade would also suggest that ETB mediated vasodilatation (via
binding of "displaced" ET-1) is not important. However, in health, the "unchallenged"
renal circulation is near-maximally dilated hence further reductions in renal vascular
resistance are unlikely. The renal vasoconstriction seen after ETB receptor blockade
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suggests that the endothelial ETB receptor is an important mediator of this dilatation.
The fact that concomitant ETA blockade abolishes this dilatation suggests that the ETA
receptor does have a constrictor function in the renal circulation that may become more
important in circumstances where the renal circulation is "challenged". As with the
systemic circulation, the data from this thesis do not support clinically relevant ETB
mediated vasoconstriction in the renal circulation in health.
14.3 Role of ET-1 and ETA in the maintenance of vascular tone in renal
failure
These studies suggest a role for ET-1 acting via the ETA receptor in the systemic and, in
contrast to health, in renal vascular tone in patients with CRT.
In respect of systemic haemodynamics, in forearm studies in patients with renal failure,
ETA receptor antagonism produced vasodilatation, but to a lesser degree than that seen
in healthy controls [195]. Similarly other studies in hypertensives [222] and patients
with heart failure [285] did not show enhanced vasodilatation to ETA receptor blockade.
Studies where patient groups do show enhanced vasodilatation after ETA receptor
blockade compared to controls [221] have used doses of ET antagonists (BQ-123: 100
nmol/min) that are, on the basis of these studies, systemically active, and therefore will
activate systemic homeostatic mechanisms that will make interpretation of results
difficult. Additionally, it is possible that, locally, this dose reaches sufficiently high
concentrations to lose ETA selectivity and begin to have effects at the ETB receptor
[198],
However, these systemic studies show an equal effect of ETA receptor antagonism on
SVR, and a greater effect on blood pressure in CRF compared to healthy controls.
Additionally, renal haemodynamic changes occur only in subjects with renal
impairment. In attributing these findings to ETA receptor blockade alone, the
preliminary dose ranging study and measurement of BQ-123 concentrations allows a
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degree of certainty in stating that maximal ETA receptor blockade has been achieved
without losing ETA selectivity. BQ-123 is not therefore directly activating the ETB
receptor in these studies.
Therefore, the presence of renal failure and (treated) hypertension may alter the vascular
sensitivity to ET receptor antagonists and reflect an enhanced activity of the ET system
in renal disease, particularly in the renal circulation. The observed increased urinary ET-
1 excretion rates in renal failure would support this argument at least in respect of the
kidney. The findings may not be consistent with local studies for the aforementioned
reasons pertaining to the extrapolation of local to systemic data. However, there are a
number of other possible explanations for these findings. Firstly, ET receptor antagonists
may be having direct effects on cardiac function [212] and venous capacitance [472] that
may alter blood pressure. An increase in ETA mediated venodilation, or an ETA
mediated decrease in CO for example, may result in a greater reduction in blood
pressure. These studies were not designed to look at these possibilities beyond a basic
measure of CI and HR. Secondly, there is the possibility of altered drug
pharmacokinetics in renal failure. BQ-123 is primarily metabolised in the liver [97].
Though these studies have demonstrated some renal excretion of BQ-123 that is GFR
dependent, this does not impact significantly on systemic pharmacokinetics and is
unlikely to be responsible for the observed differences between patients and healthy
subjects. Thirdly, there is the possibility of interactions with other drugs taken by the
patients. The studies presented in this thesis investigating the interaction of ET receptor
antagonists and ACE inhibition do raise the possibility that the different responses to ET
receptor antagonists seen between CRF patients and healthy controls, both in the degree
of systemic haemodynamic change and the presence of renal haemodynamic changes,
are all attributable to concurrent ACE inhibition in the renal patients, though it is worth
noting, that 2 patients that were not on ACE inhibitors had similar responses after ETA
receptor antagonism to the other patients.
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14.4 Role of endothelial ETB receptor mediated vasodilatation and
vascular smooth muscle ETB receptor mediated vasoconstriction in the
maintenance of vascular tone in renal failure
These studies suggest that the net effect of ETB receptor activation in renal failure is to
produce vasodilatation, evident in both systemic and renal circulations.
Forearm studies in subjects with hypertension [196] or atherosclerosis [473] have
demonstrated that ETB receptor antagonism produces vasodilatation, and augments ETA
mediated vasodilatation, suggesting an increase in the importance of ETB mediated
vasoconstriction in hypertension. It is likely, however, these findings are due to a dose of
ETB receptor antagonism (BQ-788: 50 nmol/min) that has been shown to be
systemically active in these studies.
The studies in patients with renal impairment do not suggest any increase in the
importance of vasoconstrictor ETB receptors in the systemic or renal circulations. By
contrast, the ETB receptor appears to be of greater importance in the maintenance of
systemic and renal vasodilator tone in renal failure. Not only does ETB receptor
blockade alone produce vasoconstriction, but concomitant administration of ETB
receptor blockade, does, in renal patients attenuate the haemodynamic effects of ETA
receptor blockade, suggesting that ETB mediated vasodilatation is clinically significant
in renal disease, particularly in the renal circulation. It is worth noting that absolute renal
vascular resistance at baseline in the renal patients is three times that of the healthy
volunteers indicating a basal state of renal vasoconstriction, and that the absolute
increase in renal vascular resistance, though equal in percentage terms, is also three
times that of healthy controls. This suggests that the balance of dilators and constrictors
in the blood vessels in CRF is shifted towards constrictors. Thus blockade of one of
these constrictors, ET-1 via the ETA receptor, or loss of one of the dilator functions, ET-
1 via the ETB receptor, becomes clinically more significant.
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Of course, given the demonstrated synergism between ETA receptor antagonists and
ACE inhibitors that is abolished by concomitant ETB blockade in healthy volunteers, it
is possible that the differential effect of ETA and ETA/B observed in the renal patients
but not the healthy subjects is attributable to pre-treatment with ACE inhibition. Again,
however, the 2 patients that were not on ACE inhibitors had similar responses to
combined ETA/B receptor blockade to the other patients.
14.5 Renoprotective profile of ETA receptor antagonism in renal failure
These studies suggest that ETA receptor antagonism offers a potentially renoprotective
profile.
These studies have demonstrated that, acutely ETA receptor antagonism produces
systemic vasodilatation and a clinically relevant reduction in blood pressure in patients
with renal failure, without sodium retention. This effect, though slightly greater with
ETA receptor antagonism, can be seen with combined ETA/B receptor blockade. ET
receptor antagonists have been shown in large scale studies to be effective in lowering
blood pressure [224], but, given the large numbers of anti-hypertensive agents already
available, this alone is insufficient to focus attention on ET receptor antagonists.
However, these studies have also demonstrated that ETA receptor antagonism can
reduce RVR and increase RBF in CRF patients. This renal vasodilatation is associated
with a reduction in EFF. In the absence of changes in mesangial contraction, this is
suggestive of a preferential efferent arteriolar dilatation that will therefore act to reduce
glomerular capillary perfusion pressure. Consistent with this proposed reduction in
glomerular capillary pressure, there is a reduction in proteinuria.
In support of these observations, a previous study in type I diabetics with proteinuria but
essentially normal or only mildly impaired renal function has demonstrated that 6 weeks
of ETA receptor blockade does reduce blood pressure and, though not significantly
affecting overall renal haemodynamics, does reduce proteinuria [190],
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In respect of clinical potential, it is important to note that these renal effects are not
produced by combined ETA/B receptor antagonism.
14.6 Natriuresis
These studies have not clearly demonstrated an ET mediated natriuresis.
Animal evidence to date points to a paracrine action of renal ET-1 via the ETB receptor
in salt and water homeostasis [135, 394], The peritubular distribution of ETB receptors
[11, 52] suggests that the ETB receptor also mediates these actions in man. These
studies have demonstrated that selective ETB receptor blockade does reduce sodium
excretion in both health and disease. However, correcting for GFR suggests that his anti-
natriuresis is accounted for by renal vasoconstriction and not a blockade of ETB
mediated natriuresis. Also, ETA blockade alone, though not producing sodium retention
despite a fall in blood pressure, did not increase sodium excretion despite leaving the
ETB receptor available to endogenous ET-1. These results are consistent with previous
studies in man where no clear effect can be demonstrated.
In administering exogenous ET-1 in the presence of ETA blockade, it was hoped to
stimulate an unblocked ETB receptor to observe any tubular effects, an approach used
effectively in dogs [123]. However, as discussed, the dose of ET-1 was probably too
high for the dose of BQ-123 used, resulting in drug displacement from the ETA
receptor, as evidenced by loss of ETA mediated vasodilatation. Thus the failure to
demonstrate natriuresis is not indicative of a lack of ETB tubular effects in man.
Only when ETA receptor antagonism was given in the presence of ACE inhibition was a
significant, and indeed striking, increase in sodium excretion observed. It is possible that
this is entirely a consequence of the renal vasodilatation observed, and therefore again a
haemodynamic effect. However, the renal haemodynamic effects are not as great as
those seen in renal patients, where no net changes in sodium excretion were observed.
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Animal studies suggest that the effects of exogenous ET-1 are regional within the kidney
with cortical vasoconstriction and medullary vasodilatation [474], It is possible therefore
that these regional variations are further enhanced with concomitant ETA-ACEI
treatment increasing blood flow to the medullary tubular segments promoting sodium
excretion. Because concomitant ETB receptor blockade equally abolished the renal
haemodynamic and natriuretic changes of this combination treatment, it is impossible
for us to attribute this natriuresis directly to the unblocked tubular ETB receptor
14.7 Angiotensin - endothelin interaction
These studies have demonstrated that the acute effects of ANG II are not mediated
through ET-1 via the ETA receptor.
Clinically, this is consistent with studies demonstrating an effect of ET receptor
antagonism in patients already treated with drugs blocking angiotensin activity [292,
293, 299]. The distinct nature ofANG II and ET-1, at least acutely, therefore allows for
ET receptor antagonists to be seen as an adjunctive treatment to RAAS inhibition.
However, animal studies suggest a more chronic interaction, particularly in respect of
vascular remodelling [371], that needs to be explored in man.
However, a synergistic interaction is demonstrable between ETA receptor blockade and
ACE inhibition. As shown, this is largely mediated, through an unblocked ETB receptor,
by nitric oxide but not prostaglandin. This synergism may, in part, be responsible for the
greater effect of ETA receptor antagonism in renal patients compared to healthy
controls. Another possibility, however, is a pharmacokinetic interaction between BQ-
123 and enalapril. Though BQ-123 plasma concentrations were not significantly
different in the presence or absence of enalapril, they were higher during combination
treatment. Given the small numbers of subjects studied, it is possible that a
pharmacokinetic interaction has been missed.
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These current studies cannot differentiate if the role of ACE inhibition in this interaction
is to reduce ANG II formation or reduce the breakdown of bradykinin. However, a
synergistic interaction has been demonstrated between angiotensin receptor antagonists
and ETA receptor antagonists [410] suggesting the former is more likely.
14.8 Evidence for the deleterious effect of ETB receptor blockade
These studies suggest that all the potentially beneficial haemodynamic effects of ET
receptor antagonism are mediated through the ETA receptor. All the data in this thesis
points to the net balance between endothelial and vascular smooth muscle ETB receptors
being in favour of vasodilatation. Concomitant ETB blockade, at best, does not alter the
effects of ETA receptor blockade. In these studies, it reduces the hypotensive and renal
vasodilatory effects of ETA blockade in patients with renal failure. Possibly connected
to these responses, it also abolishes the synergism that operates between ETA receptor
blockade and ACE inhibition.
Additionally ETB is known to act as a clearance receptor for ET-1 [87]. On every
occasion where the ETB receptor was blocked in these studies, plasma ET-1
concentrations increased consistent with this clearance role. Though the clinical
significance of increased plasma concentrations of this paracrine hormone is unclear,
there is some evidence that circulating ET-1 may play an important role in renal
regulation in cardiorenal states of ET activation [109].
Finally, ETB receptor blockade reduced the urinary excretion of ET-1. Given the
mitogenic potential of ET-1 [64, 65] and the association of increased intra-renal
production of ET-1 in low renal mass models correlating with glomerulosclerosis [148,
180-182], the retention of ET-1 within the kidney thus has the potential to be
deleterious.
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14.9 Studies with cyclosporin
The initial aim of high dose CyA administration to healthy subjects was to provide a
model of systemic and renal vasoconstriction for interventional studies with ET receptor
antagonists. Instead these studies demonstrated that the initial effect of CyA is to
produce vasodilatation, both in healthy subjects, and in transplant patients nai've to the
drug. This is consistent with forearm studies in transplant patients where patients on
CyA demonstrate a greater degree of endothelial dysfunction than matched controls
[467], and in healthy subjects demonstrating that CyA acutely increases NOS activity on
first exposure [466].
14.10 Future Studies
The observations in this thesis raise further questions to be answered and areas to
explore. Some of these are discussed below
1. Clarification of the effect of ETA receptor antagonism on proteinuria
The reduction in proteinuria in renal patients after ETA receptor antagonists was clearest
in subjects with higher baseline degrees of proteinuria. The renal subjects recruited had
low grades of proteinuria (all < 1.5 g/24hr). Nephrotic range proteinuria was a specific
exclusion criteria to avoid issues with altered protein binding of drugs in the circulation.
Given that evidence with ACE inhibitors is that the greater renoprotective effect is
afforded in patients with higher degrees of urinary protein leak [475], clarification of
this effect by recruiting subjects with >3g/24hrs of proteinuria (with maintained serum
albumin concentrations) would be important.
2. Natriuretic effect of ETB receptor
To demonstrate the natriuretic effect of ETB receptor activation, a further study of low
dose exogenous ET-1 administration in the presence of high grade ETA blockade is
required.
194
3. ETA-ACEI interaction - bradykinin
Having demonstrated that this interaction is ETB dependent and NO mediated, because
ACE inhibitors also block the breakdown of bradykinin, bradykinin receptor antagonism
would be useful to delineate whether the interaction with ACE inhibition is acting via a
reduction in angiotensin or an increase in bradykinin.
4. ETA-ACEI interaction - renal patients
To clarify if the greater effect of ETA antagonism in renal patients is due to an
interaction between ETA receptor blockade and ACE inhibition, or because of an altered
activity of the ET systemic in renal disease, a study needs to be performed with ETA
receptor antagonists in patients on and offACE inhibition. Recruitment will need to take
into account the requirement for equal control of blood pressure in study phases.
5. Salt sensitivity
Study 7 demonstrated a link between salt sensitivity and the response to ETA receptor
antagonism on a high salt diet. However, this was a small scale study, and only one
subject exhibited a high degree of salt-sensitivity. Examining the effects of ET receptor
antagonism in two hypertensive groups, one clearly identified as salt-sensitive, one not,
on both high and low salt diets would clarify the role of ET, particularly of renal origin
in salt sensitivity. Because salt sensitivity may be linked to a blunted increase in
endothelial NO in response to a high salt diet [426], the comparison ofETA with ETA/B
blockade may be interesting in this respect.
6. Chronic ETA receptor blockade in patients with renal impairment
Given the renoprotective profile demonstrated in our studies in renal patients, this needs
to be confirmed in chronic studies, with particular attention to any slowing of the rate of
progression of renal impairment, or reduction in proteinuria as a surrogate marker [476].
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7. Renal effects of ET receptor antagonism in patients with chronic heart
failure
Renal dysfunction occurs in CHF partly to reduced renal perfusion pressure. Its presence
is a poor prognostic marker [477]. Animal studies have suggested that ET receptor
antagonism may improve renal function in CHF. However, despite many studies in man
into the role of ET receptor antagonism in heart failure, many with non-selective
antagonists, none have specifically examined the effects on renal function. Given that
these studies suggest that ETB blockade will abolish any beneficial effects of ETA-ACE
interaction both systemically and in respect of renal haemodynamic and tubular
function, a clearer picture of the renal effects of ET receptor antagonism should be
sought in both acute and chronic studies in this condition characterised by
vasoconstriction and sodium retention.
8. Acute intervention in scleroderma hypertensive crisis
Scleroderma associated pulmonary hypertension responds to ET receptor blockade [268,
269]. Though not directly studied in this thesis, given the vasoactive nature of these
drugs, and the pro-fibrotic effects of ET-1 experimentally, this condition would
represent a potential target for ETA receptor antagonists, particularly given that the
current treatment for this condition is ACE inhibition.
9. Studies with cyclosporin
The ability of ET receptor antagonism to influence chronic CyA induced endothelial
dysfunction should be explored. However, a model of acute administration to healthy
subjects is not applicable for these purposes.
Additionally, though CyA induced hypertension is likely to be multi-factorial, the
endothelial dysfunction and sympathetic activation might be amenable to treatment with
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Endothelin Receptor Antagonists
Promising New Agents in the Management of
Cardiovascular Disorders
Jane Goddard and David J. Webb
Clinical Pharmacology Unit & Research Centre, Department of Medical Sciences, University of
Edinburgh, Scotland
Abstract Since its discovery in 1988, endothelin (ET) has been widely implicated in the
pathophysiology of cardiovascular disease. ET antagonists have favourable ef¬
fects in experimental models of these conditions and have proved useful in elu¬
cidating the role of the ET system. Orally acting ET antagonists appear very
promising in clinical trials, particularly in patients with chronic heart failure and
hypertension, but more information on the roles of the ET receptor subtypes in
health and disease is required so that an informed choice can be made between
the use of endothelin-A (ET-A) receptor-selective and nonselective receptor an¬
tagonists.
The endothelins (ET) are a family of 21 amino acid
peptides with powerful vasoconstrictor and pressor
properties that were first described by Yanagisawa et
al. in 1988.1111 Three different isopeptides, endothelin-1
(ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3),
have so far been identified, each with distinct genes
and tissue distributions.1'"31 Of the 3 peptides, ET-1
is the major endothelial isoform and is therefore
likely to be the most important in the regulation of
cardiovascular function. Therefore, this article, fo¬
cuses primarily on ET-1. Its main site of production
is the vascular endothelial cell but it is also produced
by other cell types, including renal tubular and
mesangial cells, vascular smooth muscle cells and
epicardial cells.14-61 In addition to its vasoconstric¬
tor properties, ET-1 functions as a mitogen, modu¬
lates other hormone systems and influences ion and
fluid transport in the gut and kidney.17'81
Regulation of the production of ET-1 is thought
to be at the level ofgene transcription. Enhanced gene
transcription occurs in response to a wide range of
stimuli including other vasoactive hormones [such
as angiotensin II, adrenaline (epinephrine) and
vasopressin], cytokines (such as interleukin-1 and
endotoxin), and hypoxia, glucose and oxidised low
density lipoprotein (LDL). In contrast, prostacyc¬
lin, nitric oxide (NO) and the natriuretic peptides
all inhibit transcription of endothelin genes. The
gene product is prepro-ET-l, a protein with 212
amino acids which is cleaved in stages to yield the
largely inactive big ET-1, a 38-amino-acid precur¬
sor peptide. Endothelin converting enzyme (ECE),
a metalloproteinase, then splits big ET-1 into the
active mediator, ET-1, and its C terminal frag¬
ment191 (fig. 1).
Two ET receptors have been identified and
cloned: endothelin-A (ET-A) receptors have a higher
affinity for ET-1 than either ET-2 or ET-3, whereas
endothelin-B (ET-B) receptors have equal affinity
for the 3 ET peptides.110"121 Within the circulation,
ET-A receptors are found on vascular smooth mus¬
cle cells and their activation results in vasocon¬
striction. ET-B receptors are also found on vascu¬
lar smooth muscle cells, where they mediate vaso¬
constriction. However, ET-B receptors are more
abundant on the vascular endothelium where their
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Fig. 1. The endothelin (ET) pathway: stimuli for ET production, pathway for generation and major effects mediated by ET-Aand ET-B
receptors in blood vessels. ET-1 is generated by endothelial cells and secreted abluminally to act on ET receptors on vascular smooth
muscle cells promoting contraction. ET-1 can initiate relaxation via stimulation of ET-B receptors on the vascular endothelium
promoting the generation of NO from L-arginine and PGI2 from arachidonic acid. cAMP = cyclic adenosine monophosphate; cGMP
= cyclic guanosine monophosphate; ECE = endothelin converting enzyme; ET-A = endothelin-A receptor; ET-B = endothelin-B
receptor; ET-1 = endothelin-1; PGI2 = prostacyclin; mRNA = messenger RNA; NO = nitric oxide.
activation results in vasodilatation mediated by NO
and prostacyclin. In the human kidney, ET-A recep¬
tors are localised to vascular smooth muscle, nota¬
bly in the glomeruli, vasa recta and arcuate arteries.
ET-B receptors are more numerous (ET-B to ET-A
ratio 2:1) and more widespread with a high con¬
centration in the collecting system.113' The distri¬
bution of these receptors within the kidney sug¬
gests a vasoactive role for ET-A receptors and a role
in sodium and water handling for ET-B receptors.
Signal transduction is complex and reviewed
elsewhere.191 ET-1 is removed in the renal, splanch-
© Adis International Limited. All rights reserved.
nic and pulmonary circulations, probably by ET-B
receptor binding and internalisation and also enzy¬
matic degradation by neutral endopeptidases.'14'
1. Endothelin Receptor Antagonists
Compounds that block the ET system have been
used to define the role of the endogenous ET sys¬
tem and confirm its importance in cardiovascular
function and dysfunction. Attention is now focus¬
ing increasingly on drugs that may have a role in
clinical medicine. Though ECE inhibitors and mono¬
clonal antibodies have been used experimentally,
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and the former may be a therapeutic option in the
future, most clinical work to date has been done
with ET receptor antagonists.
ET receptor antagonists can be divided into
orally active compounds and parenteral prepara¬
tions. In certain situations an intravenous prepara¬
tion will be preferred, notably to counter acute, iso¬
lated insults (e.g. cerebral ischaemia following
subarachnoid haemorrhage or stroke, unstable an¬
gina, acute myocardial infarction, acute renal fail¬
ure or postoperative pulmonary hypertension).
However, many of the anticipated indications for
ET receptor antagonists, including hypertension,
chronic heart failure and coronary restenosis, will
require chronic treatment for which oral agents are
best suited (table I).
ET receptor antagonists can be further subdi¬
vided into nonselective ET receptor antagonists
and ET-A-selective receptor antagonists. ET-A se¬
lectivity generally refers to compounds with
> 1000-fold affinity for the ET-A over the ET-B re¬
ceptor. It is important to appreciate that so-called
'nonselective' antagonists are still generally selec¬
tive for the ET-A over the ET-B receptor (table I).
More work is needed to better delineate the respec¬
tive roles of the ET-A and ET-B receptors in normal
physiology and, more importantly, in pathophysi¬
ology before conclusions can be drawn regarding
the relative benefit of nonselective versus selective
ET-A receptor blockade in a given clinical situa¬
tion.
A series of peptide antagonists that bind to, but
do not activate ET receptors have been developed
through the modification of ET peptides. Cyclic
peptides were designed to mimic the hairpin loop
of ET. For example, BQ 123 is a cyclic pentapep-
tide and ET-A-selective receptor antagonist that
was developed from BE 18257B (a natural product
of Streptomyces misakiensis). TAK 044 is a cyclic
hexapeptide with nonselective ET receptor antag¬
onist properties. A series of linear peptides with
ET-B-selective receptor antagonist properties have
also been developed (e.g. BQ 788). These peptides
are broken down in the gut and, therefore, must be
given parenterally after which they have relatively
short half-lives. Experimentally, the half-life of
BQ 123 can be increased by side-chain modifica¬
tions that reduce hepatic extraction,1161 but the clin¬
ical utility of these compounds is limited by the
lack of oral analogues.
A series of nonpeptide ET receptor antagonists
with greater bioavailability than the peptides have
been developed through the use of screening librar¬
ies and molecular modelling (table I). Bosentan
(RO 470203), is a sulfonamide with nonselective
receptor blocking activity that has the benefit of
being available as both an oral and intravenous
preparation. This will allow treatment to be rapidly
initiated with the intravenous preparation in acute
situations (e.g. exacerbations of heart failure) and
continued thereafter with the oral formulation. SB
209670, a carboxylic acid derivative, is a more po¬
tent nonselective receptor antagonist than bosen¬
tan, but it is only available as an intravenous prep¬
aration. Enrasentan (SB 217242) is an analogue of
SB 209670 with improved bioavailability that is
currently in development as an oral drug.1171
Orally active and selective ET-A receptor antag¬
onists are being developed. ABT 627 is a carbox¬
ylic acid derivative with 2000-fold greater selec¬
tivity for the ET-A versus the ET-B receptor and an
elimination half-life (ty2p) of 24 hours in humans1181
making it an attractive choice for situations requir¬
ing long term treatment (e.g. prevention of coro¬
nary restenosis). Minor structural modifications to
ABT 627 yield highly selective ET-B receptor an¬
tagonists.1'81 TBC 11251 and TA 0201 are sulfon¬
amide derivatives with high bioavailability and
ET-A receptor selectivity.1'91 TA 0201 has a ty2p of
only 0.9 hours, but it is converted to an active meta¬
bolite with demonstrable inhibitory effect 8 hours
after oral administration in rats.1201
An interesting agent in preclinical development
is L 747072, an angiotensin receptor antagonist dis¬
covered to have nonselective ET receptor antago¬
nist activity, providing the potential for a dual ther¬
apeutic approach to the treatment of hypertension
and other cardiovascular conditions.1'71
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Table I. Endothelin receptor antagonists in development3
Name Route ET-A
selectivity5
Phase Anticipated indication Structure Manufacturer
(co-developer)
Nonselective endothelin receptor antagonists
Bosentan
(RO 470203)































TAK 044 IV x18 II
I
Preclinical





RO 610612 IV NK II
Preclinical


































PO x2000 I Coronary restenosis Carboxylic acid
derivative
Abbott
TA0201 PO X2700 I Heart failure Sulfonamide Tanabe Seiyaku
(T 0201) Preclinical Pulmonary hypertension, reperfusion injury
ZD 1611 PO X1000 I
Preclinical
Pulmonary hypertension









IV X1000 I Renal failure, subarachnoid haemorrhage Sulfonamide Roche (Vanguard
Medica)
S 0139 IV NK I Cerebral vasospasm, neuroprotection Myriceric acid
derivative
Shionogi
BQ 123 IV x2500 Preclinical
Unknown
Arrhythmias, cerebral ischaemia, diabetic
complications, hypertension, ischaemic




PD 147953 IV X7000 Preclinical Heart failure, diabetic complications, Linear tripeptide Parke-Davis




a Drugs are listed (oral then IV) in order of the highest reported phase of development.
b Based on binding and functional assays.'14'151
ET-A = endothelin-A; IV = intravenous; NK = not known; PO = oral.
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2. Endothelin and the Cardiovascular
System
The importance of ET-1 in cardiovascular func¬
tion is suggested by the actions of exogenous ET-1,
the administration of which is associated with an
increase in blood pressure and peripheral vascular
resistance.'21,22' The direct effects of ET-1 on the
heart are probably species specific but a positive
inotropic response to ET-1 is seen in isolated car¬
diac tissue from rats and humans,I23'241 and in in
vivo models where coronary vasoconstriction is
countered with a vasodilator.125' The integrated hae-
modynamic response is, however, much more com¬
plicated. Increased peripheral vascular resistance
and blood pressure produce reflex reductions in
heart rate and cardiac output, and coronary vaso¬
constriction can cause myocardial ischaemia and
cardiodepression. The effectiveness of receptor an¬
tagonists should clearly be judged on their inte¬
grated effects, as well as local effects on target or¬
gans or tissues.
In addition to its haemodynamic actions, exog¬
enous ET-1 is mitogenic in vitro, thus causing cell
proliferation and vascular remodelling, and caused
renal sodium retention,'261 features of congestive
heart failure (CHF) and hypertension.
3. Coronary Artery Disease
3.1 Ischaemia and Myocardial Infarction
Inducing coronary ischaemia in patients with
coronary artery disease (CAD) results in a signi¬
ficant release of ET-1 of cardiac origin.'27' Plasma
ET-1 concentrations are high in CAD, particularly
in patients with myocardial infarction or coronary
vasospasm,'28"3'' and elevations of plasma ET-1 and
big ET-1 in unstable angina and after myocardial in¬
farction are correlated with a worse prognosis'32,33'
suggesting that an activated ET system may con¬
tribute to a poor outcome.
Activation of ET-A and -B receptors in the coro¬
nary circulation contribute to vasoconstriction'34,35'
and in isolated porcine and canine coronary arter¬
ies, TAK 044 inhibits ET-1-induced coronary vaso¬
constriction to a greater extent than BQ 123.'35'
These data suggest that nonselective receptor
blockade may be more effective than selective. In
patients with CAD, acute intravenous administra¬
tion of the nonselective antagonist bosentan in¬
creased the diameter of coronary epithelial arter¬
ies; an effect that was not augmented by adminis¬
tration of intravenous nitrates. This effect was,
however, only clear in normal or mildly diseased
arteries and was correlated inversely with plasma
LDL-cholesterol levels.'36'
Both ET-A-selective (BQ 123) and nonselec¬
tive (TAK 044) ET receptor antagonists have been
shown to reduce infarct size in coronary ligation
models.I37,38' Though these animal studies are prom¬
ising, studies in humans with myocardial infarc¬
tion have not been published.
3.2 Atherosclerosis
Plasma ET-1 concentrations are elevated in pa¬
tients with atherosclerosis'39' and increased ET-1
levels has been demonstrated in atherosclerotic
lesions'40' and throughout the vessel walls of pa¬
tients with CAD'6' suggesting up-regulation of the
ET system in atherosclerosis.
In hypercholesterolaemic hamsters, ET-A re¬
ceptor inhibition decreases the progression of ath¬
erosclerosis mainly by reducing the number and
size of macrophage-foam cells.'41' In addition, apo-
lipoprotein E-deficient mice, which are genetically
predisposed to severe atheroma and endothelial dys¬
function, are protected from atherosclerosis when
treated with ET-A receptor antagonists and show an
increase in NO-mediated endothelium-dependent
relaxation.'42' Similarly, hypercholesterolaemic pigs
treated for a prolonged period with both selective
and nonselective ET receptor antagonists have im¬
proved coronary vascular function.'43' In view of
these results, it is possible that the failure of bo¬
sentan to significantly dilate severely diseased
coronary arteries in humans'36' may relate to the
greater degree of endothelial dysfunction in these
arteries, and that this may respond to longer term
administration of the drug.
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3.3 Postangioplasty Restenosis
ET-1 has a mitogenic effect on vascular smooth
muscle cells in vhro.144,451 In animal studies, ex¬
pression of messenger RNA (mRNA) for all of the
components of the ET system is increased at bal¬
loon angioplasty sites,1461 and intra-arterial admin¬
istration of ET-1 after angioplasty increases neoin-
tima formation.1471 In humans, an increase in plasma
ET-1 concentration proportional to the duration and
pressure of the balloon inflation is seen distal to the
angioplasty site.148,491 Nonselective ET receptor an¬
tagonism with SB 209670 or its analogue enrasentan
has reduced neointima formation after endothelial
injury by balloon angioplasty, whereas selective
ET-A receptor antagonism with BQ 123 has been
ineffective.147,50,511 However, highly selective ET-
A receptor blockade with the potent oral agent ABT
627 has been shown to reduce restenosis, indicat¬
ing that combined receptor antagonism may not be
required to achieve this effect4521 Thus, prevention
of restenosis with ET antagonists seems possible,
although many other potentially useful agents have
failed to fulfil their promise in this condition.
3.4 Arrhythmias
In animals, both combined ET receptor antago¬
nism with SB 209670 and selective ET-A receptor
antagonism with LU 135252 reduce the incidence
of arrhythmias induced by ischaemia or exogenous
ET-1.115,53,541 Of note, however, while low doses
(10 Ug/kg/min) of BQ 123 reduced the frequency
of ischaemic arrhythmias in rats, higher doses (100
p.g/kg/min) increased mortality rates because of an
increase in refractory ventricular fibrillation.155!
4. Congestive Heart Failure
There is considerable evidence that ET-1 plays
a role in CHF. ET-1 causes hypertrophy of cardiac
myocytes156! and has a direct toxic effect on these
cells.1571 In animal models of CHF, increased car¬
diac and pulmonary ET-1 synthesis has been docu¬
mented.158611 In a Dahl salt-sensitive, hypertensive
rat model, the initial compensated left ventricular
hypertrophy (LVH) was not associated with an in¬
crease in cardiac ET-1 levels, but a 5-fold increase
was noted after the development of left ventricular
(LV) dilatation and global hypokinesis.1621 ET-Are-
ceptors are more numerous than ET-B receptors in
both the normal and failing heart, but ET-A recep¬
tors may be up-regulated in the failing heart sug¬
gesting that they may be the major therapeutic tar¬
get.124,581 As with CAD, however, some evidence
points to the enhancement of vascular smooth mus¬
cle ET-B mediated vasoconstriction in CHF.163"651
Also, although the contractility of myocytes ob¬
tained from animals and humans with CHF is at¬
tenuated in response to exogenous ET-1,124,66,671
there is some evidence that endogenous ET-1 is
involved in the maintenance of cardiac function in
CHF.1581 Thus, caution is necessary in contemplat¬
ing blockade of the ET system in patients with heart
failure.
Animal models of CHF have shown substan¬
tially improved survival with both selective ET-A
and nonselective ET-A/B receptor antagonists. In
rats with CHF induced by coronary artery ligation,
though acute ET-A receptor blockade with BQ 123
reduced myocardial contractility,1591 long term treat¬
ment resulted in a 90% survival rate, compared with
40% in nontreated animals.1581 This improved sur¬
vival was associated with an amelioration of LV
dysfunction and prevention of ventricular remodell¬
ing. Treatment with the nonselective receptor an¬
tagonist bosentan for 9 months in a coronary artery
ligation model of CHF resulted in beneficial alter¬
ations in haemodynamics, cardiac geometry and
function and an 18% increase in survival compared
with controls.1681 In the Dahl salt-sensitive, hyper¬
tensive model of CHF, long term treatment with bo¬
sentan, started at the stage of compensated LVH, did
not alter LV mass but improved survival by 36%.1621
Of note, in a pacing CHF model, long term (6 weeks)
nonselective receptor antagonism (L 753037) in¬
creased coronary sinus NO concentrations and im¬
proved endothelium-dependent relaxation in coro¬
nary arteries.1691
In humans, the increase in circulating big ET-1
or ET-1 seen in patients with CHF is correlated with
the severity of symptoms and with prognosis.170,711
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A series of clinical trials point towards potential
usefulness of ET receptor antagonists in this con¬
dition (table II), though it is unclear whether selec¬
tive or nonselective receptor antagonism will pro¬
vide the greatest benefit.
Studies with bosentan have consistently reported
marked haemodynamic benefits both acutely and
in the longer term.172-74! In patients on chronic triple
therapy of ACE inhibitors, diuretic and digoxin, acute
administration of intravenous bosentan (300mg in
total) 2 days after withdrawal of the ACE inhibitor,
resulted in a 33% decrease in pulmonary vascular
resistance (PVR).'721 Oral bosentan (lg twice daily
for 2 weeks) improved systemic vascular resistance
index (SVR; -25%), PVR (-20%) and cardiac index
(CI; +15%) on day 1 of treatment. After 2 weeks of
continuous oral therapy, additional haemodynamic
improvements (PVR; -10%, SVR; -10%, CI; +15%)
were documented in patients receiving ongoing
ACE inhibitor therapy.'73' The REACH study, in
which 370 patients with CHF received bosentan
(500mg twice daily) or placebo for 6 months, was
terminated early because of asymptomatic, revers¬
ible increases in hepatic transaminases in the treat¬
ment group, but improvements in symptoms, and
fewer hospitalisations were reported in bosentan-
treated patients who completed the 6 month proto¬
col.'74' Further clinical studies of bosentan in CHF
are being planned.
The theoretical benefits of selective ET-A re¬
ceptor antagonism in patients with CHF have, so
far, only been explored in small acute studies. Intra¬
venous BQ 123 (100 nmol/min for 60 min for 2 pa¬
tients; 200 nmol/min for 60 min for 8 patients)'75'
andTBC 11251 (1.5 or3 mg/kg)'77' have produced
significant systemic and pulmonary haemodyna¬
mic benefits, respectively (table II). Acute ET-B
receptor antagonism with BQ 788, caused systemic
vasoconstriction in CHF patients, an effect which
was reversed by the addition ofBQ 123, suggesting
that ET-B receptors contribute to vasodilator tone
in CHF.'76' Longer term studies with selective ET-
A receptor antagonists have yet to be performed.
Similarly, the long term effects of ET antagonism
on vascular and ventricular remodelling remain to
be explored in patients with CHF.
5. Hypertension
Exogenous administration of ET-1 increases
peripheral vascular resistance and elevates blood
pressure, and studies with ET receptor antagonists
have revealed that endogenous ET-1 has an impor¬
tant role in the maintenance of normal vascular tone.
It is also possible that ET-1 may modulate blood
pressure by renal mechanisms, by altering the bal¬
ance between its potentially favourable natriuretic
action (ET-B receptors)'78' and sodium retention as
a consequence of renal vasoconstriction (ET-A
Table II. Studies with endothelin receptor antagonists in patients with congestive heart failure (CHF)
Trial Study
design
n Drug Route and
duration of
administration
NYHA MAP PAP SVR PVR HR CI
Kiowski et al.[72] nb, nc 24 Bosentan IV bolus III i i I i T
Sutsch et all731 r, db, pc 36 Bosentan Oral 14 days III i i i i <-> T
Packer et al.'741 r, db, pc 370 Bosentan Oral 6 months IIIB-IV Clinical improvement = reduced hospital admissions
Cowburn et aid751 nb, nc 10 BQ 123 IV bolus Stable CHF i i i (T) <T"> T
Cowburn et al.[76l 8 BQ 788 IV bolus Stable CHF T (t) t (t) ns I
7a BQ 788 +
BQ 123
IV bolus i i i i ns T
Givertz et aid771 r, db, pc 24 TBC 11251 IV bolus lll-IV I <-> I <-» ns
a Seven patients of the original 8 received BQ 123 + BQ 188.
CI = cardiac index; db = double-blind; HR = heart rate; IV = intravenous; MAP = mean arterial pressure; n = number of participants; nb =
nonblind; nc = noncomparative; ns = not specified; NYHA = New York Heart Association grade of CHF; PAP = pulmonary artery pressure;
pc = placebo-controlled; PVR = pulmonary vascular resistance; r = randomised; SVR = systemic vascular resistance; T = significant increase;
I = significant decrease; <-> = no change; (t) = nonsignificant increase; (I) = nonsignificant decrease.
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receptors),'261 by interactions with other hormone
systems, such as the renin-angiotensin system,'791
by effects on the central and peripheral nervous sys¬
tem,'801 and, in the longer term, by its mitogenic
properties, which will influence the calibre and re¬
sponsiveness of blood vessels.'44,451 Knockout ro¬
dentmodels suggest that ET-B receptors participate
in blood pressure regulation by causing vasodilata¬
tion and natriuresis.115,781 Forearm models in healthy
human volunteers have shown that selective ET-A
receptor antagonism (BQ 123) causes local vasodi¬
latation, combined ET-A and ET-B (BQ 123 plus BQ
788) or nonselective ET-A/B receptor antagonism
(TAK 044) causes vasodilatation, but to a lesser extent
than ET-A antagonism alone, whereas selective ET-
B blockade (BQ 788) causes vasoconstriction.'81"841
Systemic studies with nonselective and selective
ET-A or -B receptor antagonists have confirmed
these local findings; selective ET-A (BQ 123) and
nonselective receptor antagonists (TAK 044) pro¬
duce similar reductions in mean arterial pressure
and SVR while ET-B-selective receptor antagonists
(BQ 788) produce an increase in peripheral vascu¬
lar resistance.'85-871
With respect to the pathophysiology of hyper¬
tension, production of ET-1 is increased in some
(e.g. Dahl salt-sensitive and stroke-prone spontane¬
ously hypertensive rats), but not all rat models.'881
Those models in which ET-1 production is increased
(mostly, but not exclusively salt-dependent types)
are associated with increased vascular growth and
are responsive to both selective and nonselective
ET receptor antagonists. This response comprises
not only a modest reduction in blood pressure but
also a marked regression of vascular growth.'881
In humans, elevated plasma ET concentrations
are found in hypertension, though this is not con¬
sistent.'89' These high concentrations would appear,
mostly, to be a feature of severe hypertension or
indicative of the presence of complications or co¬
existing disease. Levels of prepro-ET-1 and ECE
mRNA are increased in the vascular smooth muscle
cells of patients with hypertension,'6' and there is
evidence that endothelial function, specifically en-
dothelium-dependent vascular relaxation, is im¬
paired both in patients with hypertension and in
groups at risk of developing hypertension.'90,911
Forearm studies with selective ET-A or -B receptor
antagonism (BQ 123 and BQ 788, respectively)
suggest increased vascular ET activity in patients
with essential hypertension compared with normo-
tensive controls, and demonstrate a greater re¬
sponse to nonselective antagonism compared with
selective ET-A antagonism.'92' These data need to
be confirmed, but suggest a mechanism for ET in
the pathogenesis of hypertension.
To date, one major study has examined the anti¬
hypertensive effects of an ET receptor antagonist
in humans. In 293 patients with hypertension, oral
bosentan 500 to 2000 mg/day for 4 weeks achieved
a reduction in blood pressure equivalent to that
achieved with 20mg of enalapril.'931 This reduction
was achieved without a reflex increase in the activ¬
ity of the sympathetic nervous system (as measured
by plasma noradrenaline levels and heart rate) or
renin-angiotensin system. Further confirmatory work
is needed, but given the range of available anti¬
hypertensive drugs, a new class of agents would
have to demonstrate greater efficacy, a better ad¬
verse effect profile, or other benefits in addition to
blood pressure lowering properties in order to ob¬
tain a place in the therapy for hypertension. In ad¬
dition to antihypertensive effects, the potential
benefits of ET antagonists in patients with hyper¬
tension might include reducing long term structural
changes in blood vessels (vascular hypertrophy or
atherogenesis) or the myocardium, ameliorating
endothelial dysfunction, and/or beneficial effects
on salt and water balance. Subgroups such as salt-
sensitive individuals or black patients with hyperten¬
sion (with higher plasma ET levels and/or impaired
endothelium-dependent relaxation'89,91') might
benefit the most from these agents.
6. Vasospastic Conditions
A role for ET has been suggested in vasospastic
conditions, such as migraine and Raynaud's disease,
because higher plasma ET concentrations are seen
during active episodes in patients with these con¬
ditions.'801 It must be remembered, though, that ET
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plays an important role in normal developmental
biology. '78' ET antagonists are teratogenic in the
first trimester of pregnancy and therefore use of
these drugs in women of child-bearing age is pre¬
cluded, limiting their usefulness in these and other
conditions. However, this limitation is probably less
important in the delayed cerebral vasospasm seen
after subarachnoid haemorrhage or in ischaemic
stroke. Selective and nonselective ET receptor an¬
tagonists (RO 611790 and SB 217242, respec¬
tively) have both been shown to reduce ischaemic
brain injury in animals.'94"96' Phase II trials with
ET antagonists for these indications are currently
in progress.
7. Pulmonary Hypertension
ET-l is elevated in animal models of pulmonary
hypertension'97' and in humans, possibly because of
increased pulmonary production, as the pulmonary
venous concentration of ET-l exceeds the arterial
concentration.198' In addition, tissue levels ofmRNA
for ET-1 appear to be correlated with the PVR.'99'
Thus, pulmonary hypertension, a disease character¬
ised by endothelial injury, vascular smooth muscle
cell proliferation and pulmonary vasoconstriction,
is another potential therapeutic target for ET recep¬
tor antagonists.
Nonselective and selective ET-A receptor antag¬
onism both prevent NG-monomethyl-L-arginine-
induced pulmonary vasoconstriction in a rat mono-
crotaline model of pulmonary hypertension.'97' The
lack of effect of ET-B antagonism suggests this is
an ET-A-mediated effect. In a pig hypoxic model
of pulmonary hypertension, selective ET-A and non¬
selective receptor antagonists were equally effec¬
tive in countering hypoxia-induced increases in
pulmonary artery pressure; ET-B-selective drugs
had no effect."00' Both ET-A-selective and nonse¬
lective drugs (table I) are currently in development
for this indication.
8. Conclusion
ET receptor antagonists have been, and con¬
tinue to be, crucial experimental tools in elucidat¬
ing the role of the ET system in cardiovascular phy¬
siology and pathophysiology. With the increasing
availability of orally administered selective and non¬
selective antagonists, it should be possible to more
fully establish the clinical role of these drugs in
patients with cardiovascular disease. If they live up
to their promise, ET receptor antagonists could offer
a wide range of benefits including the reduction of
pre- and after-load, reduction of pulmonary and
systemic blood pressure, improvement in coronary
blood flow, and, in the longer term, a reduction in
abnormal ventricular and vascular remodelling and
atherosclerosis. Through these effects, they might
be useful in the management of patients with CAD,
hypertension and CHF. Though the cardiovascular
system appears to be a promising target for these
new drugs, further work is needed to clarify when
selective as opposed to nonselective antagonism is
required.
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Plasma Endothelin Concentrations in Hypertension
Jane Goddard and David J. Webb
Clinical Pharmacology Unit & Research Centre, Department ofMedical Sciences, University ofEdinburgh,
Edinburgh, Scotland, U.K.
Summary: The endothelins comprise a family of potent vasocon-
stricting peptides. Endothelin-1 appears to be the predominant iso-
form produced by the vascular endothelium, acting mainly in a
paracrine fashion on vascular smooth muscle cells to cause vasocon¬
striction. It also has a range of other local actions - in the kidney, in
the nervous system and on other hormone systems - that could,
potentially, play a part in the genesis of hypertension. The association
of raised plasma endothelin concentrations in human hypertension
has caused much interest, but the literature is not consistent. Given
the generally low plasma concentration of the endothelins, and their
mainly paracrine actions, it remains unclear whether plasma endothe¬
lin has a functional role in hypertension. Additionally, problems
remain with the measurement of plasma endothelin that raise doubts




The endothelins (ETs) are a family of 21-amino-acid
peptides with vasoactive, inotropic and mitogenic proper¬
ties and the ability to modulate other hormone systems, as
well as gut, kidney and lung function. Three different pep¬
tides, endothelin (ET)-l, ET-2 and ET-3, each with dis¬
tinct genes and tissue distributions, have so far been
identified. ET-2 differs from ET-1 by two amino acids and
ET-3 from ET-1 by six amino acids. Each has a common
structure of a hydrophobic C terminal end and two intra-
chain disulphide bonds that form a hairpin structure (l^f).
ET-1 is primarily produced by endothelial cells but is
also found in a variety of other cell types in heart (epi-
cardium), lung (bronchial epithelial cells), kidney (tubu¬
lar cells), central and peripheral nervous system tissue
(astrocytes/nerve plexi/pituitary tissue), macrophages
and vascular smooth muscle cells. ET-2 mRNA is found
to a lesser extent in endothelial cells and also in other
cells in heart and kidney. ET-3 is found in gut, kidney,
adrenal secretory tissue, macrophages and CNS tissue
but not endothelium (2,5-7).
ET-1 is synthesized from preproendothelin-1, the 212-
amino-acid gene product. Endothelin genes are thought
to be regulated at the transcription level with stimuli to
Address correspondence and reprint requests to Professor David
Webb at the Clinical Pharmacology Unit & Research Centre,
gene transcription including hormones (such as adrena¬
line, angiotensin II, insulin and arginine vasopressin),
cytokines (such as platelet-derived growth factor and
transforming growth factor beta), hypoxia, oxidized low
density lipoprotein and cyclosporin. Inhibition has been
documented in response to prostacyclin, nitric oxide,
atrial and other natriuretic peptides and heparin (4,7,8).
Preproendothelin-1 is processed to form proendothe-
lin-1 which is then cleaved by intracellular furin-like pro¬
teases to generate big ET-1 (38 amino acids) which is
biologically inactive. Endothelin-converting enzyme
(ECE), a metalloprotease, then cleaves big ET-1 to the
biologically active ET-1 and a 17-amino-acid C-terminal
fragment-1 (CTF-1). A group of ECEs for ET-1 have been
identified, each with a different tissue distribution and dif¬
ferent pH at which they act. ECEs have not yet been iden¬
tified that are selective for ET-2 and ET-3 (9).
Two receptors for ET have been identified. ETA recep¬
tors are found in the aorta, heart, kidney and vascular
smooth muscle cells where their activation causes cell
contraction. They exhibit a marked selectivity for ET-1.
ETb receptors are present on endothelial cells where their
activation results in the production of nitric oxide and
prostacyclin, resulting in vasodilatation. They are also
present on vascular smooth muscle cells where their acti-
Departmenl of Medicine, The University of Edinburgh, Western
General Hospital, Crewe Road, Edinburgh EH4 2XU, Scotland, U.K.
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vation causes vasoconstriction. They have equal affinity
for ET-1, ET-2 and ET-3. Signal transduction is via
G protein coupling and activation of intracellular phos-
pholipase-C with subsequent hydrolysis of phosphatidyl
inositol and changes in intracellular calcium. Removal of
ET-1 from the circulation is by receptor binding and
internalization (ETB effect), renal clearance and enzy¬
matic degradation by neutral endopeptidases (8-10).
MEASUREMENT
Plasma endothelin-like immunoreactivity is said to com¬
prise around 60% big ET-1 and 30% ET-1. ET-3 but not ET-
2 also circulates in the blood but at lower concentrations
(-10%) (4,11,12). Most of the focus has been on plasma
ET-1 because it is the major active isoform in blood,
although it is possible that big ET-1 could act as a circulat¬
ing hormone which is processed to ET-1 at its site of action.
There are many problems associated with the meas¬
urement and interpretation of plasma ET-1 concentra¬
tions. Most ET-1 (-90%) is released from endothelial
cells abluminally (13) where it acts on endothelial and
smooth muscle cells as a predominantly autocrine and
paracrine mediator. Plasma ET-1 may not, therefore, be
an accurate reflection of endothelial synthesis of ET-1. In
addition, the ET-1 concentration in plasma is likely to
reflect a balance between production/overspill and its
clearance. Under normal circumstances, ET-1 is rapidly
cleared from the circulation by ETB receptors, the kidney
and neutral endopeptidases and so plasma concentrations
may be largely determined by production. Consistent
with this, although ET-1 exerts effects for up to 60 min,
the plasma half-life in healthy subjects is only -1 min
(14). Reduction in ETB receptor numbers, enzymatic
degradation, or renal function, or administration of an
ETb receptor antagonist, may reduce this clearance and
increase plasma ET-1 half-life.
Hence, in a number of situations, plasma ET-1 concen¬
trations can be altered without a change in ET-1 produc¬
tion. It may not, therefore, be valid to draw conclusions
about ET-1 production from plasma concentrations.
Plasma big ET-1 has been proposed as a more reliable
measure of endothelial ET-1 synthesis because its removal
from the circulation is slower and less variable (15,16).
Turning to measurement techniques, plasma ETs are
currently analysed by either radioimmunoassay (RIA) or
enzyme-linked immunoassay (ELISA). Because normal
plasma concentrations are in the low picomolar range
(12,17-25), direct measurement in the plasma is difficult
and both RIA and ELISA require ET to be extracted from
the plasma and concentrated prior to measurement.
Recovery rates during extraction are variable depending
on, for example, the size and nature of the extraction
columns and the fluid used to elute the ET; acetic acid
extraction (26) achieves the highest recovery rate of 90%
but recovery can be as low as around 50% (see Table 1).
ET-1 is also partly degraded during the extraction process
(26), further reducing the amount of plasma ET-1 that
will then be assayed.
Antibodies commonly used in current assays exhibit
cross-reactivity between the subtypes of ET, depending
on which part of the molecule the antibody is raised
against and depending on the antibody used; for example,
using ET-1 detection of 100% as the standard, cross-
reactivity of the antibody can range between 0 and 200%
with big ET-1, between 10 and 1300% for ET-2, and
between 0% and 120% for ET-3 (see Table 1). Many
papers quote the concentration of 'plasma ET-1', when a
more realistic term, given the cross-reactivity of the anti¬
bodies used, is 'plasma ET-like immunoreactivity'. As a
separate issue, it is not clear whether the ET assayed in
blood comprises mature peptides or degraded fragments
of these. Therefore, it is possible that the high plasma
ET-1 concentrations, for instance in renal failure, may
bind ET antibodies but not be biologically active.
The sensitivity of a good immunoassay may be suffi¬
cient to detect levels down to 0.5 pg/ml. However, some
kits have a sensitivity no lower than 8 pg/ml, higher than
the range in which blood concentrations in healthy sub¬
jects are found. Also, intra- and inter-assay variability
tends to be relatively high for ET assays, with inter-assay
variations of > 10% reported, thus reducing the precision
of the measurement (see Table 1). In addition, sample
handling is important because haemolysis can increase
measured ET concentrations tenfold. Lipaemic or icteric
samples also give falsely high readings. Furthermore,
dilution curves of synthetic pure ET-1 from different sup¬
pliers also show considerable variation (26). Hence, the
reference point for biological samples varies depending
on the supplier of the standard. Finally, the conditions
under which blood is sampled must be borne in mind
given that changes in position (45), temperature (24) and
mental stress (46) have been reported to affect plasma
ET-1 concentrations, and given the known interaction
between ET-1 and other neurohumoral mechanisms
(41,47,48). Taking these many factors into account, com¬
parisons between studies performed in different laborato¬
ries are currently probably not warranted, although the
ratios of concentrations in patients relative to controls
may be a useful measure (Table 2).
PLASMA ENDOTHELIN AND ESSENTIAL
HYPERTENSION
ET-1 is a profound vasoconstrictor, causes cell prolif¬
eration, and is involved in the maintenance of basal vas¬
cular tone in a balance between constricting and dilating
substances. It also activates the sympathetic nervous sys¬
tem and the renin-angiotensin-aldosterone axis. Hence,
a role has been sought for the peptide in the pathophys¬
iology of essential hypertension, a condition character¬
ized by endothelial dysfunction and increased vascular
tone (1). In this review, we have considered measure¬
ments of plasma ET concentration in patients with
essential hypertension in all papers published in English
or abstracted in English that appear on Medline.
Although plasma ET-1 levels have been reported as ele¬
vated in patients with essential hypertension in some
J Cardiovasc Pharmacol*™. Vol. 35 (Suppl. 2). 2000
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TABLE 2. Plasma immunoreactive endothelin concentrations [adaptedfrom Nelson et al. (49)]
Number of subjects
Disease state Reference (controls) Plasma ET (pg/ml) Ratio (disease/normal)
Systemic sclerosis Yamane 1992 (50) 31 (25) 1.9 1.5
Advanced atherosclerosis Lerman 1991 (51) 40(100) 8.0 2.3
Advanced prostate cancer Nelson 1995 (49) 79 (26) 13.2 2.6
Sepsis Pittet 1991 (52) 11 (14) 19.9 3.3
Congestive cardiac failure Wei 1994 (53) 8(6) 23.2 3.3
Acute myocardial infarction Yasuda 1990 (54) 9(25) 3.8 7.6
Hepatorenal syndrome Moore 1992 (55) 11 (11) 36.5 9.1
Haemangioendothelioma Yokokawa 1991 (56) 2(8) 12.7 12.7
Cardiogenic shock Cernacek 1989 (57) 6(14) 3.7 14.0
studies (11,20,25,27-36,58), this is by no means univer¬
sal (19,22-24,37-44).
Plasma ET concentrations, even when elevated, are gen¬
erally not as high as those associated with haemodynamic
effects when ET-1 is given exogenously in man (59-61).
However, when ET-1 is given exogenously there is likely
to be a gradient of concentration of ET-1 between blood
and the endothelium/smooth muscle interface, such that
the vascular smooth muscle is exposed to less ET-1 than is
indicated by assays of plasma concentration. In contrast,
the gradient is in the opposite direction for endogenously
generated ET-1, so that the concentration in plasma is con¬
siderably less than at the endothelium/smooth muscle
interface. Therefore, for the same plasma concentration,
vascular smooth muscle 'sees' considerably more ET-1
when it is generated endogenously than given exoge¬
nously. Indeed, in prostatic carcinoma, where plasma ET-
1 concentrations are as high as 50 pg/ml, but are probably
not generated at the endothelium/smooth muscle interface,
blood pressure is not raised (49). Hence, comparisons
based on plasma concentrations are unlikely to be valid
and locally increased ET-1 generation may occur in the
blood vessels of hypertensive subjects without it being
clearly reflected in the blood, and may have important
effects on vascular structure and function, either directly or
indirectly, such as through potentiation of the sympathetic
nervous system (41).
Why do only some studies show an elevated plasma
ET concentration in hypertension? It may relate to the
use of different assays with different cross-reactivities.
First, if the main plasma ET species are ET-1 and big
ET-1, with a smaller contribution from ET-3, then those
assays purporting to measure ET-1 but with a high cross-
reactivity for these other species might give artificially
high values. However, this does not appear to explain the
disagreement because even those groups using antibodies
with a low (< 10%) cross-reactivity for these species are
divided in their findings with respect to plasma ET-1 con¬
centrations in hypertension (see Table 1). Second, two
groups have reported that the plasma ET immunoreactiv-
ity in patients with essential hypertension has the same
high performance liquid chromatography (HPLC) profile
as in normotensives i.e. the same relative concentrations
of the ET subtypes (11,62). Hence, inaccuracy in ET-1
measurement resulting from cross-reactivity should be
the same for hypertensive and normotensive groups and a
true difference, therefore, still exist whatever the cross-
reactivity of the antibody used in the assay.
Does the size of the populations studied account for
the difference of opinion? Davenport et al. (37) studied
25 patients and 25 controls and showed no differences in
plasma ET-1 concentrations. They calculated that for the
power of the test to be able to detect a 25% difference in
concentrations, at a 5% significance level, 100 patients
would be required. No study meets this size requirement.
From Table 1 it can be seen that, although there is one
larger study failing to detect an elevation in plasma ET-1
in hypertensives, the majority of larger studies are in the
group that do detect a difference. Whereas the published
studies mostly account for other important confounding
factors, including age, creatinine and antihypertensive
drugs, a meta-analysis is likely to be unhelpful because
the assays and the populations are not comparable, or
sufficiently defined, and a strong possibility of publica¬
tion bias for the positive studies exists.
It does appear, though, fairly consistently, that patents
with severe hypertension are much more likely to have
elevated plasma ET-1 concentrations. Several groups
who report a difference in plasma (ET-1) note this is lim¬
ited to patients with more advanced disease, in terms of
target organ damage or higher blood pressures (11,
28-30,58). Additionally, one group who observed no sig¬
nificant difference did see a trend towards higher plasma
ET-1 concentrations in severe disease (44). This could be
explained by the observation that patients with athero¬
sclerosis (a common condition in hypertensive patients)
have higher circulating ET-1 concentrations irrespective
of blood pressure (51) but groups specifically excluding
patients with vascular disease have still detected this
effect (25). If plasma ET-1 levels are higher in more
severe hypertension, one might expect to find a correla¬
tion between plasma ET-1 and blood pressure. Some
groups do observe such a correlation (11,25,30,31,33),
even when no absolute difference has been detected
(38,40) whereas some do not (19,23,42,43) even when a
difference between groups is observed (28,29,34,35).
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Indeed, one study observed a significant negative corre¬
lation between blood pressure and plasma ET-1 in the
hypertensive group (37). Fogari et al. (32) did not find a
correlation between plasma ET concentration and blood
pressure measured in the clinic (three readings, supine)
but did find a significant correlation when blood pressure
was measured using 24-h ambulatory blood pressure
monitoring. Interestingly, in relation to the plasma find¬
ings in severe hypertension, Schiffrin et al. (44) have
recently demonstrated an increase in ET-1 gene expres¬
sion in resistance arteries that is confined to patients with
severe hypertension, and only associated with a trend for
plasma ET-1 to be elevated, suggesting that ET-1 produc¬
tion may be increased in hypertension but this is poorly
reflected by changes in plasma ET-1.
Ergul et al. (35) report a striking threefold higher
plasma ET-1 concentration in black patients with hyper¬
tension compared to white patients with hypertension.
Hoffman et al. (23) did not detect this racial difference
but the numbers in each group in both studies were small
and the issue needs clarification with a larger study. In
salt-sensitive compared to salt-resistant patients with
essential hypertension findings are similarly equivocal
(23, 63). What is clear is that a substantial overlap in
plasma ET-1 concentrations exists between the hyperten¬
sive group, however it is described, and the control group
in all of the studies. Thus, with respect to plasma ET con¬
centrations in essential hypertension, they are neither a
sensitive nor a specific index of this condition.
Two groups have found abnormalities in ET-1 clear¬
ance in hypertensive patients with normal renal function,
suggesting an abnormality in renal ET handling consis¬
tent with reduced ET-1 clearance or renal production
(23,25). This is in marked contrast to the situation in
renal failure where ET-1 clearance/glomerular filtration
rate (GFR) ratio is substantially raised (25). Within the
kidney, ET has the potential to generate hypertension by
several mechanisms. The effect of exogenous ET-1 on the
renal vasculature is to cause vasoconstriction (which will
activate the renin-angiotensin system) and profound salt
and water retention, both having the potential to raise
blood pressure (64). It is not clear yet whether the ele¬
vated plasma ET-1 concentrations seen in various disease
states are able to cause such renal vasoconstriction but it
is known that ET-1 can cause a reduction in renal blood
flow and GFR at concentrations that do not alter systemic
haemodynamics (65). However, ET-1 is also produced by
inner medullary collecting duct cells (IMCD) where it
inhibits the arginine vasopressin (AVP) stimulated reten¬
tion of water (66). There is evidence that extracellular
sodium concentrations may regulate IMCD ET-1 produc¬
tion (67) and hence ET-1 may have a role in the renal reg¬
ulation of volume homeostasis. If, as the urinary data
suggest (23,25), nephron ET-1 production or handling is
altered in essential hypertension, there may be inappro¬
priate sodium and water retention aiding the development
or maintenance of hypertension. Interestingly, sponta¬
neously hypertensive rats have been shown to have
reduced medullary ET-1 levels (68), whereas in the rem¬
nant kidney model of renal failure ET-1 production is
increased (69).
CONCLUSIONS
Studies using receptor antagonists show that the ETs
are important mediators in physiological blood pressure
regulation in humans (70,71). Endothelin antagonists
have also been shown to reduce blood pressure in hyper¬
tensive patients (72) and may have additional benefits in
terms of potential effects on the heart, blood vessels and
kidney (73). Measurement of plasma ET concentrations in
hypertension is likely to be of limited value, and a poor
reflection of ET-1 generation, although it may indicate
hypertensive subgroups in whom ET antagonists might be
particularly effective.
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(typed double-spaced) in length and may be subject to editing or abridgment.
Endothelin Antagonists and Hypertension:
A Question of Dose?
To the Editor:
We read with interest the recent report in Hypertension from
Martin et al1 on the effects of intra-arterial administration of the
endothelin ET^ receptor antagonist, SB 209670, on forearm
blood flow in hypertensive subjects and matched controls. Their
finding of forearm vasodilation to intra-arterial SB 209670 in
healthy controls suggests a role for endothelin-1 (ET-1) in
regulation of basal vascular tone and is consistent with our own
work2-4 and that of some,4-5 but not all other groups,6-7 with both
ETa receptor selective and ETa/B receptor antagonists. Also,
contrary to some earlier work,6-7 they find no difference from
controls in the in vivo response of the resistance vessels of
hypertensive subjects to ET receptor antagonism.
Our early intra-arterial studies were undertaken with the ETA
selective antagonist, BQ-123, at a dose of 100 nmoL/min.2 We
have since undertaken pharmacodynamic and kinetic dose-
ranging systemic studies with BQ-123 and find that this dose of
BQ-123 has modest systemic effects, more on vascular resistance
than blood pressure.8-9 Maximum plasma concentrations of
BQ-123 at 100 nmol/min were 585±158 nmol/L,8 and IC50
values for BQ-123 at the ETA and ETB receptors in vitro are 9 to
24 nmol/L and 10 to 18 000 nmol/L, respectively, depending on
cell type.10 Hence, when given locally into the forearm (blood
flow *=50 mL/min) rather than the systemic circulation (=5 000
mL/min), this dose of BQ-123 will achieve concentrations (=60
000 nmol/L) that may have functionally important inhibitory
effects at the ETB receptor.
On this basis, our laboratory has more recently delivered
BQ- 123 in forearm studies at a dose of 10 nmol/min, with which,
if anything, greater effects on local blood flow have been seen.4
This may be explained by the major role of the vascular ETB
receptor being to mediate vasodilation,4-11 such that combined
ET^ inhibition may, by blocking ETB mediated effects, atten¬
uate the vasodilation associated with selective ETA receptor
antagonism.4 We have also used BQ-788 intra-arterially (at 1
nmol/min) as an ETB selective antagonist, here based on systemic
studies showing that 30 nmol/min, but not 3 nmol/min, increases
systemic vascular resistance."
However, a key issue arises for the published body of work
using intra-arterial administration of ET receptor antagonists.
These investigations have generally used high doses that are
likely to be both nonselective and systemically active, conditions
that interfere with a clear interpretation of these studies. Cardillo
and colleagues gave BQ-123 (at 100 nmol/min) and BQ-788 (at
50 nmol/min) by intra-arterial coadministration to hypertensives
and controls to achieve dual ET receptor blockade.6 However, it
would now appear that both of these agents were given at
systemically active doses. A similar problem of using a system¬
ically active dose of TAK-044 may account for a rather modest
effect on vascular tone in healthy subjects in one study7 and the
lesser effect of a greater dose ofTAK-044 in another.3 By giving
systemic doses of the pharmacological probes, responses in the
infused forearm may have been influenced directly by changes in
systemic vascular resistance or indirectly by the activation of
reflex neurohormonal mechanisms.12 In this regard, there must
remain some uncertainty about interpretation of work examining
the role of endothelin in hypertension and other vascular diseases
using drug administration via the brachial artery until these
studies are repeated with doses of drugs that are demonstrably
confined to a local action.
Jane Goddard
Lecturer in Renal Medicine
Clinical Research Centre
The University of Edinburgh
David J. Webb
Professor of Clinical Pharmacology
Clinical Research Centre
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Response
We thank Doctors Goddard and Webb for their comments
regarding intra-arterial infusion of endothelin (ET) antagonists.
Goddard andWebb raise a number of relevant issues. They reiterate
the importance of using subsystemic doses of vasoactive substances
to test hypotheses regarding direct effects on the vasculature. The
key issue is how to establish that doses are indeed subsystemic. The
usual approach includes careful assessment of systemic blood
2 Letters to the Editor
pressure and heart rate responses and/or measurement of forearm
blood flow and vascular resistance in the contralateral limb.1 This is
really a general issue of the technique itself and not limited to
endothelin blockade as the vasoactive substance.
Specific to endothelin blockade, however, is the issue of selec¬
tivity of the receptor antagonist. Goddard and Webb suggest that
doses of the ETA-"selective" antagonist BQ-123, assumed to be
subsystemic in a number of studies,2-3 may indeed be systemically
active4 and also block ETB-mediated vasodilation.5 However, this
still does not explain differences in vascular responses to this agent
given at the same dose and at the same infusion rate over similar
periods of time. We used SB209670 in our study6 specifically
because it is nonselective, and we wished to test the impact of
blockade of all major ET receptor subtypes on the vasculature,
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Systemic ETA receptor antagonism with BQ-123 blocks ET-1
induced forearm vasoconstriction and decreases peripheral vascular
resistance in healthy men
'James C.S. Spratt, 'Jane Goddard, 'Neil Patel, 'Fiona E Strachan, 2Andrew J. Rankin &
*'David J. Webb
'Clinical Pharmacology Unit & Research Centre, Department of Medical Sciences, University of Edinburgh, Western General
Hospital, Edinburgh, EH4 2XU and "Department of Experimental Medicine, Clinical Sciences, Pfizer Global Research &
Development, Sandwich, Kent, CT13 9NJ
1 The effect on systemic haemodynamics of BQ-123, a selective endothelin A (ETA) receptor
antagonist, was investigated in healthy men by giving, on separate occasions, ascending intravenous
doses of 100, 300, 1000 and 3000 nmol minBQ-123, each for 15 min, in a randomized, placebo-
controlled, double-blind study. The response of forearm blood flow to brachial artery infusion of
endothelin-1 (ET-1; 5pmolmin-1 for 90 min) was also studied using bilateral forearm
plethysmography, after systemic pre-treatment, on separate occasions, with one of two doses of
BQ-123 (300 and 1000 nmol min 1 for 15 min) or placebo.
2 Systemic BQ-123 dose-dependently decreased systemic vascular resistance (R<0.01 for all doses
vs placebo) and mean arterial pressure (Re 0.05 for 300 nmol min 1 and R<0.01 for 1000 and
3000 nmol min ') during the 60 min following infusion. There were concurrent increases in heart
rate and cardiac index. BQ-123, when infused systemically for 15 min, appeared to reach a
maximum effect at 1000 nmol min-'.
3 Intra-brachial ET-1 infusion, after pre-treatment with placebo, caused a slow onset progressive
forearm vasoconstriction without systemic effects. This vasoconstriction was attenuated by pre-
treatment with BQ-123 at 300 nmol min-1 and abolished by BQ-123 at 1000 nmol min-1 (P<0.01
vs placebo).
4 These effects occurred at concentrations of BQ-123 in the plasma (510 + 64 nmol 1~') that were
ETA receptor selective, and were not accompanied by an increase in plasma ET-1 that would have
indicated ETB receptor blockade.
5 We conclude that ETA-mediated vascular tone contributes to the maintenance of basal systemic
vascular resistance and blood pressure in healthy men.
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Introduction
Endothelin-1, which was first identified by Yanagisawa et al.
(1988), is a well characterized, potent and sustained
vasoconstrictor and pressor agent involved in the endothe-
lium-mediated regulation of vascular tone (Haynes & Webb,
1998). Two ET receptor subtypes have been identified at a
molecular level and characterized pharmacologically in blood
vessels. ETA receptors (Arai et al., 1990) have higher affinity
for ET-1 than ET-3, are found on vascular smooth muscle
cells, and mediate vasoconstriction. ETB receptors have equal
affinity for ET-1 and ET-3 (Sakurai et al., 1990) and are
found on vascular endothelial cells, where they mediate
endothelium dependent vasodilatation (De Nucci et al., 1988;
Tsukahara et al., 1994). ETB receptors are also present on
vascular smooth muscle cells, where they may contribute to
*Author for correspondence; E-mail: j.goddardln ed.ac.uk
vasoconstriction (Clozel et al., 1992; Reizebos et al., 1994;
Seo et al., 1994; Tschudi & Luscher, 1994).
Local studies in human forearm resistance vessels using
phosphoramidon, an endothelin converting enzyme inhibi¬
tor, and BQ-123, a selective ETA receptor antagonist, first
demonstrated the importance of ET-1 in maintaining basal
resistance vessel tone, in large part through an action on
the ETA receptor (Haynes & Webb, 1994). These
observations have since been confirmed by others (Berra-
zueta et al., 1997; Verhaar et al., 1998). Responses in the
forearm resistance vessels are usually predictive of those in
the systemic circulation (Webb, 1995), so these data
suggested that systemic ETA receptor antagonism would
produce systemic vasodilatation. Recently, however, acute
systemic administration of the selective ETA antagonist,
BQ-123, was reported to have no effect on systemic
haemodynamics (Schmetterer et al., 1998; Montanari et
al., 2000).
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We hypothesized that a systemic haemodynamic effect of
ETA receptor blockade was not seen in these studies because
the doses of BQ-123 used provided insufficient ETA receptor
blockade to affect blood pressure. In addition, because
healthy subjects have a number of reflex mechanisms that
serve to defend blood pressure, we hypothesized that an
important effect on systemic vascular resistance might have
been missed by measurement of blood pressure alone. We
also hypothesized that systemically effective ETA antagonism
with BQ-123 might be associated with inhibition of the
vasoconstriction to exogenous doses of infused ET-1
sufficient to cause modest effects on forearm vascular
resistance. We, therefore, undertook two studies. First, we
assessed the haemodynamic effects of increasing doses of BQ-
123, using bioimpedance cardiography, with the aim of
achieving a high degree of ETA selective receptor blockade.
Second, we examined whether haemodynamically active
doses of BQ-123 would antagonize the response to
exogenous ET-1, by infusion of local doses of ET-1 into
the forearm circulation, after administration of BQ-123




Five healthy men (age range 18-30 years) were recruited to
each of the two studies, which were performed in the Clinical
Research Centre at the Western General Hospital, Edin¬
burgh, with the approval of the local research ethics
committee and the written informed consent of each subject.
The investigations conformed to the principles outlined in the
Declaration of Helsinki. No subject received vasoactive
medication in the week before each phase of the study, and
all subjects were asked to abstain from alcohol, nicotine and
caffeine-containing products for 24 h and from food for at
least 4 h before any measurements were made. All studies
were performed from 08.30 h, in a quiet room kept at a
controlled temperature (22-24°C).
Drugs
BQ-123 (Clinalfa AG, Laufelfingen, Switzerland, molecular
weight 632.7) at doses ranging from 100-3000 nmol min"1
was used as a selective ETA receptor antagonist, with 2500
lower affinity for the ETB receptor (IC5o ETA of 7.3 nM
against IC50 ETB of 18 /j.m) (lhara et al., 1992). The dose
range was selected from previous studies investigating the
local effects of BQ-123, which suggested that 100 nmol min 1
is the threshold around which systemic effects might be
observed (Haynes & Webb, 1994). BQ-123 was dissolved in
physiological saline (0.9%, Baxter Healthcare Ltd, Thetford,
U.K.). Saline was also used as placebo. BQ-123 and placebo
were administered in a double-blind manner and infused
intravenously at a constant rate of 1 ml min"1 for 15 min via
an 18 standard wire gauge (SWG) cannula sited in the right
antecubital fossa (Study 1) or right distal forearm (Study 2).
ET-1 (Clinalfa AG, molecular weight 2492) was dissolved
in physiological saline to a concentration of 5 pmol min
(Haynes & Webb, 1994) and infused into the left brachial
artery via a 27 SWG steel cannula at a constant rate of
1 ml min"1 for a total of 90 min.
All solutions were prepared from sterile stock solutions on
the day of the study. For the forearm studies 1% lignocaine
(Astra Pharmaceuticals, Stockholm, Sweden) was used as a
local anaesthetic.
Measurements
Systemic haemodynamics Haemodynamic measurements
were made at 10 min intervals from 30 min pre-dose until
60 min post-dose, then at 30 min intervals until 2 h, then
hourly until 4 h post-dose. Blood pressure was recorded in
duplicate at each time-point using a well-validated semi-
automated non-invasive oscillometric sphygmomanometer
(Takeda UA-751 sphygmomanometer, Takeda Medical Inc)
(Wiinberg et al., 1988), in the right arm. Cardiac output (CO)
and heart rate (HR) were recorded using a well validated
non-invasive bioimpedance technique as previously described
(NCCOM 3; BoMed Medical Manufacturer Ltd) (Goldstein
et al., 1986).
Forearm blood flow Blood flow was measured in both
forearms by venous occlusion plethysmography using
mercury-in-silastic gauges (Benjamin et al., 1995; Webb,
1995) that were securely applied to the widest part of
each forearm. The hands were excluded from the
circulation during each measurement period by inflation
of a wrist cuff to 220 mmHg. Upper arm cuffs were
intermittently inflated to 40 mmHg for 10 in every 15 s
to temporarily prevent venous outflow from the forearm
and thus obtain plethysmographic recordings. Recordings
of forearm blood flow were made repeatedly at 10 min
intervals over 3-min periods. Voltage output from a
dual-channel Vasculab SPG 16 strain gauge plethysmo-
graph (Medasonics Inc) was transferred to a Macintosh
personal computer (Performa 475, Apple Computer Inc,
Cupertino, CA, U.S.A.) using a MacLab analogue digital
converter and Chart software (v. 3.2.8; both from AD
Instruments, Castle Hill, NSW, Australia). Calibration
was achieved using the internal standard of the Vasculab
plethysmography units.
Plasma ET-1, big ET-1 and BQ-123 During Study 1, 10 ml
of venous blood was obtained from a cannula inserted in the
left antecubital vein before and at 5, 15 and 240 min after
BQ-123 infusion for measurement of plasma ET-1 and big
ET-1. In addition, during the 300 and 1000 nmol min"1
phases, sub-aliquots of the samples were used for plasma BQ-
123 assay. Samples were collected into sterile EDTA tubes
(K3 EDTA, Vacutainer, Becton Dickinson) centrifuged at
2000 xg for 20 min and stored in plain tubes at — 80°C prior
to assay. Plasma ET-1 and big ET-1 concentrations were
determined by standard radioimmunoassay (Peninsula La¬
boratories), as previously described (Newby et al., 1998a).
BQ-123 assay BQ-123 concentrations in plasma were
measured by high performance liquid chromatography
(HPLC) with fluorescence detection. One volume of plasma
was precipitated with 4 volumes of ethanol, ultracentrifuged
at 4°C for 15 min at 10,000 xg, and the resulting supernatant
injected into the HPLC column. The HPLC system consisted
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of a Waters 510 HPLC pump, WISP (Waters Intelligent
Sample Processor) and Spherisorb S5 ODS column (Waters
Ltd, Watford, Herts. U.K.) with detection by an LS-5
fluorometric detector (Perkin-Elmer Ltd, Beaconsfield, Bucks,
U.K.), with excitation and emission wavelengths of 284 and
348 nm respectively. The mobile phase consisted of 60:40
acetonitrile: de-ionized water with tri-fluoroacetic acid at a
concentration of 0.1%. The peptide TAK-044 was found to
fluoresce at identical wavelengths to BQ-123 and was eluted
from the column with a retention time similar to but not
identical with BQ-123, allowing its separate measurement.
Hence, TAK-044 was used as a standard in this assay.
Recovery of BQ-123 from plasma was found to be 107% and
the intra- and inter-assay variations were 5.8 and 9.6%
respectively.
Study design
Study 1: Systemic haemodynamic study This was a double-
blind, placebo-controlled, balanced, 5-way crossover study in
five subjects, investigating the responses to four doses of BQ-
123 (100, 300, 1000 and 3000 nmol min"1) and placebo
(0.9% saline). An ascending dose regimen was followed,
allowing safety and tolerability of lower doses to be assessed
before proceeding. Total doses of BQ-123 administered were
1.5, 4.5, 15 and 45 /«nol (or 0.95, 2.84, 9.5 and 28.4 mg). The
order of the placebo dose was randomly allocated so that
each subject received it on a different visit. Each visit was
separated by at least 5 days. Subjects rested supine for 20 min
before any haemodynamic measurements, and baseline
measures were then made in the 30 min before study drug
administration.
Study 2: ET-1 challenge study This was a double-blind,
placebo-controlled, 3-way crossover study in five subjects
(three of whom participated in the systemic study),
investigating the effects of intra-arterial ET-1 on forearm
blood flow (FBF), after treatment with either 300 or
1000 nmol min"1 of BQ-123 or placebo. After baseline
infusion of saline for 30 min, subjects received a 15 min
intravenous infusion of BQ-123 (300 or 1000 nmol min"1) or
placebo via a cannula in the right forearm, followed
immediately by an intra-arterial infusion of ET-1 at a dose
of 5pmolmin~' for a total of 90 min via a left brachial
artery cannula.
Data analysis
Study 1: Systemic haemodynamics Data were stored and
analysed using the Microsoft Excel data analysis package
(Excel 5.0, Microsoft Ltd). Blood pressure data at each time
point were calculated as the mean of two recordings and
represented as mean arterial pressure (MAP), calculated as
diastolic BP+ 1/3 pulse pressure. Bioimpedance data at each
time point were calculated as the mean of four recordings.
Data were corrected using body surface area to give cardiac
index (CI) for direct comparison of subjects. Systemic
vascular resistance index (SVRI) was calculated by dividing
MAP by CI and expressed in arbitrary units. Baseline data
were calculated as the mean of —10 and 0 min recordings.
Haemodynamic data are expressed as placebo-corrected
percentage change from baseline+ s.e.mean. Statistical ana¬
lysis was performed on untransformed data. Responses were
examined by repeated measures analysis of variance
(ANOVA) and Bonferroni correction was applied to examine
significance at each time point. Statistical significance was
taken at the 5% level.
Using MAP & SVRI measurements from a previous
placebo-controlled study over 4 h (Strachan et al., 1999),
the study was calculated to have a power of ~90% to detect
a 15% change in MAP and 20% change in SVRI (P = 0.05)
with five subjects. The number of subjects was agreed with
the local ethics committee on that basis.
Study 2: ET-1 challenge Plethysmographic data listings
were extracted from the chart data files and forearm blood
flows calculated for individual venous occlusion cuff
inflations using a template spreadsheet (Excel 4.0; Micro¬
soft Ltd). As flow only stabilizes alter 60 s ol wrist cult
inflation, recordings made in the first 60 s were not used
for analysis. The last five flow recordings in each
measurement period were calculated and averaged for the
infused and non-infused arms (Webb, 1995). To reduce the
variability of blood flow data, the ratio of flows in the two
arms was calculated for each time point, in effect using the
non-infused arm as a contemporaneous control for the
active treatment arm (Benjamin et al., 1995). Forearm
blood flow results are shown as the percentage change
from basal values in the ratio of blood flow between
infused and non-infused arm. Data were examined by
repeated measures analysis of variance (ANOVA) and
Bonferroni correction was applied to examine significance
at each time point. Statistical significance was taken at the
5% level.
From FBF measurements in a previous study using ET-1
at 5 pmol min"1 (Newby et al., 1998b), the study was
calculated to have a power of 99% to detect abolition of
the vasoconstriction response to ET-1 by BQ-123, and a
power of ~80% to detect a 66% attenuation of this response
(P = 0.05) with five subjects.
Results
Study 1: Systemic haemodynamics
All five subjects (mean age 26 + 2 years) completed all parts
of the study. No adverse effects of treatment were reported.
Plasma ET-1 and big ET-1 Baseline values of plasma ET-1
and big ET-1 concentrations ranged from 4.4 to 5.2 pg ml"1
and 25 to 42 pg ml 1 respectively. There were no significant
differences between baseline plasma ET-1 or big ET-1
concentrations in any phase of the study. Neither ET-1 nor
big ET-1 changed significantly following treatment with any
dose of BQ-123 or placebo (Table 1A,B).
Plasma BQ-123 concentrations Plasma concentrations of
BQ-123 were undetectable with both doses at baseline. For
300 nmol min 1 BQ-123, mean plasma concentrations were
126+11 nmol l"1 at 5 min rising to 174±20 nmol 1"' at
15 min. For 1000 nmol min"1 BQ-123, they were
424±33 nmol 1~' and 510 + 64 nmol l"1 respectively (ETA
receptor IC50 7.3 nM; ETB receptor IC50 18 /(M) (Ihara et al.,
British Journal of Pharmacology vol 134 (3)
J.C.S. Spratt et al Systemic ETA antagonism in vivo 651
Table 1 (A) Plasma ET-1 (pg ml ') levels at baseline, 5, 15 and 240 min following infusion of BQ-123. (B) Plasma big ET-1 (pg ml ')
levels at baseline, 5, 15 and 240 min following infusion of BQ-123
BQ-123 Baseline 5 min 15 min 240 min
(nmol min"') (Pg ml"1) (pg ml"1) (pg ml"1) (pg ml"1)
(A)
Placebo 4.91+0.69 5.16 + 0.74 5.81+0.50 5.77 + 0.75
100 4.57 + 0.48 4.08 + 0.39 3.95 + 0.65 4.44 + 0.29
300 5.23 + 0.52 5.29 + 0.49 5.49 + 0.95 5.88 + 0.65
1000 4.43 + 0.28 6.07 + 0.49 5.56 + 0.95 5.80 + 0.65
3000 2.88 + 0.10 4.08 + 0.49 4.03 + 0.63 4.22 + 0.41
(B)
Placebo 45.7+14.4 49.3+10.7 66.2+ 14.4 38.8 + 7.1
100 37.8 + 7.4 29.2+1.9 26.0 + 2.4 35.8 + 5.2
300 40.2 + 6.5 38.5 + 6.3 49.5+14.1 48.4 + 6.0
1000 57.5 + 9.1 51.9 + 8.5 51.4 + 9.4 51.5 + 9.2
3000 26.6 + 6.7 34.7 + 0.6 30.7 + 3.1 30.1+4.6




100 79.2 + 2.3
300 80.8 + 3.5
1000 78.2 + 2.1




SVRI (L min"1 m~") (b.p.m.)
22.7+1.3 3.52 + 0.21 64.2 + 6.6
21.9+1.7 3.69 + 0.25 57.1+5.2
21.8+1.8 3.80 + 0.31 63.9 + 6.6
22.5 + 2.9 3.63 + 0.38 54.5 + 4.8
23.5 + 2.2 3.45 + 0.35 57.3 + 5.9
*■0 II OO P = 0.89 P= 0.69
1992). BQ-123 was no longer detectable in the plasma by 4 h
at either dose,
Haemodynamic parameters Baseline measurements for hae-
modynamic parameters were similar during all treatment
periods (Table 2). After BQ-123 administration, changes were
apparent in all parameters by the first measurement at
10 min. Maximal changes occurred between 40 and 60 min,
with a prolonged effect occurring at the two highest doses,
excepting changes of heart rate, which were maximal at
15 min.
MAP decreased in a dose-dependent fashion. This was
statistically significant at 300, 1000 and 3000 nmol min
BQ-123 (300 nmol min'"1: ANOVA P<0.05 vs placebo, 1000
and 3000 nmol min P<0.01 vs placebo) with a maximum
mean placebo-corrected reduction of 12.4 + 3.5% after
3000 nmol min""1. Placebo corrected SVRI also decreased in
a dose dependent fashion. This decrease was significant for all
doses of BQ-123 (ANOVA P<0.01 vs placebo). The
maximum decrease in SVRI (23.3 + 4.3%) occurred with
3000 nmol min"1 of BQ-123 (Table 3 and Figure 1).
CI and HR increased significantly at all doses (Re 0.01;
ANOVA. Table 3 and Figure 1).
Study 2: ET-1 challenge
Subjects who received placebo followed by local infusion of
ET-1 developed a slow onset progressive vasoconstriction in
the infused arm compared to the non-infused arm (maximum
reduction in FBF: —48+10% at 90 min). This response was
attenuated by 300 nmol min"1 BQ-123 ( — 27 + 8% at 90 min
P>0.5 vs placebo) and abolished by 1000 nmol min 1 BQ-
123 (—8%±3%, P<0.01 vs placebo, Figure 2).
Discussion
We have shown, in healthy humans, that BQ-123 causes
substantial systemic vasodilatation, associated with a small
but significant reduction in arterial blood pressure. A dose-
dependent effect was observed, with little additional effect
occurring above 1000 nmol min"1. This work confirms the
importance of the endothelin system, and of the vascular
ETA receptor in controlling vascular tone and blood pressure
(Haynes & Webb, 1998), and is in accord with the results of
previous local forearm infusion studies (Haynes & Webb,
1994; Berrazueta et al., 1997; Verhaar et al., 1998).
We have several reasons for concluding that the effects on
vascular tone and blood pressure are mediated by the ETA
receptor. Measured BQ-123 concentrations in plasma at both
300 and 1000 nmol min "' were substantially greater than the
IC5o for BQ-123 at the ETA receptor. Even so. at
1000 nmol min"1 the plasma concentration of 510 nmol I"1,
was more than 35 fold lower than the IC50 for the ETB
receptor (18 ^m), consistent with effective but selective ETA
receptor blockade (Ihara et al., 1992). In addition, there is a
substantial body of evidence that the ETB receptor is a
clearance receptor for ET-1 (Fukuroda et al., 1994; Ozaki et
al., 1995; Dupuis et al., 1996) and that agents that block the
ETB receptor in vivo cause increases in plasma ET-1
concentrations (Haynes et al., 1996; Weber et al., 1996;
Sutsch et al., 1998; Strachan et ah, 1999). In contrast, in this
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Table 3 Haemodynamic changes after BA-123 administration
BQ-123 MAP CI HR
(nmol min-1) (mrnHg) SVRI (Lmin~'m~2) (b.p.m.)
100 —4.8 + 2.6% -15.8 + 7.6% 14.3 + 8.9% 23.8±13.4%t
(-4.0 + 2.5) (-3.9 + 2.1) (0.49 + 0.32) (12.1 + 6.5)
300 -6.8 + 3.6% -20.6 + 3.0%* 13.0 + 2.2%* 11.8 + 4.4%
(-5.4+ 2.8) (-4.5 + 0.7) (0.47 + 0.07) (6.8 + 2.4)
1000 -8.2 + 3.1%+ -22.7 + 5.2%+ 17.9 + 5.7%+ 20.0 + 5.9%+
(-6.4+ 2.4) (-5.4+1.9) (0.59 + 0.16) (11.6 + 3.0)
3000 -12.4+ 3.5%+ -23.3 + 4.3%+ 12.7+1.6% 18.7 + 6.8%*
(-10.1+3.2) (-5.6 + 2.6) (0.43 + 0.04) (10.7 + 3.1)
Results given are maximum placebo corrected percentage change from baseline±s.e.mean. *R>0.05 vs placebo, +P>0.01 vs placebo:
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Figure 1 Change in MAP against time for ascending doses of BQ-
123; change in SVRI against time for ascending doses of BQ-123;
change in CI against time for ascending doses of BQ-123; change in
HR against time for ascending doses of BQ-123.
study, there was no significant increase in either big ET or
ET-1 plasma concentration at any dose of BQ-123 (Table
1A,B). Finally, we have previously shown that the net effect
of systemic ETB receptor blockade is to cause systemic
vasoconstriction, and therefore, we would anticipate that any
ETB blockade would attenuate the vasodilatation associated
with ETA blockade. Indeed, this effect may contribute to the
lack of further vasodilatation at the highest dose of BQ-123,
which was associated with a tendency for a rise in plasma
ET-1 concentration, also consistent with a threshold effect on
the ETB receptor at this dose.
Doses sufficient to lower blood pressure (300 and
1000 nmol min-1) also antagonized the forearm vasoconstric¬
tion to brachial artery administration of ET-1 and, in keeping
with its submaximal effect on SVRI, the lower dose of BQ-
123 (300 nmol min-1) only partially antagonized forearm
vasoconstriction to ET-1. Of note, however, in the presence
of a higher degree of ETA blockade, exogenous ET-1 failed
to produce vasodilatation. This possibly reflects the local
balance of dilator and constrictor effects mediated by
endothelial and vascular smooth muscle ETB receptors.
However it is also possible that the locally administered
ET-1 was washed out by an increase in forearm blood flow
consequent upon the vasodilatation induced by systemic BQ-
123. Comparison with a constrictor agent unaffected by ETA
antagonism would be needed to clarify this further.
Previous studies in healthy men (Schmetterer et al., 1998;
Montanari et al., 2000) failed to demonstrate a significant
effect of BQ-123 on basal haemodynamics. However, the
doses used were substantially lower, at 23.7 nmol min-' for
60 min, followed by 94.8 nmol min 1 for 60 min (Schmet¬
terer et al., 1998) and ~9 nmol min"1 for 90 min (Montanari
et al., 2000). These should be compared with 100 nmol min-1
BQ-123 for 15 min as the threshold dose for a systemic
haemodynamic effect in our studies. In addition, both other
studies measured blood pressure but not systemic vascular
resistance, whereas, from the current study, the latter was a
more powerful measure of the vascular effect of BQ-123,
underlining the importance of this measurement in detecting
modest haemodynamic influences. In this regard, other
published studies in humans with endothelin antagonists do
appear to show modest (~10mmHg) reductions in blood
pressure, with both bosentan (mixed ETA/ETB) (Weber et
al., 1996) and ABT-627 (ETA selective) (Verhaar et al., 2000).
In the latter study, although systemic haemodynamics were
only recorded at 30 min and 8 h after dosing, systemic
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Figure 2 Graph illustrating response in forearm blood flow to intra-artcrial ET-I. when pre-treated with placebo or BQ-123 (either
300 or 1000 nmol min-' for 15 min).
vascular resistance was measured and significant effects on
this parameter were found in both acute and chronic dosing.
It should be noted that we have also previously failed to
detect significant systemic effects, as measured by blood
pressure and heart rate, at our lowest dose of BQ-123
(100 nmol min-1) when administered into the brachial artery
(Haynes & Webb, 1994). These current results suggest that
100 nmol min-' does have a small systemic action, most
apparent in its effects on systemic vascular resistance, that
was not detected in forearm studies, perhaps because the
major vasodilatation is in other vascular beds. In recognition
of this potential problem, we have more recently used a 10
fold lower dose of 10 nmol min 1 BQ-123, (Verhaar et al.,
1998), as a local dose for forearm studies. The current study
confirms the rationale for this approach.
It is also interesting to note that a 15 min infusion of BQ-
123 produces haemodynamic effects for up to 4 h at the
higher doses. Although we have plasma estimations of BQ-
123 concentrations only at 0, 15 and 240 min in the current
study, subsequent experiments, with identical dosing sche¬
dules of BQ-123, demonstrate that the peak concentration is
achieved at the end of the infusion, falls to ~ 10% by 30 min
and is undetectable by 75 min post infusion (unpublished
data). This suggests that the observed responses are a
pharmacodynamic effect rather that a reflection of the
plasma half-life of BQ-123. This is similar to our experience
with the non-selective ET antagonist TAK 044 where the
systemic haemodynamic effects of a 15 min bolus were still
observable at 24 h, whereas the peptide had a plasma half-life
of 30-60 min (Haynes et al., 1996).
In the current study, there was an increase in heart rate
similar to that observed in other acute studies (Weber et al.,
1996; Wenzel et al., 1998). These effects are not generally seen
in chronic dosing studies with endothelin antagonists in
patients with either hypertension or heart failure (Krum et
al., 1998; Sutsch et al., 1998). For this reason, the effects are
probably mediated through the activation of a cardiopul¬
monary reflex response to systemic vasodilatation rather a
direct chronotropic effect on the heart.
Although the total number of subjects studied was low
(n = 5), the power of the study was sufficient to allow clear
conclusions to be drawn. Given the limited experience with
BQ-123 at these systemic doses, there were safety reasons for
keeping the number of subjects to a minimum. In this regard,
it is reassuring to note that, despite substantial systemic
vasodilatation, and significant lowering of the mean arterial
pressure, no side effects were observed or reported by the
subjects.
In conclusion, this study with BQ-123 demonstrates that
systemic ETA receptor antagonism causes substantial per¬
ipheral vasodilatation and modest lowering of blood
pressure, consistent with an important role for the endothelin
system in the maintenance of vascular tone in man. It
remains to be seen, in direct comparison between selective
ETA and mixed ETA/B receptor antagonists, which of the
therapeutic approaches will offer the greater haemodynamic
benefit in specific clinical indications.
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Endothelin-A Receptor Antagonism Reduces Blood Pressure
and Increases Renal Blood Flow in Hypertensive Patients
With Chronic Renal Failure
A Comparison of Selective and Combined Endothelin Receptor Blockade
Jane Goddard, MBChB, MRCP; Neil R. Johnston, MSc; Malcolm F. Hand, MD, MRCP;
Allan D. Cumming, MD, FRCP; Ton J. Rabelink, MD, PhD;
Andrew J. Rankin, PhD; David J. Webb, MD, FRCP
Background—Endothelin (ET) is implicated in the pathophysiology of chronic renal failure (CRF). We therefore studied
the systemic and renal hemodynamic effects of ET receptor antagonists in CRF and examined differences between
selective ETA, selective ETB, and combined ETA/B receptor blockade.
Methods and Results—We conducted a randomized, placebo-controlled, double-blind, Away crossover study comparing
selective ET receptor antagonists BQ-123 (ETA) and BQ-788 (ETB), given alone and in combination, in acute studies
in 8 hypertensive CRF patients and 8 matched healthy controls. BQ-123, alone and in combination with BQ-788,
reduced blood pressure in CRF, particularly with BQ-123 alone (mean arterial pressure: controls —4±2%, CRF
—13±2%, PC0.01 versus placebo). In CRF, in the face of this fall in blood pressure, BQ-123 substantially increased
renal blood flow (38.8±23.9%, P<0.01 versus placebo) and reduced renal vascular resistance (—44.5±11.3%, P<0.01
versus placebo) when given alone but not when combined with BQ-788. These changes were accompanied by a
reduction in effective filtration fraction. BQ-123, alone or in combination with BQ-788, had minimal effects on the renal
circulation in healthy controls, and BQ-788 alone produced both systemic and renal vasoconstriction in CRF and healthy
controls.
Conclusions—ETA receptor antagonism was highly effective in lowering blood pressure in CRF patients currently treated
for hypertension. In addition, there were effects consistent with a renoprotective action. However, because the ETB
receptor appears to play a key role in the maintenance of tonic renal vasodilation, combined ETA/B receptor antagonism,
although it lowered blood pressure, did not confer these renal benefits. (Circulation. 2004;109:1186-1193.)
Key Words: blood flow ■ blood pressure ■ endothelin ■ kidney ■ hemodynamics
The endothelins are powerful vasoconstrictor peptides, ofwhich endothelin-1 (ET-1) is the major isoform. It is
produced by vascular endothelium and acts through 2 recep¬
tors1-2 in the blood vessels to modulate vascular tone.
Endothelin-A (ETA) and endothelin-B (ETB) receptors are
found in vascular smooth muscle, where their activation medi¬
ates vasoconstriction.3 4 ETB receptors are also found on vascu¬
lar endothelium, where their activation promotes vasodilation
through the release of nitric oxide and prostaglandins.4 Addi¬
tionally, vascular ETB receptors act as a major source of ET-1
clearance from the circulation,'' and renal tubular ETB receptors
may contribute to natriuresis.6 Studies in humans show the
importance of ET-1 in the maintenance of vascular tone7 and
blood pressure8 and suggest therapeutic potential for endothelin
receptor antagonists in pathophysiological states characterized
by vasoconstriction, such as essential hypertension and pulmo¬
nary arterial hypertension.9-10
Chronic renal failure (CRF) is characterized by systemic
and renal vasoconstriction and commonly associated with
hypertension. Given that endothelin receptor antagonists
cause vasodilation,7-11 lower blood pressure,911 and amelio¬
rate renal dysfunction in experimental models of kidney
disease,12 they may be useful in the treatment of CRF. The
aim of the present study was to show whether endothelin
receptor antagonists would produce beneficial systemic or
renal hemodynamic effects in CRF. Because of the potential
opposing effects at ETA and ETB receptors, we directly
compared the effects of regimens involving ETA and ETB
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TABLE 1. Subject Demographic Data
Healthy Renal
Volunteers Patients P (f Test)
Age, y 47 ±5 (23-64) 46±5 (25-67) NS
Body mass index, kg/m2 26±2 (18-31) 27±1 (24-33) NS
MAP, mm Hg 92.8±3.1 (83.0-103.6) 98.8±3.5 (78.8-109.5) NS
Creatinine, p.mol/L 85±5 (62-111) 255 ±41 (122-434) <0.01
Cholesterol, mmol/L 5.3±0.3 (3.9-6.1) 5.6±0.2 (4.5-6.7) NS
Urinary sodium excretion, mmol/24 h 136± 14 (56-199) 150± 14 (74-246) NS
Urinary protein excretion, mg/24 h 0* 476±110 (n=7; 27-2033)+ <0.01
Values are mean±SEM (range).
•Values below limit of laboratory assay.
tn=7; 1 value below limit of detection.
receptor blockade separately and in combination in CRF
patients and matched healthy controls.
Methods
Subjects
We aimed to recruit 8 men with stable CRF and 8 matched healthy
controls to the studies, which were performed in the University of
Edinburgh's Clinical Research Centre with the approval of the local
research ethics committee and the written informed consent of each
subject. The investigations conformed to the principles outlined in
the Declaration of Helsinki.
For 3 days before each study, subjects adhered to a standard diet
containing 150 mmol of sodium. All subjects abstained from alcohol,
nicotine, and caffeine-containing products for 24 hours and had a
light breakfast before attending on each study day. All studies were
performed in a quiet, temperature-controlled room at 22°C to 24°C,
with the subject recumbent throughout, except when voiding urine.
Healthy subjects who had taken any medications in the previous 2
weeks were excluded from the study. Patients continued taking their
normal medication up to and including each study day with the
exception of diuretics, which they omitted that morning. To enhance
homogeneity and avoid other influences on vascular reactivity,
patients with vasculitis, other systemic inflammatory disease, poly¬
cystic kidney disease, nephrotic syndrome, or obstructive uropathy
were excluded. Additionally, patients with significant comorbid
disease, including diabetes mellitus, heart or lung disease, peripheral
vascular disease, or hypercholesterolemia, were excluded. The 2
study groups were matched for age, weight, serum cholesterol, and
blood pressure (Table 1).
Drugs
BQ-123 (Clinalfa AG), a selective ETA receptor antagonist,13 was
infused at 100 and 1000 nmol/min for 15 minutes at each dose. These
doses were selected from a previous study as having a threshold and
maximum hemodynamic effect in healthy controls.8 BQ-788 (Cli¬
nalfa), a selective ETB receptor antagonist,14 was infused at 30 and
300 nmol/min for 15 minutes, doses shown to be hemodynamically
active in a previous systemic dose-ranging study.15 Drugs were
dissolved in physiological saline (0.9%; Baxter Healthcare Ltd) and
infused intravenously at a constant rate of 1 mL/min. Saline was
administered as placebo.
Para-aminohippurate sodium (PAH; Clinalfa) and inutest (Frese-
nius Pharma, AustriaGmbH) were dissolved in dextrose 5% (Baxter)
and administered as a bolus loading dose of 0.4 g of PAH and 3.5 g
of inutest in 100 mL of dextrose over 15 minutes and a maintenance
infusion of 6.6 g/L PAH and 10 g/L inutest at a rate of 2 mL/min. For
subjects with a calculated glomerular filtration rate (GFR) <40
mL/min, doses of PAH and inutest were reduced by one third.
Assays
At prespecified time points, venous blood was collected into EDTA
tubes (Sarstedt) for measurement of PAH, inulin, and hematocrit
(Hct), plasma ET-1, plasma renin activity, angiotensin II, and
aldosterone, and into plain tubes (Sarstedt) for the measurement of
serum sodium. Additionally, 20-mL aliquots of urine from each
voiding were collected into plain tubes for the measurement of
urinary PAH, inulin, sodium, and protein.
Hct was measured on whole blood with a Coulter counter. All
other blood samples were centrifuged immediately at lOOOg at 4°C
for 20 minutes, and plasma and urine were stored in plain tubes at
— 80°C. Inulin was determined by spectrophotometry after hydroly¬
sis to fructose, and PAH and BQ-1238 were determined by high-per¬
formance liquid chromatography. BQ-788 assay was not sufficiently
sensitive for its detection in plasma. Urinary and plasma sodium
concentrations were measured by flame photometry. ET-1, angio¬
tensin II, plasma renin activity, and aldosterone were determined by
radioimmunoassay.16-18
Study Protocol
This was a randomized, double-blind, placebo-controlled study.
Subjects attended for 4 visits, receiving placebo, BQ-123, BQ-788,
or the combination of BQ-123 and BQ-788. Because previous
studies with the same doses of BQ-123 or BQ-788 have demon¬
strated that hemodynamic changes return to baseline after 4 hours,815
each visit was separated by £7 days to ensure complete washout of
the study drugs. An individual otherwise unconnected with the study
prepared the drugs to maintain blinding. On each study day, an 18
standard wire gauge cannula was sited in an antecubital vein in each
arm. Diuresis was induced by 500 mL of 5% dextrose over 30
minutes through the left arm cannula. After 15 minutes, loading
doses of PAH and inutest were administered through the same
cannula. Thereafter, maintenance infusions of PAH and inutest and
5% dextrose at 260 mL/h continued throughout the study. Blood
pressure, cardiac output and heart rate were recorded by validated
noninvasive automated techniques every 15 minutes,19-20 and urine
was collected every 30 minutes by spontaneous voiding. After a
2-hour equilibration period, baseline measurements were made over
2 30-minute urine-collection periods. The low dose of antagonist was
then administered through the right antecubital cannula, followed by
3 30-minute collection periods. The higher dose of antagonist was
then administered, followed by 5 further 30-minute collection
periods.
At the midpoint of each collection period, blood was sampled
from the right antecubital cannula for PAH, inulin, sodium, and Hct.
At 0, 60, and 90 minutes after the start of low- and high-dose
antagonist and at the end of the study, additional samples were taken
for plasma hormone measurements. BQ-123 was measured before
and at 15, 45, and 90 minutes after the start of each dose of
antagonist and at the end of the study.
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TABLE 2. Renal Patients; Diagnosis and Medications
Subject Cause of Renal Impairment Drugs Used
1 IgA nephropathy Enalapril
2 IgA nephropathy Ranitidine
3 IgA nephropathy Enalapril, doxazosin, bicarbonate, omeprazole
4 IgA nephropathy/HSP Labetalol
5 Proliferative GN Fosinopril, atenolol
6 Proliferative GN Enalapril, metoprolol, nifedipine, allopurinol, frusemide
7 Renal calculi, single kidney Enalapril, bicarbonate, 1 -a calcidol
8 Not known; late presentation Lisinopril, bicarbonate, omeprazole, frusemide
HSP indicates Henoch-Schonlein purpura; GN, glomerulonephritis.
Data Analysis
Data were stored and analyzed with Microsoft Excel (version 5.0,
Microsoft Ltd). Demographic data are expressed as mean±SEM, and
comparisons between groups were examined by unpaired Student's
t tests. Blood pressure at each time point was calculated as the mean
of 2 recordings and represented as mean arterial pressure (MAP=di-
astolic blood pressure+1/3 pulse pressure). Bioimpedance data at
each time point were calculated as the mean of 4 recordings, each the
average of 15 consecutive heart beats. Data were corrected with body
surface area to give cardiac index for direct comparison of subjects.
Systemic vascular resistance index (SVRI) was calculated by divid¬
ing MAP by cardiac index and expressed in dyne ■ s • m"2 • cm'5.
GFR and effective renal plasma flow (ERPF) were calculated from
inulin and PAH clearances, respectively.21 Effective renal blood flow
(ERBF) was calculated by dividing ERPF by (1—Hct), effective
renal vascular resistance (ERVR) by dividing MAP by ERBF, and
effective filtration fraction (EFF) by dividing GFR by ERPFX100%.
Urinary sodium excretion was calculated as urinary sodiumX urinary
flow rate and fractional excretion as urinary sodiumXplasma inulin
divided by plasma sodiumXurine inulin.
Baseline data were calculated as the mean of the 2 time points that
immediately preceded administration of the first study drug. Hemo¬
dynamic results are expressed as mean±SEM placebo-corrected
maximum change from baseline. Statistical analysis was performed
on untransformed data. Four comparisons of interest were preiden-
tified as placebo versus BQ-123, versus BQ-788, and versus BQ-
123/788, and BQ-123 versus BQ-123/788. Responses were exam¬
ined by repeated-measures ANOVA, and Bonferroni correction was
used to assess significance at specific time points. Statistical signif¬
icance was taken at the 5% level.
Results
Twelve renal patients were recruited; 1 developed nausea
after receiving BQ-123, and 1 was unable to void urine at
30-minute intervals. Two withdrew for reasons unrelated to
the study. Eight patients and all healthy controls completed
all phases of the study without adverse events. The renal
diagnosis and concomitant medication taken by the patients
who completed the study are given in Table 2. Baseline
parameters are shown in Table 3.
Systemic Hemodynamics
In CRF patients, placebo was associated with increases in
SVRI to study end (3478±240 versus 3797±301 dyne • s •
m~2 • cm-5, P<0.05) and MAP (100.7±3.8 versus
108.0±4.1 mm Hg, P<0.01), consistent with the waning
effects of antihypertensive medication (Figures 1 and 2).
TABLE 3. Baseline Data
Healthy Volunteers Renal Patients P(fTest)
MAP, mm Hg 94.0± 2.2 (86.5-104.9) 100.5±4.0 (76.9-110.1) NS
SVRI, dyne ■ s • itt2 ■ cm'5 3089±269 (1558-4068) 3479±270 (2296-4478) NS
Cardiac index, L • min-1 • m-2 2.6±0.3 (1.9-4.6) 2.4±0.2 (2.0-3.2) NS
Heart rate, bpm 58.2±2.3 (47.2-67.4) 56.6+1.8(49.1-62.4) NS
ERBF, mL/min 683±41 (534-844) 295 ±58 (81-571) <0.01
ERVR, mm Hg ■ min-1 • L~1 148±12 (108-191) 489 ±101 (208-973) <0.01
EFF, % 25.4±2.0 (17.8-36.3) 20.8±1.8 (13.5-30.7) NS
GFR, mL ■ min"1 ■ 1.73 m-2 116± 11 (80-164) 39±6 (19-67) <0.01
UNaV, /xmol/min 143± 11 (56-215) 180± 31 (70-341) NS
Urinary protein, mg/L 0* 453 ±82 (101—1435)t <0.01
Plasma ET-1, pg/mL 4.2±0.3 (2.9-5.3) 5.6±0.3 (4.6-7.3) <0.01
PRA, pg ■ mL"1 ■ h"1 3.6+0.5(2.2-6.4) 10.5 ±2.3 (3.3-20.6) <0.05
Plasma ANG II, pg/mL 7.7 ±1.0 (4.4-12.6) 7.6± 1.1 (4.2-13.8) NS
Plasma aldosterone, pg/mL 61 ±4 (45-81) 88 ±28 (33-274) NS
NS indicates not significant; UNaV, urinary sodium excretion; PRA, plasma renin activity; and ANG
II, angiotensin II .
Values are given as mean of 2 baseline periods over the 4 study days ±SEM (range).
"Values below limit of laboratory assay.
fn=7; 1 value below limit of detection.






Figure 1. Systemic hemodynamics after endothelin
receptor antagonism. Values are given as mean
placebo-corrected % change from baseline ±SEM.
Black blocks, Administration of endothelin antago¬
nist/placebo; red diamonds, BQ-123; green circles,
BQ-123/788; and blue triangles, BQ-788. *P<0.05
vs placebo, +P<0.01 vs placebo, **P<0.05 vs
BQ-123 (ANOVA plus Bonferroni correction for sig¬
nificance at specific time points).
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SVRI was reduced to a similar extent by BQ-123 and
BQ-123/788 (BQ-123 -630±145 dyne • s • m"2 • cm"5,
BQ-123/788 —617±158 dyne • s • m~2 • cm"5, both P<0.01
versus placebo). MAP was reduced in CRF patients after
BQ-123/788 (—7.4± 1.6 mm Hg, P<0.01 versus placebo) but
to a greater extent after BQ-123 alone (BQ-123
—12.9±1.7 mm Hg, P<0.01 versus placebo and BQ-123/
788). Systemic hemodynamic responses to endothelin recep¬
tor antagonism showed no correlation with baseline blood
pressure.
In healthy controls, placebo did not alter systemic hemo¬
dynamics. Both BQ-123 and BQ-123/788 reduced SVRI to a
similar extent, equivalent to that seen in CRF (BQ-123
-591 ±104 dyne • s • m"2 • cm"5, BQ-123/788 -498±159
dyne • s • m~2 • cm"5, both P<0.01 versus placebo). The
reductions in MAP after BQ-123 and BQ-123/788 were equal
(BQ-123 —3.6± 1.4 mm Hg, BQ-123/788 -3.7±1.6 mm Hg,
both P<0.01 versus placebo) and less than those seen in CRF
(PC0.05). BQ-788 increased MAP (CRF 7.0±1.6 mmHg,
healthy controls 5.8± 1.5 mmHg, both P<0.01 versus pla¬
cebo) and SVRI (CRF 454±114 dyne • s • m"2 • cm"5,
P<0.01 versus placebo; healthy controls 390±76 dyne • s"1
• m 2 • cm"5, P<0.05 versus placebo) to a similar extent in
CRF patients and controls.
Renal Hemodynamics
In CRF patients, BQ-123 but not BQ-123/788 produced
striking increases in ERBF and reductions in ERVR and EFF
(ERBF 102±74 mL/rnin, ERVR -243 ±91 mm Hg • min • L"1,
EFF —4.2±2.9%; all P<0.01 versus placebo and BQ-123/788).
GFR did not change. By contrast, in healthy controls, BQ-123
and BQ-123/788 were neutral with respect to ERBF, ERVR,
EFF, and GFR. (See Figures 2 and 3.)
In both groups, BQ-788 reduced ERBF (CRF —11 ±12
mL/min, healthy controls —134±47 mL/min; both P<0.05
versus placebo) and increased ERVR (CRF 112±63 mmHg
• min • L"1, healthy controls 39±12 mm Hg • min • L"1; both
P<0.05 versus placebo). These changes were apparent even
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Figure 2. Maximum effects of post-endothelin
receptor antagonism on systemic and renal he¬
modynamics. Values are given as mean of maxi¬
mum placebo-corrected change from baseline
±SEM. Low dose: red hatched bars, BQ-123;
green hatched bars, BQ-123/788; blue hatched
bars, BQ-788. High dose: solid red bars, BQ-123;
solid green bars, BQ-123/788; solid blue bars,
BQ-788. *P<0.05 vs low dose (f test).
at the low dose and were associated with a reduction in GFR
and an increase in EFF.
Urinary Sodium Excretion and Protein Excretion
No changes in sodium excretion or fractional excretion were
observed in either CRT or healthy controls. Urinary protein
excretion was undetectable for 1 CRF subject and all healthy
controls. In the remaining 7 CRF patients, with measurements
uncorrected for changes in GFR, BQ-788 produced a small
increase in urinary protein excretion (P<0.01 versus pla¬
cebo), but no changes were observed after BQ-123 or
BQ-123/788 (Figure 4). After correction for GFR, BQ-788
and BQ-123/788 did not affect proteinuria, but BQ-123
reduced protein leak by 46% (—8.1±4.9 /xg/min; ANOVA
P<0.01 versus placebo, P<0.05 versus BQ-123/788), an
effect most apparent in subjects with higher baseline urinary
protein excretion.
Plasma Hormone and BQ-123 Concentrations
Plasma ET-1 increased to a similar extent after high dose
BQ-788 and BQ-123/788 but was unaltered by placebo or
BQ-123 (Figure 5). Other hormones were unaffected by
endothelin receptor antagonism. BQ-123 was detectable in
plasma at 15 minutes after low-dose BQ-123 and at 15 and 45
minutes after high-dose BQ-123 and did not differ between
CRF and healthy controls (CRF 1.52±0.36 pg/mL, healthy
controls 1.21 ±0.17 pg/mL at 15 minutes after high dose).
BQ-123 concentrations were unaffected by coadministration
of BQ-788 (CRF 1.62±0.20 pg/mL, healthy controls
1.26±0.20 pg/mL).
Discussion
This is the first clinical study to directly compare ETA, ETB,
and combined ETA and ETB receptor antagonism at systemic
doses in humans. We have shown in CRF patients that
selective ETA receptor antagonism produces substantial re-













Figure 3. Renal hemodynamics after endothelin
receptor antagonism. Values are given as mean
placebo-corrected % change from baseline
±SEM. Black blocks, Administration of endothe¬
lin antagonist/placebo; red diamonds, BQ-123;
green circles, BQ-123/788; and blue triangles,
BQ-788. +P<0.01 vs placebo; **P<0.05 vs
BQ-123 (ANOVA + Bonferroni correction for sig¬
nificance at specific time points).
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ductions in blood pressure associated with renal vasodilation.
Additionally, the reduction in filtration fraction and protein¬
uria in CRF patients suggests a potentially renoprotective
action. Combined ETA/B receptor blockade was less effec¬
tive in lowering blood pressure, had no effect on renal
hemodynamics, and reduced ET-1 clearance. Selective ETB
receptor antagonism alone produced substantial systemic and
renal vasoconstriction. By contrast, in healthy subjects, the
systemic hemodynamic effects of ETA and ETA/B receptor
blockade were similar to each other but less than those seen
in CRF, and there were no effects on renal hemodynamics.
These data confirm the physiological importance of ET-1,
through activation of the ETA receptor, in the maintenance of
basal systemic but not renal vascular resistance.8 22 They also
show that ET-1 plays a major role in regulating blood
pressure and renal vascular resistance in CRF, consistent with
activation of the endothelin system in this condition. The
reduction in filtration fraction after ETA receptor antagonism
suggests an effect primarily on efferent arteriolar tone, which
may serve to reduce glomerular pressure. Consistent with our
observations, an ETA receptor-selective antagonist has been
shown to reduce proteinuria in type 1 diabetes.23
The effects of BQ-788, whether in the presence of BQ-123
or not, suggest that the net effect of ETB receptor activation
on the circulation in health and renal disease is to produce
vasodilation. Therefore, similar to observations in healthy
subjects15-24 and patients with heart failure,25 any enhanced
effects of constrictor ETB receptors that potentially exist in
CRF are outweighed by ETB receptor-mediated vasodilation.
Of particular interest, ETB receptor antagonism increased
renal vascular resistance twice as much as systemic vascular
resistance, which suggests that tonic ETB receptor-mediated
renal vasodilation plays a key role in maintenance of renal
vascular tone. This is likely to be of particular importance in
CRF, in which baseline renal vascular resistance is high, and
suggests ETA receptor antagonism and not dual ETA/B
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Figure 4. Effective filtration fraction (%) and uri¬
nary protein excretion (/xmol/min) after endothelin
receptor antagonism. Values are given as mean
placebo-corrected change from baseline ±SEM.
Black blocks, Administration of endothelin antago¬
nist/placebo; red diamonds, BQ-123; green cir¬
cles, BQ-123/788; and blue triangles, BQ-788.
blockade might be the best approach in renal patients.
However, based on earlier work, the present study was
designed to achieve effective and selective blockade of the
ETA and ETB receptor815-24 and not specifically to reproduce
the effects of existing endothelin receptor antagonists, all of
which block ETA to a greater extent than ETB receptors.26
Therefore, although the main effects of therapeutic interest in
the present study appear to derive from ETA receptor
blockade and are countered by ETB blockade, drugs that
cause only modest ETB receptor inhibition might produce
similar effects.
Perhaps surprisingly, given the evidence for ETB receptor-
mediated natriuresis shown in animal studies,6 no changes in
sodium excretion or fractional excretion were observed in the
present study. However, during ETA receptor blockade,
despite substantial systemic and renal vasodilation, sodium
retention did not occur, which is important if these drugs are
to be prescribed safely to patients with CRF.
As a limitation, the present studies were acute studies. We
also studied a relatively homogeneous CRF population.
Therefore, longer-term studies are now needed in a broader
population of patients with kidney disease, including those
with low renal perfusion pressure. In particular, because ACE
inhibitors are most effective as renoprotective agents in
patients with proteinuria >3 g per 24 hours, studies are
needed in patients with higher degrees of urinary protein leak
to address what may be a major benefit of these agents.
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tinue their regular medications. We therefore cannot exclude
an effect of prior drug therapy on our findings. However,
patients with CRF generally require several drugs to control
blood pressure, and we have been able to demonstrate an
effect of endothelin antagonists on top of treatment that
included ACE inhibitors in 6 of the 8 patients. Blood pressure
and the kinetics of BQ-123 were not significantly different in
CRF patients and so are unlikely to account for any differ¬
ences in renal responses to endothelin antagonists between
patients and controls.
In conclusion, we have shown that selective ETA receptor
antagonists may be valuable antihypertensive drugs in pa¬
tients with CRF as well as offering additional benefits,
including renoprotection. Endothelin receptor antagonists
also improve endothelial function,27 reduce inflammation and
fibrosis,28 and reverse vascular remodeling29 and so may offer
additional benefits to renal patients, who are at high cardio¬
vascular risk. On this basis, longer-term studies in patients
with CRF are justified, with particular attention to effects on
proteinuria as a surrogate marker for the progression of renal
disease.
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Endothelin A Receptor Antagonism and Angiotensin-
Converting Enzyme Inhibition Are Synergistic via an
Endothelin B Receptor-Mediated and Nitric Oxide-Dependent
Mechanism
JANE GODDARD,* CORINE ECKHART,* NEIL R. JOHNSTON,*
ALLAN D. CUMMING,* ANDREW J. RANKIN,"r and DAVID J. WEBB*
*Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; and fPfizer
Global Research & Development, Sandwich, United Kingdom
Abstract. Animal studies suggest that endothelin A (ETA)
receptor antagonism and angiotensin-converting enzyme
(ACE) inhibition may be synergistic. This interaction and the
role of ETB receptors and endothelial mediators were investi¬
gated in terms of systemic and renal effects in humans in two
studies. In one study, six subjects received placebo, the ETA
receptor antagonist BQ-123 alone, and BQ-123 in combination
with the ETB receptor antagonist BQ-788 after pretreatment
with the ACE inhibitor enalapril (E) or placebo. In the other,
six subjects who were pretreated with E received placebo,
BQ-123, and BQ-123 with concomitant inhibition of nitric
oxide (NO) synthase or cyclo-oxygenase (COX). Both were
randomized, double-blind, crossover studies. Mean arterial
pressure was reduced by BQ-123, an effect that was doubled
during ACE inhibition (mean area under curve ± SEM; BQ-
123, -2.3 ± 1.8%; BQ-123 + E, -5.1 ± 1.1%; P < 0.05
versus placebo). BQ-123 increased effective renal blood flow
(BQ-123, -0.1 ± 2.4%; BQ-123+E, 10.9 ± 4.2%; P < 0.01
versus BQ-123), reduced effective renal vascular resistance
(BQ-123, -1.2 ± 3.1%; BQ-123 + E, -12.8 ± 3.0%; P <0.01
versus placebo and versus BQ-123), and increased urinary
sodium excretion markedly (BQ-123, 2.6 ± 12.8%;
BQ-123+E, 25.2 ± 12.6%; P < 0.05 versus BQ-123, P < 0.01
versus placebo and versus E) only during ACE inhibition.
These effects were abolished by both ETB receptor blockade
and NO synthase inhibition, whereas COX inhibition had no
effect. In conclusion, the combination of ETA receptor antag¬
onism and ACE inhibition is synergistic via an ETB receptor-
mediated, NO-dependent, COX-independent mechanism. The
reduction of BP and renal vascular resistance and associated
substantial natriuresis make this a potentially attractive thera¬
peutic combination in renal disease.
Endothelin-1 (ET-1) is a vasoactive peptide that is produced
by the vascular endothelium (1) and acts through two re¬
ceptors to regulate vascular tone. Vascular smooth muscle
ETA and ETB receptors (2,3) mediate vasoconstriction,
whereas endothelial ETB receptors mediate vasodilation
through generation of nitric oxide (NO) and prostanoids (3).
Angiotensin II (Ang II) is another powerful vasoconstrictor
involved in the regulation of vascular tone, and there is
considerable evidence for an interaction between the endo¬
thelin and renin-angiotensin systems (4). Ang II increases
ET-1 transcription and secretion in vitro in a variety of cell
types, including endothelial and vascular smooth muscle
cells (5,6), and ET receptor antagonists attenuate the acute
hemodynamic effects of Ang II in rats in vivo (7,8). How-
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ever, this is by no means a uniform finding (9) and has not
been replicated in dogs (10) or humans (11). Data in animals
suggest that concomitant ET blockade and angiotensin-con¬
verting enzyme (ACE) inhibition produce changes greater
than those seen with blockade of either system alone (12-
15). In addition, clinical studies that demonstrated major
hemodynamic effects of ET receptor antagonists have gen¬
erally been performed in patients who were already receiv¬
ing ACE inhibitors (16,17).
ACE inhibition, by promoting the effects of bradykinin
(18), and ET-1 acting on endothelial ETB receptors (19)
both enhance endothelium-dependent vasodilation. Vascular
studies in humans suggest that the vasodilator effects of
ETA receptor antagonism are dependent on the unblocked
ETB receptor and NO generation (20). The aim of this
study, therefore, was to explore the possible systemic and
renal interaction between ET receptor antagonism and ACE
inhibition and the mechanisms by which such an interaction
might occur. We hypothesized that previous ACE inhibition
would augment the systemic and renal hemodynamic re¬
sponse to ETA receptor antagonism and that this interaction
would be dependent on NO production and mediated, at
least in part, through the ETB receptor.
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Materials and Methods
A total of eight healthy men (six in each protocol) were recruited
to the studies, which were performed in the University of Edinburgh's
Clinical Research Centre with the approval of the local research ethics
committee and the written informed consent of each participant. The
investigations conformed to the principles outlined in the Declaration
of Helsinki.
For 3 d before each study, participants adhered to a standard diet
that contained 150 mmol of sodium. All participants abstained from
over-the-counter medication for 2 wk, alcohol, nicotine, and caffeine-
containing products for 24 h and had a light breakfast before attending
on each study day. All studies were carried out in a quiet, temperature-
controlled room, at 22 to 24°C, with the participant recumbent
throughout, except when voiding urine.
Drugs
BQ-123 (Clinalfa AG, Laufelfingen, Switzerland), a selective ETA
receptor antagonist (21), was infused at 100 and 1000 nmol/min for 15
min at each dose. These doses were selected from a previous study as
having a threshold and maximum hemodynamic effect in healthy
control subjects (22). The higher dose produces a peak plasma con¬
centration of BQ-123 (22) 7-fold higher than the K, for ETA receptor
inhibition and 20-fold lower than the Kl for ETB receptor inhibition
(21), confirming ETA selectivity, and did not increase plasma ET-1,
an index of ETB receptor blockade (23). BQ-788 (Clinalfa AG), a
selective ETB receptor antagonist (24), was infused at 30 and 300
nmol/min for 15 min, doses shown to be hemodynamically active in
a previous systemic dose-ranging study (25). Drugs were dissolved in
physiologic saline (0.9%; Baxter Healthcare Ltd, Thetford, UK) and
infused intravenously at a constant rate of 1 ml/min via an 18 standard
wire gauge (SWG) cannula sited in the right antecubital fossa. Saline
was administered as placebo.
Enalapril (Dexcel Pharma Ltd, Daventry, UK) was the chosen ACE
inhibitor and was administered orally for 5 d before each visit at a
dose of 20 mg twice daily, taking the final dose at 8:30 a.m. on each
study day. This dose was chosen from data suggesting that it would
achieve significant inhibition of serum ACE activity (26,27), with
steady-state plasma concentrations reached by 3 to 4 d (28). With this
dosing regimen, the maximal effect of enalapril occurs 2 to 3 h after
administration and persists for 5 to 7 h (27,29). By administering a
final dose 2.5 h before baseline measurements, therefore, we aimed to
achieve maximal ACE inhibition throughout each study visit.
The nonselective cyclo-oxygenase (COX) inhibitor indomethacin
was administered as a single 100-mg oral dose at 8:30 a.m. on the
relevant study day to reach peak plasma concentrations by the time of
baseline measurements. The dose is known to inhibit prostaglandin
production over the time course of the study, as evidenced by de¬
creased urinary excretion rates of prostaglandins (30). A^-monometh-
yl-L-arginine (L-NMMA; Clinalfa AG, Laufelfingen, Switzerland)
was administered at a dose of 3 mg/kg over 5 min as an NO synthase
inhibitor, with each dose of BQ-123, during the relevant study day.
This dose is sufficient to cause a small transient increase in BP (by -7
to 10%) and decrease renal blood flow (by -10%) (31). Thereafter, BP
returns to baseline by 30 min and renal blood flow by 60 min, with a
plasma half-life of 75 min (31).
Para-aminohippurate sodium (PAH; Clinalfa AG) and inutest (Fre-
senius Pharma, Austria) were dissolved in dextrose 5% (Baxter
Healthcare) and administered as a bolus loading dose of 0.4 g of PAH
and 3.5 g of inutest in 100 ml of dextrose over 15 min and a
maintenance infusion of 6.6 g/L PAH and 10 g/L inutest at a rate of
2 ml/min via an 18 SWG cannula in the left antecubital fossa. All
drugs were prepared from sterile stock solutions on the day of the
study.
Assays
At prespecified time points, venous blood was collected into tubes
that contained EDTA (Sarstedt, Newton, CA) for the measurement of
PAH, inulin, and hematocrit (Hct) and into plain tubes (Sarstedt) for
the measurement of plasma sodium. Twenty-milliliter aliquots of
urine from each voiding were collected into plain tubes for the
measurement of urinary PAH, inulin, and sodium.
Hct was measured on whole blood using a Coulter counter. All
other blood samples were centrifuged immediately at 1000 X g at 4°C
for 20 min, and plasma and urine were stored in plain tubes at — 80°C.
Inulin concentrations were determined by spectrophotometry after
hydrolysis to fructose, and PAH and BQ-123 (22) were determined by
HPLC. BQ-788 assay was not sufficiently sensitive for its detection in
plasma. Urinary and plasma sodium concentrations were determined
using standard flame photometry. Subaliquots of plasma were used to
measure serum ACE activity by generation of Ang II from Ang I (32).
Study Design
Both studies were double blind and placebo controlled. Visits were
separated by at least 1 wk. The first study was designed to examine the
interaction between ET receptor antagonism and ACE inhibition, and
the second was designed to examine the effect of NO synthase
inhibition and inhibition of prostaglandin synthesis on this interaction.
Study 1. Participants attended a total of six visits. On two sets of
three visits, they received placebo, BQ-123, or the combination of
BQ-123 and BQ-788 in a randomized order. With one set, they
received pretreatment with enalapril and the other placebo.
Study 2. Participants attended a total of four visits. On each visit,
they received pretreatment with enalapril. During the study day, they
then received placebo, BQ-123, BQ-123 + indomethacin, or BQ-123
+ L-NMMA in a randomized order.
Study Protocol
On each study day, 18-SWG cannulae were sited in an antecubital
vein in each arm. At 8:30 a.m., diuresis was induced by the admin¬
istration of 500 ml of 5% dextrose over 30 min through the cannula in
the left arm. The loading dose of PAH and inutest was administered
through the same cannula from 8:45 a.m.. Thereafter, maintenance
infusions of PAH and inutest, and 5% dextrose at 260 ml/h, continued
throughout the study. BP, cardiac output, and heart rate were recorded
using well-validated noninvasive automated techniques every 15 min
(33,34), and urine was collected every 30 min by spontaneous void¬
ing. After a 2-h equilibration period, baseline measurements were
made over two 30-min urine collection periods. The lower dose of ET
receptor antagonist was then administered at 12:00 p.m. through the
right antecubital cannula, followed by three 30-min collection periods.
At 1:30 p.m., the higher dose of antagonist was administered followed
by five additional 30-min collection periods.
At the midpoint of each urine collection period, blood was sampled
from the right antecubital cannula for the measurement of PAH,
inulin, sodium, and Hct. BQ-123 was measured before and at 15, 45,
and 90 min after the start of each dose of antagonist and at the end of
the study, and serum ACE activity was determined at 8:30 a.m. and at
2:30 p.m. (60 min after the start of the higher dose of antagonist).
Statistical Analyses
Data were stored and analyzed using a Microsoft Excel data anal¬
ysis package (Excel 5.0, Microsoft, Wokingham, UK). Demographic
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data are expressed as mean ± SEM. BP at each time point was
calculated as the mean of two recordings and represented as mean
arterial pressure (MAP; = diastolic BP + 1/3 pulse pressure). Bio-
impedance data at each time point were calculated as the mean of four
recordings, each the average of 15 consecutive heart beats. Data were
corrected using body surface area to give cardiac index for direct
comparison of participants. Systemic vascular resistance index
(SVRI) was calculated by dividing MAP by cardiac index and ex¬
pressed in dyne.s m2/cm5. GFR and effective renal plasma flow
(ERPF) were calculated from inulin and PAH clearances, respectively
(35). Effective renal blood flow (ERBF) was calculated by dividing
ERPF by (1 — Hct); effective renal vascular resistance (ERVR) was
calculated by dividing MAP by ERBF. Effective filtration fraction
(EFF) was calculated as GFR divided by ERPF X 100%. Urinary
sodium excretion rate was calculated as urinary sodium X urinary
flow rate; and fractional excretion of sodium (FeNa) was calculated as
urinary sodium X plasma inulin, divided by plasma sodium X urine
inulin.
Study baseline data were calculated as the mean of the two time
points immediately preceding the administration of the first study
drug. Hemodynamic results are expressed as maximum placebo-
corrected change from baseline (mean ± SEM). Statistical analysis
was performed on untransformed data, and responses were examined
by repeated measures ANOVA. In addition, area under the curve was
calculated as a summary statistic of each time curve, and responses
were compared by paired t test. Statistical significance was taken at
the 5% level. Power calculations from previous studies (22,36) sug¬
gested that, with n = 6 participants, the studies had 80% power to
achieve statistical significance for systemic hemodynamic indices. In
study 1, the response to BQ-123 and BQ-123/788 in the presence or
absence of enalapril was preidentified as the comparison of interest. In
study 2, comparison of BQ-123 + enalapril with the other three drug
combinations individually was preidentified as the comparison of
interest.
Results
Six participants were recruited to study 1, and seven were
recruited to study 2. Participants completed all phases of study
1 without adverse event. During study 2, one participant ex¬
perienced an increase in MAP of 50 mmHg after indomethacin
administration and before receiving BQ-123 and was with¬
drawn from the study. Baseline characteristics for the eight
participants who completed the studies (four of whom were
common to both studies) are shown in Table 1.
Study 1: Interaction between ET Receptor Antagonism
and ACE Inhibition
Systemic and Renal Hemodynamics. Administration of
placebo, either alone or after pretreatment with enalapril, did
not alter systemic hemodynamics. MAP was reduced after both
BQ-123 by 4.2 ± 1.6 mmHg (ANOVA P < 0.05 versus
placebo) and BQ-123/788 by 4.4 ± 2.0 mmHg (Figure 1A).
After pretreatment with enalapril, the BP reduction after BQ-
123 was almost doubled, with MAP falling by 8.3 ± 3.0
mmHg (P < 0.01 versus BQ-123 alone). However, this syn¬
ergy was not seen when BQ-788 was co-administered with
BQ-123, when MAP was reduced by 4.3 ± 3.3 mmHg. SVRI
followed a similar pattern (Figure IB).
Placebo, enalapril alone, BQ-123, and BQ-123/788 all were
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Table 1. Participant demographic data3
Age (yr) 47 -i- 5 (23-64)
BMI (kg/m2) 25 2 (18-31)
Mean arterial pressure 88.5 + 2.7 (71.4-99.4)
(mmHg)
Creatinine (mg/dl)b 1.01 -h 0.08 (0.70-1.35)
Creatinine clearance (ml/min) 96 7 (70-132)
24-h urinary sodium excretion 118 15 (64-185)
(mEq/24 h)
Cholesterol (mg/dl)c 201 12 (151-236)
"Values are given as mean ± SEM with the range of values
given in parentheses.
b To convert to /xmol/L, multiply by 88.4.
cTo convert to mmol/L, multiply by 0.0259.
neutral in respect of ERBF, ERVR, EFF, and GFR. After
pretreatmentwith enalapril, BQ-123 increased ERBF by 146 ±
41 ml/min (P < 0.01 versus placebo and versus BQ-123
alone), reduced ERVR by 32 ± 15 mmHg/min per L (P < 0.01
versus placebo and versus BQ-123 alone), and reduced EFF by
3.4 ± 2.5% (P < 0.05 versus placebo, P < 0.01 versus
BQ-123 alone; Figure 2). By contrast, after pretreatment with
enalapril, BQ-123/788 reduced ERBF by 224 ± 31 ml/min (P
< 0.01 versus placebo and versus BQ-123/788 alone) and
increased ERVR by 26 ± 6 mmHg/min per L (P < 0.05 versus
BQ-123/788 alone).
Sodium Excretion. No significant natriuresis was ob¬
served after placebo, enalapril alone, and either BQ-123 or
BQ-123/788 alone. However, after pretreatment with enalapril,
BQ-123 produced a striking increase in urinary sodium excre¬
tion with a maximum excretion rate of 58 ± 27 p.mol/min (P
< 0.01 versus placebo and BQ-123 alone). FeNa followed a
similar pattern. As with renal hemodynamics, this increase was
not observed with BQ-123/788 (Figure 3).
Serum ACE Activity. Compared with placebo, pretreat¬
ment with enalapril reduced serum ACE activity by 75% at
baseline (36.4 ± 4.3 versus 9.1 ± 2.3 U; P < 0.01) and by
79% at 150 min (26.5 ± 2.1 versus 5A ± 1.7 U; P < 0.01). ET
receptor antagonist administration did not alter ACE activity.
Plasma BQ-123. BQ-123 was detectable in plasma at 15
min after the start of the low-dose and at 15 and 45 min after
the start of the high-dose infusion. Peak BQ-123 concentra¬
tions tended to be higher after pretreatment with enalapril,
although the difference was not statistically significant (BQ-
123, 1.26 ± 0.18 pg/ml; BQ-123/788, 1.32 ± 0.23; BQ-123 +
enalapril, 2.06 ± 0.65; BQ-123/788 + enalapril, 2.32 ± 0.53).
Study 2: Effect ofNO Synthase Inhibition and
Inhibition ofProstaglandin Synthesis on Combined
ETA Receptor Antagonism and ACE Inhibition
Systemic and Renal Hemodynamics. MAP was reduced
by 6.0 ± 1.7 mmHg after BQ-123 in the presence of enalapril.
This effect was augmented by indomethacin, with MAP falling
by 11.0 ± 2.3 mmHg at the end of the study (P < 0.01 versus
BQ-123; Figure 4) and abolished by L-NMMA (P < 0.01
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Figure 1. (A) Effects of endothelin (ET) receptor antagonism and angiotensin-converting enzyme (ACE) inhibition on mean arterial pressure.
(Left) Mean of percentage change from baseline ± SEM; □, placebo; ■, placebo + enalapril; O, BQ-123; ♦, BQ-123 + enalapril; O,
BQ-123/788; •, BQ-123/788 + enalapril; |, administration of study drug. (Right) Mean area under curve of percentage change from baseline
± SEM; □, placebo; ■, placebo + enalapril; m, BQ-123; BQ-123 + enalapril; BQ-123/788; 8, BQ-123/788 + enalapril. *P < 0.05
versus placebo, +P < 0.05 versus placebo + enalapril, §P < 0.05 versus BQ-123. (B) Effects ofET receptor antagonism and ACE inhibition
systemic vascular resistance index. Legend as for A.
versus BQ-123). Again, SVRI followed a similar pattern (Fig¬
ure 4). Indomethacin did not affect the renovascular changes
induced by BQ-123 + enalapril, but L-NMMA abolished the
effects of BQ-123 + enalapril on both ERBF and ERVR (P <
0.01) (Figure 4).
Sodium Excretion. The natriuresis produced by the com¬
bination of BQ-123 and enalapril was attenuated by indometh¬
acin (P < 0.01 versus BQ-123 + enalapril) and abolished by
L-NMMA (P < 0.01 versus BQ-123 + enalapril) (Figure 4).
Discussion
In these studies, we demonstrated a synergy between the
effects of ACE inhibition and ETA receptor antagonism in
humans, affecting both systemic and renal hemodynamics,
as well as renal tubular function. This synergy is abolished
by either ETB receptor blockade or NO synthase inhibition
but not COX inhibition. We conclude that ETA receptor
antagonism and ACE inhibition act synergistically through
an ETB receptor-mediated, NO-dependent, and COX-
independent mechanism.
The ET and renin-angiotensin systems are known to interact
(4), and an in vivo synergistic effect between ETA receptor
antagonism and ACE inhibition has been demonstrated in animals
(12) and between ET receptor antagonism and angiotensin ATI
receptor antagonism in humans (37). We have shown, in healthy
men who were subjected to systemic ACE inhibition with a
clinically relevant dose of enalapril, that the effects of ETA
receptor blockade on systemic hemodynamics are enhanced. With
respect to BP, ACE inhibition almost doubled the hypotensive
effect of ETA receptor blockade. In addition, in contrast to the
absence of an effect of ETA receptor antagonism alone on the
renal circulation, the combination with ACE inhibition increased
renal perfusion, in association with a fall in EFF. Thus, by infer¬
ence, this combination causes preferential efferent renal arteriolar
vasodilation that should be associated with a fall in glomerular
capillary pressure. Such changes in glomerular hemodynamics
have the potential to be renoprotective in a manner analogous to
the effect of ACE inhibition alone. In addition, this combination
produced a striking natriuresis that was still developing to the end
of the study, 4 h after initial administration of BQ-123. At its
maximum, this natriuresis measured 10 mmol/h, a clinically im¬
portant degree of sodium loss.
Our results also demonstrate that although maximal hemo¬
dynamic changes occurred after the higher dose of BQ-123,
potentially useful systemic and renal hemodynamic changes
were achieved after a lower dose ofBQ-123 in the presence of
ACE inhibition. As adverse effects in clinical trials with ET
receptor antagonists seem to be largely dose related (38), this
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Figure 2. (A) Effects of ET receptor antagonism and ACE inhibition on effective renal blood flow. Legend as for Figure 1A. (B) Effects of
ET receptor antagonism and ACE inhibition on effective renal vascular resistance. Legend as for Figure 1A. (C) Effects of ET receptor
antagonism and ACE inhibition on effective filtration fraction. Legend as for Figure 1A.
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Figure 3. Effects of ET receptor antagonism and ACE inhibition on fractional urinary excretion of sodium. Legend as for Figure 1A.
combination might allow the use of a lower and better tolerated
dose of ETA receptor antagonist without compromising
efficacy.
Montanari et al. (37) demonstrated that ETA receptor an¬
tagonism can produce renal hemodynamic changes under con¬
ditions of angiotensin ATI receptor blockade and that this
action is inhibited by NO synthase inhibition. We demon¬
strated a similar synergy between ETA receptor antagonism
and ACE inhibition, again dependent on NO, but extended this
work by showing that this synergistic effect is abolished, for all
indices studied, when the ETB receptor is blocked, suggesting
that the ETB receptor is crucial to the mechanism of this
interaction. As both L-NMMA and BQ-788 are vasoconstric¬
tors, it is possible that their ability to abolish the vasodilator
effect of enalapril and BQ-123 is nonspecific. However, indo-
methacin has also been shown to produce renal vasoconstric¬
tion in healthy subjects (39) but had no effect on the renal
vasodilation seen in this study after enalapril and BQ-123.
Similarly, previous studies in healthy volunteers have demon¬
strated that although this dose of BQ-788 alone produces
systemic and renal vasoconstriction, it does not abolish the
vasodilator effects of BQ-123 (36), suggesting that the effect
seen here is specific to the interaction between ACE inhibition
and ETA receptor antagonism. In an experimental rat model of
interstitial renal fibrosis, enalapril treatment was shown to
increase ETB mRNA expression (40), providing a possible
mechanism for this ET-l/ACE interaction. It is possible that
ETA receptor antagonism then results in displacement of en¬
dogenous ET-1 from the ETA receptor onto the unblocked,
upregulated ETB receptor.
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Figure 4. Systemic and renal hemodynamic and tubular effects of A^-monomethyl-L-arginine (L-NMMA) and indomethacin on the response
to the combination of BQ-123 and enalapril. (Left) Mean of percentage change from baseline ± SEM, except for effective filtration fraction
(EFF), which was mean change from baseline (%); Q, placebo + enalapril; O, BQ-123 + enalapril; •, BQ-123 + enalapril + indomethacin;
A, BQ-123 + enalapril + L-NMMA; |, administration of study drug. (Right) Mean area under curve of percentage change from baseline ±
SEM (EFF, mean change from baseline [%]). Q placebo + enalapril; 5, BQ-123 + enalapril; □, BQ-123 + enalapril F indomethacin; §1,
BQ-123 + enalapril + L-NMMA. +P < 0.05 versus placebo -I- enalapril, §P < 0.05 versus BQ-123 + enalapril.
These studies were performed in subjects in a salt-replete
state (mean 24-h urine excretion, 119 ± 6 mmol). A recent
study suggested that ET-1 plays a role in angiotensin-depen-
dent hypertension in humans (41), particularly with respect to
BP and proteinuria. Salt depletion, with enhancement of renin-
angiotensin activity, therefore might further enhance the syn¬
ergy seen between ETA receptor antagonism and ACE
inhibition.
2608 Journal of the American Society of Nephrology J Am Soc Nephrol 15: 2601-2610, 2004
It is interesting that in the presence of ACE inhibition in our
study, combined ETA/B receptor antagonism tended to in¬
crease renal vascular tone and reduce blood flow, underlining
the importance of ETB-mediated vasodilation. This finding has
important implications for the therapeutic use of ET receptor
antagonists, suggesting that, in conjunction with ACE inhibi¬
tors, ETA receptor antagonists may be superior to nonselective
ETA/B receptor antagonists with respect to some important
hemodynamic effects. Indeed, we previously demonstrated in
patients who had chronic renal failure and were already being
treated with ACE inhibitors that ETA but not combined ETA/B
receptor antagonism increases renal blood flow (36). The cur¬
rent demonstration of an ETB receptor-dependent, synergistic
interaction between ETA receptor antagonism and ACE inhi¬
bition suggests that these differences observed in renal patients
may, at least in part, be due to concomitant chronic treatment
with ACE inhibitors.
Although prostacyclin is the major COX product ofmacro-
vascular endothelium in vitro, COX activity can produce both
vasoconstrictor and vasodilator achidonic acid derivatives.
Prostaglandins stimulate renin release (42). Thus, indometha-
cin may produce both vasodilation, by inhibition of renin-
mediated Ang II generation and COX-1-mediated thrombox¬
ane A2 synthesis, and vasoconstriction, by blocking synthesis
of vasodilator prostanoids. Studies in animals also suggest that
vasoconstrictor COX products, such as thromboxane A2 and
prostaglandin H2, might be implicated in ET-l-induced vaso¬
constriction, particularly in disease models (43-47). The
greater fall in BP when indomethacin was co-administered
with enalapril and BQ-123 may represent blockade of the
action of these constrictor COX products. There is evidence
from studies in animals that vasodilator prostaglandins may
additionally be involved in the actions of ET-1 in the renal
circulation, particularly the renal medulla (45,48). We could
not demonstrate, however, any inhibitory effect of indometh¬
acin on either the systemic or the renal hemodynamic effects of
the combination of ACE inhibition and ETA receptor antago¬
nism. With respect to renal blood flow, however, clearance
studies only measure total renal blood flow. It is possible,
therefore, that opposite changes are occurring in the renal
cortex and medulla.
With respect to natriuresis, knockout and antagonist studies
in animals have implicated ETB receptors, linked to NO pro¬
duction, in ET-l-mediated sodium excretion (49). COX inhi¬
bition, however, augments big ET-l-mediated natriuresis, sug¬
gesting an antinatriuretic role for prostaglandins (50). Our
studies demonstrate, in the presence of ACE inhibition, an
ETB-dependent natriuresis that is mediated by both NO and, to
a lesser extent, prostanoids.
In summary, in this mechanistic study, we demonstrated that
ACE inhibition increases the systemic hemodynamic effects of
ETA receptor antagonism, at both low and high dose, and
unmasks a renal hemodynamic and tubular effect. This synergy
is mediated mainly by NO and requires an unblocked ETB
receptor. These findings would preferentially support the fur¬
ther investigation of selective ETA receptor antagonism, over
combined ETA/B receptor antagonism, as a useful adjunct to
ACE inhibition in the management of the systemic and renal
vascular consequences of diseases characterized by vasocon¬
striction. This may be particularly important in circumstances
in which sodium loss would also be beneficial, such as hyper¬
tension and chronic renal failure. This interaction should now
be explored in longer term studies in patients with such
conditions.
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